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PROLOGUE
Since 2005, new pharmaceuticals called 'biologies' or 'biological therapies' have been 
registered and reimbursed in The Netherlands for the treatment of patients with moderate 
to severe plaque psoriasis. The introduction of these drugs heralded an entirely new era in 
the management of psoriasis. Recent improvement in the knowledge of the pathogenesis of 
psoriasis was fundamental for the development of these novel targeted treatment options.
At the same time, the utilization of these drugs lead to new insights in the pathogenesis of 
different immune-mediated inflammatory diseases, including psoriasis.
Biologics were implemented in daily clinical practice after years of thorough investigation 
on the efficacy and safety of these drugs in randomized controlled trials. The introduction 
of biological therapies provided new perspectives for patients with severe, recalcitrant 
psoriasis ('high-need' population), but also created new challenges for dermatologists.
Despite extensive research on these therapies in randomized controlled trials, the 
implementation of these drugs in daily clinical practice gave rise to many uncertainties.
Are these biologics as effective as claimed in publications on randomized controlled trials?
W hat do we know about the safety of these products on longer term? What happens when 
I treat a patient with biologics who is not as 'healthy' as a clinical trial participant? What do 
the high medication costs mean for the society as a whole? And last but not least: What 
are the implications of these therapies for my routine as a dermatologist?
To be able to study these themes, a patient registry was set up by investigators of the
Radboud University Nijmegen Medical Centre department of dermatology, enabling the
collection of efficacy and safety data on biological therapies for the treatment of patients
with psoriasis. The purpose of this registry was to follow all patients with psoriasis treated
with biological therapies in daily clinical practice. The content of this thesis is largely based
on the data collected in the registry. Specific themes were studied, including efficacy, 11
safety, costs, procedures en comorbidities.
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CHAPTER 1
CHAPTER 1 
Epidemiology, pathogenesis and clinical features of psoriasis 
In troduction
Psoriasis is a common chronic skin disease, characterized by sharply demarcated, 
erythematous, scaly plaques. It often has a significant negative impact on the physical, 
emotional and psychosocial wellbeing of affected patients. Furthermore, psoriasis has 
a major impact on health care systems and on society in general. Although the exact 
pathogenesis of psoriasis is still not entirely demystified, research has demonstrated 
scientific evidence for a role for genetic, environmental and immunological factors. This 
chapter describes the epidemiology, pathogenesis and clinical and histological features of 
psoriasis.
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PART I
E pidem io logy
Psoriasis was recognised as being a specific clinical entity that was different from leprosy 
by Robert Willan in the beginning of the 19th century. In the 1840s, Ferdinand von Hebra 
laid the foundation for the classification of psoriasis in its current form.1 
The prevalence of psoriasis in various locations throughout the world has been estimated
0.6 to 4.8%. In a recent study from the United States, a prevalence in adults of approximately 
3% was demonstrated.2 Although some studies find minor deviations, psoriasis is equally 
common in males and females. Psoriasis can present at any age, but is most likely to 
appear between the ages of 15 and 30 years.3
Pathogenesis
Psoriasis is supposed to be initiated by an interplay between genetic, environmental, and 
immunological factors, eventually leading to the evolution of psoriatic lesions.
Genetic factors
Population studies clearly indicate that the incidence of psoriasis is greater among first- 
degree and second-degree relatives of patients than among the general population. 
Moreover, the risk of psoriasis is two to three times as high among monozygotic twins 
as among dizygotic twins. Nevertheless, the mode of inheritance of psoriasis is complex. 
Classic linkage analysis and genomewide association scans have identified different 
genes associated with psoriasis. The strongest associations have been observed in the 
psoriasis susceptibility 1 (PSORS1) region, which probably accounts for 35 to 50% of 
the heritability of the disease.4 Other major psoriatic gene variants include the genes 
encoding the interleukin-23 receptor (IL23R) and the untranslated region of the interleukin- 
128 (IL12B).5;6 Recent findings indicate that both genomic copy number variation at the 
p-defensin cluster and deletion of the late cornified envelope (LCE) genes may be risk
16 factors for psoriasis as well.78
Environmental factors
Multiple environmental factors have been implicated in the pathogenesis of psoriasis. 
Some of these appear to be able to trigger the disease, including streptococcal throat 
infections, medications, trauma to the skin, stressful life events and smoking. These 
factors, as well as many others, have also been shown to exacerbate or modify the disease 
in different patients. Other relevant environmental factors that may influence the disease 
course of psoriasis are human immunodeficiency virus (HIV) infection, obesity, alcohol, 
and ultraviolet (UV) radiation.3
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Immunological factors
Key cells and mediators in the immunopathogenesis of psoriasis include keratinocytes, 
dendritic cells, T lymphocytes, and cytokines. Before the mid-1980s, research into 
the pathogenesis of psoriasis mainly focused on the differentiation and proliferation of 
keratinocytes. However, the observation of dramatic clearing of psoriasis by ciclosporin, a 
T-cell inhibitor, was highly suggestive of a pivotal role for T cells in psoriasis development.
This hypothesis was confirmed more than a decade later, when the efficacy of psoriasis 
treatment with biologically engineered T-cell modulators, including alefacept and 
efalizumab, was established.9 Besides, the impressive response of psoriasis to tumor 
necrosis factor a (TNF-a) and interleukin-12 (IL-12)/ interleukin-23 (IL-23) blocking drugs 
indicate an important role for cytokines as well. (See Chapter 2: Biological therapies)
A proposed schema of the evolution of psoriatic lesions is provided in Figure 1. Initial 
triggers such as physical trauma or bacterial products start a cascade of events that lead 
to the activation of myeloid dermal dendritic cells through production of key cytokines 
(TNF-a, interferon-a, interferon-Y, interleukin-1p, and interleukin-6) by innate immune cells.
Activated dendritic cells present antigens and secrete mediators such as interleukin-12 and 
interleukin-23, leading to the differentiation of type 1 and type 17 helper T cells (Th1 and 
Th17), respectively. T cells, in turn, secrete mediators (e.g., interleukin-17A, interleukin-17F, 
and interleukin-22) that activate keratinocytes and induce the production of antimicrobial 
peptides (e.g., LL-37 cathelicidin and p-defensins), proinflammatory cytokines (TNF-a, 
interleukin-lp, and interleukin-6), chemokines (CXCL8 through CXCL11 and CCL20) and 
S100 proteins. These soluble mediators feed back into the proinflammatory disease cycle 
and shape the inflammatory infiltrate.4
C lin ica l and h is to log ica l features
17
Clinical features
Psoriasis is characterized by sharply demarcated, erythematous, scaly plaques of different 
sizes. Plaques are usually distributed symmetrically, and occur most commonly on the 
extensor aspects of elbows and knees, scalp, lumbosacral region, and umbilicus. Psoriasis 
vulgaris is the commonest type of psoriasis, accounting for 90% of all cases. Other types 
include flexural (inverse) psoriasis, guttate psoriasis, generalised pustular psoriasis (von 
Zumbusch), and palmoplantar pustulosis. About 50% of patients with psoriasis have 
distinctive nail changes, most commonly observed in patients with psoriatic arthritis.10
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Figure 1. P roposed (s im plified) 
schem e o f the evo lu tion  o f 
pso ria tic  lesions. (Modified from 
Nestle FO, Kaplan DH, Barker J. 
Psoriasis.4)
PSORS1, Psoriasis Susceptibility 1; LCE, Late 
Cornified Envelope; TNF, Tumor Necrosis 
Factor; Th1, type 1 helper T-cell; Th17, type 17 
helper T-cell.
18
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Histological features
Fully developed clinical plaques show marked epidermal hyperplasia with regular 
elongation of epidermal rete ridges. There is marked hyperkeratosis, often composed of 
alternating orthokeratosis and parakeratosis.11 The inflammatory infiltrate consists mainly 
of T cells, dendritic cells and macrophages. T cells in psoriatic lesions are polarized as 
type 1 helper T cell (Th1; CD4+) and cytotoxic T cell (Tc1; CD8+) subsets, but probably also 
include a separate population of type 17 helper T cells (Th17).12 CD11c+ dendritic cells are 
detected mainly in the upper part of the epidermis.4 Collections of neutrophils within the 
parakeratosis (Munro's microabscesses) are present in most cases and less commonly 
within the spinous layer (spongiform pustules of Kogoj).11 Furthermore, psoriatic epidermis 
expresses high levels of host defense proteins, especially human p-defensin-2.13
19
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CHAPTER 2 
Treatment of psoriasis
In troduction
Psoriasis can be treated with many different therapies, singly or in combination. In 
general, three therapeutic modalities are available, i.e. topical agents, UV therapy 
(phototherapy) and systemic medications. A few years ago, a new class of systemic 
pharmaceuticals, called “biologics” or “biological therapies” have been introduced into the 
therapeutic arsenal for psoriasis. The “psoriasis treatment ladder” refers to the concept 
that medications with the least potential for adverse reactions should preferentially be 
employed and that therapies with greater potential toxicity are used only if the treatment 
goal is not achieved by the former treatment. This step up scheme respectively includes 
topical therapies, phototherapy and (conventional) systemic therapies. Whether biological 
therapies are part of the third step, or must be reserved for therapy resistant patients, 
remains an issue of debate, as long-term safety and efficacy data on these therapies are 
sparse. This chapter describes different treatment modalities for psoriasis, with special 
emphasis on methotrexate and biological therapies.
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PART I
Topical therapy
Topical monotherapy remains the mainstay of treatment for most patients with psoriasis, 
especially those with limited disease. Topical therapies commonly used for psoriasis 
include corticosteroids, vitamin D analogues, calcineurin inhibitors, dithranol and coal tar. 
The most widely prescribed topical therapies are corticosteroids, which are available in 
classes with different potency. Vitamin D analogues show lower initial clinical responses 
than higher potency corticosteroids, but their longer-term safety profile makes them 
valuable for maintenance therapy.1
Phototherapy
Phototherapy denotes treatment with UV radiation in different wavelength spectra. Types 
of phototherapy used for psoriasis are broadband UVB, narrow-band UVB and Psoralen- 
UVA (PUVA). Broadband UVB has lost its popularity nowadays, although it is still used 
in some units. UV radiation induces growth arrest of keratinocytes and influences the 
pathologic immune response in the skin, leading to a significant improvement of psoriasis 
symptoms.2
C onventiona l sys tem ic  therapies
A wide range of systemic drugs are registered for the treatment of psoriasis. Frequently 
used traditional therapies are methotrexate, ciclosporin, acitretin, and fumaric acid esters. 
Except for methotrexate, these therapies will not be outlined further.
Methotrexate
Methotrexate has been one of the most frequently prescribed therapies for psoriasis for 
more than 50 years. Although biological therapies have recently demonstrated to be highly 
effective in psoriasis, methotrexate has remained popular for the treatment of patients with 
22 psoriasis. In contrast to biologics, methotrexate is a cheap drug with a well-know long-term 
efficacy and safety profile. Therefore, most guidelines for the use of biological therapies 
for psoriasis recommend to use methotrexate prior to biologics, and to use biological 
therapies only in patients in whom methotrexate treatment is ineffective, contraindicated, 
or causes side effects. Furthermore, the combination of biologics with methotrexate has 
proven highly beneficial, especially in rheumatic diseases.3
Methotrexate competitively inhibits the enzyme dihydrofolate reductase, thus decreasing 
the synthesis of folate cofactors needed to produce nucleic acids. This leads to inhibition of 
epidermal proliferation, but more importantly, of proliferation of lymphoid tissue. The latter 
supports the concept that the therapeutic effect of low-dose methotrexate in psoriasis is a
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result of its effects on the immune system.4
The use of methotrexate is restricted by the risk of organ toxicity, in particular 
myelosuppression, pulmonary fibrosis, and hepatotoxicity. To prevent the development 
of serious liver injury, routine performance of liver biopsies is advocated for all patients 
using methotrexate. However, this recommendation has been an issue of debate, as 
rheumatologists deem the liver biopsy as unnecessary in their patients.5 Therefore, current 
research focuses on potentially alternative markers for liver injury associated with lower 
morbidity and mortality compared to liver biopsies. One of these markers is amino-terminal 
propeptide of type III procollagen (PIIINP), which has proven to effectively reduce the 
requirement for liver biopsies.6
B io log ica l therapies
The term “biologics” or “biological therapies” is used for a class of pharmaceuticals that 
are produced by means of biological processes involving recombinant deoxyribonucleic 
acid (DNA) technology. DNA is isolated from natural sources, including animals and 
humans. For psoriasis, two types of biological therapies are available nowadays, either 
receptor fusion proteins or monoclonal antibodies. Receptor fusion proteins currently used 
for psoriasis treatment are alefacept and etanercept, recognizable by a generic name 
with the suffix “-cept”. Monoclonal antibodies used in psoriasis are efalizumab, infliximab, 
adalimumab and ustekinumab, recognizable by a generic name with the suffix “-mab”. As 
reflected in Table 1, biological therapies are named following specific guidelines based on 
structural classification of molecules.7
Table 1. Nom enclature o f 
b io log ica l therap ies.7
23
Suffix Used for
-cept Receptor molecules
-mab Monoclonal antibodies
Infix preceding suffix Used for
-u- Human
-xi- Chimera
-zu- Humanized
-kin- Interleukins
-li(m)- Immunomodulators
-ner- Tumor necrosis factor
-lefa- Lymphocyte function-associated antigen
Additionally, biological therapies can be classified according to their mechanism of action. 
Two types of biologics are used for the treatment of patients with psoriasis, i.e. T-cell
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inhibitors and cytokine inhibitors. T-cell inhibitors include alefacept and efalizumab. 
Cytokine inhibitors include etanercept, infliximab, and adalimumab, which are inhibitors of 
TNF-a, and ustekinumab, which inhibits both IL-12 and IL-23 (Figure 1).8
Figure 1. Pathogenesis-based targeted therapy fo r  psorias is . (Modified from Nestle 
FO, Kaplan DH, Barker J. Psoriasis.8)
CD, Cluster of Differentiation; LFA, Lymphocyte Function-associated Antigen; ICAM, Intercellular Adhesion 
Molecule; TNF, Tumor Necrosis Factor.
24 The efficacy and safety of biological therapies has been thoroughly investigated in 
randomized, controlled trials (RCTs). However, few studies directly compare active 
treatments for psoriasis, and only one head-to-head RCT comparing biological agents has 
been performed yet.9 Therefore, until more data from head-to-head trials are available, 
comparative estimates of treatment efficacy and safety must be derived from systematic 
literature reviews and meta-analyses (Table 2). For the current introduction, data on the 
efficacy of biological therapies (ustekinumab excluded) were adapted from a systematic 
review and meta-analysis by Bansback et al.10
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Psoriasis Area and Severity Index
The primary efficacy measure in most RCTs is the percentage reduction in Psoriasis 
Area and Severity Index (PASI) compared to baseline. The PASI is a composite score 
of erythema, induration, and desquamation of plaques, multiplied by a score for the 
affected body surface area in different regions, i.e. head, trunk, arms and legs. Scores 
range from 0.0 (no disease) to 72.0 (maximal disease).11 In most RCTs on biological 
therapies for psoriasis, only patients with a PASI of at least 10 at baseline are eligible for 
study participation. Likewise, most national guidelines state that treatment of psoriasis 
with biologics in daily practice is indicated only for patients with a PASI of at least 10 at 
screening. Many RCTs focus on a specific primary efficacy outcome, i.e. the number of 
patients achieving a 50%, 75%, 90% or 100% reduction in PASI relative to baseline (PASI 
50, PASI 75, PASI 90 and PASI 100, respectively).
T-cell inhibitors
Alefacept (Amevive®)
Alefacept is a dimeric fusion protein that consists of the extracellular CD2-binding portion 
of the human lymphocyte function-associated antigen-3 (LFA-3) linked to the Fc portion 
of human immunoglobulin G1 (IgG1). Alefacept interferes with lymphocyte activation 
by specifically binding to the lymphocyte antigen CD2, thereby inhibiting LFA-3/CD2 
interaction. The recommended dose of alefacept is 7.5 milligram (mg) given once weekly as 
an intravenous (IV) bolus or 15 mg given once weekly as an intramuscular (IM) injection.12 
In RCTs, a PASI 50 at week 14 was achieved by 24% of patients with psoriasis using 
alefacept 15 mg IM weekly. In the same trials, a PASI 75 was achieved by 9 to 21% of 
patients using the same dosage and route of administration (Table 2).10 
Common adverse events in RCTs investigating alefacept in patients with psoriasis were 
pharyngitis, chills, headache, pruritus and infections. The incidence of serious adverse 25 
events was greater in IV-dosed patients and lower in IM-dosed patients compared with 
placebo.13 Alefacept is approved as monotherapy for the treatment of moderate to severe 
psoriasis vulgaris only in the United States of America, Australia, Canada, Argentina, 
Switzerland, Kuwait, and Israel.
Efalizumab (Raptiva®)
Efalizumab is a recombinant humanized monoclonal antibody that binds specifically to the 
CD11a subunit of lymphocyte function-associated antigen-1 (LFA-1) By this mechanism, 
efalizumab inhibits the binding of LFA-1 to intercellular adhesion molecule-1 (ICAM-1),
Table 2. Efficacy of biological therapies for moderate to severe psoriasis. Results from a systematic review and meta-analysis.
(Adapted from Bansback et al. Efficacy of systemic treatments for moderate to severe psoriasis: systematic review and meta-analysis.10)
PASI 50 PASI 75 PASI 90
Trial Data Meta-Analysis Trial Data Meta-Analysis Trial Data Meta-Analysis
Range POR (95% Cl) Range POR (95% Cl) Range POR (95% Cl)
Alefacept (week 14) 7.5 mg/week IV 38-60 - 14-33 - - -
Alefacept (week 14) 15 mg/week IM 24 34 (25-43) 9-21 15 (9-21) 4 (2-6)
Efalizumab (week 12) 1 mg/kg/week SC 52-61 53 (48-59) 22-39 29 (24-34) 4-12 9 (7-12)
Etanercept (week 12) 2 x 25 mg/week SC 58-70 - 30-34 - 11-12 -
Etanercept (week 12) 2 x 50 mg/week SC 74-77 74 (67-80) 47-49 50 (43-58) 21-22 22 (17-28)
Infliximab (week 10) 5 mg/kg IVa 82-97 93 (91-96) 76-88 81 (75-86) 45-58 54 (47-63)
Adalimumab (week 12/16) 40 mg EOW SC 76-88 88 (83-93) 53-80 71 (63-79) 24-52 42 (33-52)
Ustekinumab (week 12) 45 mg SCb 84' - 67' - 42' -
Ustekinumab (week 12) 90 mg SCb 86-89 - 66-76 -
LOrC^O -
Presented numbers indicate the percentage of patients (range) and the probability of achieving a specific PASI response. POR, Probability of response; Cl, Confidence Interval; 
IV, Intravenous; IM, Intramuscular; SC, Subcutaneous; EOW, Every Other Week. aDose administered every 8 weeks following doses at 0, 2 and 6 weeks. bDose administered at 
week 0 and 4. Adapted from the PHOENIX 1 (Leonardi et al.21) and PHOENIX 2 (Papp et al.22) study.
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which interferes with T lymphocytes adhesion to other cell types. The recommended 
dose of efalizumab for psoriasis is an initial single subcutaneous (SC) injection of 0.7 mg/ 
kilogram (kg) followed by weekly SC injections of 1.0 mg/kg.14
In RCTs, a PASI 50 at week 12 was achieved by 52 to 61% of patients with psoriasis using 
efalizumab 1 mg/kg SC weekly. A PASI 75 and PASI 90 was achieved by 22 to 39% and 
4 to 12% of patients, respectively (Table 2).10 The most common adverse events were 
headaches, infections and chills. The pooled relative risk for incidence of one or more 
serious adverse events in efalizumab-treated patients was 1.43, which was not statistically 
significant in a comprehensive analysis of five trials.13
In February 2009, the European Committee for Medicinal Products for Human Use 
recommended the suspension of the marketing authorisation of efalizumab, because 
its benefits in the treatment of psoriasis were modest, while there was a risk of serious 
side effects in patients receiving the medicine, including the occurrence of progressive 
multifocal leukoencephalopathy (PML). Consequently, the Marketing Authorisation Holder 
for efalizumab (Raptiva®, Serono Europe Limited) voluntarily withdrew the marketing 
authorisation for the product.
Cytokine inhibitors
Etanercept (Enbrel®)
Etanercept is a dimeric fusion protein consisting of the 75-kilodalton (p75) tumor necrosis 
factor receptor-2 (TNFR2) linked to the Fc domain of human IgG1. Etanercept competitively 
inhibits TNF-binding to its cell surface receptors, thereby inhibiting the biological activity 
of both TNF-a and lymphotoxin-a (TNF-p). The recommended dose of etanercept for 
psoriasis is 25 mg SC twice a week or 50 mg SC once a week. Alternatively, 50 mg may 
be given twice a week for up to 12 weeks, followed by 25 mg twice a week or 50 mg once 
a week.15 27
In RCTs, a PASI 50 at week 12 was achieved by 74 to 77% of patients with psoriasis using 
etanercept 50 mg SC twice weekly. A PASI 75 and PASI 90 was achieved by 47 to 49% 
and 21 to 22% of patients using the same dosage and route of administration, respectively 
(Table 2).10 The most common adverse events reported were injection-site reactions, 
headache and upper respiratory tract infections. The most common serious adverse events 
were malignancies, serious infections and worsening psoriasis.13 Etanercept is currently 
approved for the treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, 
psoriatic arthritis, ankylosing spondylitis, and adult and paediatric plaque psoriasis.
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Infliximab (Remicade®)
Infliximab is a chimeric human-murine monoclonal antibody that binds with high affinity 
to both soluble and transmembrane forms of TNF-a, but not to lymphotoxin-a, thereby 
inhibiting the functional activity of TNF-a. The recommended dose of infliximab for psoriasis 
is 5 mg/kg given as an IV infusion over a two-hour period, followed by additional 5 mg/kg 
infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter.16 
In RCTs, a PASI 50, PASI 75 and PASI 90 at week 10 was achieved by 82 to 97%, 76 to 
88% and 45 to 58%, respectively, of patients with psoriasis using infliximab 5 mg/kg IV at 
week 0, 2 and 6 (Table 2).10 The most common adverse events in RCTs studying infliximab 
in patients with psoriasis were upper respiratory tract infections, headache, increased 
hepatic enzymes and infections. Some of the most common serious adverse events 
reported were malignancies, serious infections, serious infusion reactions and lupus-like 
syndrome.13 Infliximab is currently approved for the treatment of rheumatoid arthritis, adult 
and paediatric Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis 
and psoriasis.
Adalimumab (Humira®)
Adalimumab is a recombinant human monoclonal antibody, which binds specifically to 
TNF-a and neutralizes the biological function of TNF-a by blocking its interaction with 
the p55 and p75 cell surface TNF receptors. The recommended dose of adalimumab for 
psoriasis is an initial dose of 80 mg SC, followed by 40 mg SC given every other week 
starting one week after the initial dose.17
In RCTs, a PASI 50 at week 12 or 16 was achieved by 76 to 88% of patients with psoriasis 
using adalimumab 40 mg SC every other week. In the same trials, a PASI 75 and PASI 
90 was achieved by 53 to 80% and 24 to 52% of patients, respectively (Table 2).10 The 
most common adverse events in RCTs were nasopharyngitis, injections site reactions and 
28 headache. The most frequently reported serious adverse events were malignancies and 
serious infections.18 Adalimumab is currently approved for the treatment of rheumatoid 
arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, 
Crohn's disease and psoriasis.
Ustekinumab (Stelara®) /  ABT-874 (briakinumab)
Ustekinumab is a fully human IgG1K monoclonal antibody that binds with high affinity and 
specificity to the p40 protein subunit of the human cytokines IL-12 and IL-23. Ustekinumab 
inhibits the activity of human IL-12 and IL-23 by preventing these cytokines from binding 
to their IL-12Rp1 receptor protein expressed on the surface of immune cells.19 ABT-874
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(briakinumab), which is now under investigation for the treatment of psoriasis, exhibits 
the same mechanism of action.20 The recommended dose of ustekinumab is 45 mg SC 
administered at week 0, followed by 45 mg SC at week 4, then every 12 weeks thereafter. 
For patients with a body weight above 100 kg the dose is 90 mg SC administered at week
0, followed by 90 mg SC at week 4, then every 12 weeks thereafter.19 
Currently, two RCTs have been published in which the efficacy and safety of ustekinumab 
for psoriasis was investigated. In these studies, 84% of patients using ustekinumab 45 mg 
SC at week 0 and 4 achieved a PASI 50 at week 12. A PASI 75 and PASI 90 was achieved 
by 67% and 42% of patients, respectively (Table 2). Commonly reported adverse events 
were upper respiratory tract infections, nasopharyngitis, headache, arthralgias, cough, 
and injection site erythema. Rates of serious infections and malignancies were low.2122 
Ustekinumab is currently approved for the treatment of psoriasis.
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CHAPTER 3 
Comorbidities in psoriasis
In troduction
Psoriasis is associated with comorbidities of different nature, although the origin of the 
associations is often complex.1 Psoriasis is related to immune-mediated inflammatory 
diseases, such as psoriatic arthritis and Crohn's disease.2 Furthermore, psoriasis is 
associated with impaired quality of life (QOL), which may lead to depression and psychosocial 
problems.3 Since the introduction of biological therapies, psoriasis has been considered a 
chronic systemic inflammatory disease, predisposing patients to cardiovascular disease. 
However, the cardiovascular risk of patients with psoriasis may also be increased by 
unhealthy lifestyle behaviour, such as smoking and alcohol consumption.4 Additionally, 
psoriasis therapies may cause specific health related problems, such as hypertension 
and liver fibrosis, induced by ciclosporin and methotrexate, respectively. This chapter 
describes common comorbidities in psoriasis, including psoriatic arthritis, cardiovascular 
disease and emotional, psychosocial and socioeconomic problems.
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Psoria tic  a rth ritis
Psoriatic arthritis (PsA) is a rheumatoid factor seronegative arthritis associated with 
psoriasis. Typical clinical features are distal interphalangeal joint involvement, asymmetric 
distribution, dactylitis, enthesitis, spinal involvement, and the association with human 
leukocyte antigen B27 (HLA-B27). Based on these characteristics, PsA has been 
classified with the HLA-B27-associated spondyloarthropathies.5 Historically, the principle 
classification criteria for PsA have been the Moll and Wright criteria.6 In 2006, new 
classification criteria for PsA have been developed, known as the CASPAR (ClASsification 
criteria for Psoriatic Arthritis) criteria.7 The estimated prevalence of PsA in patients with 
psoriasis varies extremely between different studies; a recent national survey in Germany 
revealed a prevalence of 19%.8 PsA can be treated with nonsteroidal anti-inflammatory 
drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs) or biological therapies.
C ard iovascu la r disease
Studies on cardiovascular diseases suggest that the risk of incident myocardial infarction, 
angina pectoris, atherosclerosis, peripheral vascular disease and stroke is increased 
in patients with psoriasis.9-13 The cardiovascular risk of patients with psoriasis may be 
influenced by the high incidence of cardiovascular risk factors, e.g. hypertension, diabetes 
mellitus, obesity, and dyslipidaemia, as well as by unhealthy lifestyle behaviour.4 However, 
there seems to be an increased risk of mortality due to psoriasis independent of major risk 
factors, especially in severely affected patients.14
There has currently been much debate about whether it is beneficial to induce systemic 
anti-psoriatic therapies in an early phase to reduce cardiovascular morbidity and 
mortality. Large prospective studies are needed to confirm this concept. On the other 
hand, knowledge about comorbidities including cardiovascular diseases is required for an 
adequate choice and dosing of systemic medication.
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Em otional, psychosoc ia l and soc ioeconom ic  problem s
In 1999, Rapp et al. found that health-related QOL was markedly reduced in patients 
with psoriasis, and that the impact of psoriasis on QOL was comparable to that seen 
in cancer, arthritis, hypertension, heart disease, diabetes, and depression.15 Prominent 
sequelae of psoriasis are embarrassment, shame, impaired self-image, low self-esteem, 
self-consciousness and stigmatisation.16 Moreover, the prevalence of mood disorders 
including depression in patients with psoriasis is high.17-19
Physical and emotional problems associated with psoriasis may lead to behavioural 
avoidance, and may influence a patient's potential to earn income and gain full
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employment.20 Consequently, psoriasis has a major economic impact on the society as a 
whole, as a result of direct health care costs and indirect costs due to production losses.21-23
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CHAPTER 4 
Observational studies
In troduction
When new therapies are introduced, randomized controlled trials (RCTs) are needed to 
study the efficacy and safety of these therapies, as RCTs provide the most robust estimate 
of causal effects.1 Randomization enables an unbiased allocation of treatment and the 
application of statistical theory on the basis of random sampling.2 In contrast, after approval 
and implementation of new therapies in daily practice clinical care, observational studies 
may provide additional information on these therapies which cannot be acquired by RCTs. 
When studying psoriasis therapies, especially biologics, the treatment course in clinical 
practice is different from the setting in which trials are conducted. In clinical practice, 
the aim is to provide an optimal treatment for an individual patient. Dose adjustments, 
treatment interruptions or combinations with other antipsoriatic therapies are instrumental 
to reach this goal. Clinical practice, therefore, is principally different from the artificial 
situation of clinical trials with predefined inclusion, exclusion and discontinuation criteria. 
In the current thesis, the outcomes of observational studies on biological treatment for 
severe psoriasis in daily practice are described. Most study data are obtained from a 
patient registry, in which efficacy and safety data on biological therapies for psoriasis were 
prospectively collected.
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Patient reg istries
Following the licensing of the first biological therapy for the treatment of severe rheumatoid 
arthritis, several countries initiated independent registries for the long-term evaluation 
of the efficacy and safety of this new generation of drugs. Today, many small or large, 
national or international registries exist on biological therapies for different indications.3-5 
These registries are useful drug surveillance tools, as they allow long-term follow-up of 
large groups of patients in a natural setting, which is important for the assessment of rare 
and long-term outcomes.6 Furthermore, registration of efficacy and safety data regarding 
systemic therapies for different indications gives the opportunity to compare the outcomes 
of these therapies in different diseases. Besides, the systematic collection of patient and 
treatment data directly reflects a patient's treatment course, which may invite the physician 
to critically consider his proceedings.
C ontinuous A ssessm ent o f P soriasis Treatm ent Use R egistry (CAPTURE)
Immediately after the registration and reimbursement of etanercept and efalizumab for 
the treatment of patients with moderate to severe psoriasis in The Netherlands, a patient 
registry was set up by investigators of the Radboud University Nijmegen Medical Centre 
department of dermatology, enabling the collection of efficacy and safety data on biological 
therapies for the treatment of patients with psoriasis in daily clinical practice. All patients 
with psoriasis treated with biologics were included in this registry, and each patient was 
followed prospectively. The first patient was included in February 2005; nowadays, the 
registration of patients is still operational. In 2008, after additional inclusion of therapies for 
childhood psoriasis, the registry was nominated “CAPTURE”, an acronym for Continuous 
Assessment of Psoriasis Treatment Use Registry.
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CHAPTER 5 
Outline of the thesis
In troduction
In this chapter, the outline of the thesis is described, representing study objectives and 
related questions.
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S tudy ob jectives
This thesis includes the outcomes of observational studies on psoriasis in daily clinical
practice. The objective of these studies was:
1. To prospectively investigate the effects and side effects of biological treatment in 
patients with severe psoriasis in daily practice.
Specific themes were studied, including:
a. The efficacy and safety of biological therapies in daily practice compared with 
RCTs.
b. The influence of clinical strategies and patient characteristics on treatment 
outcome.
c. The influence of combining etanercept with methotrexate on treatment outcome.
d. The influence of antibody formation against adalimumab on treatment outcome.
2. To investigate the economic impact of psoriasis and psoriasis treatment, including 
biological therapies.
3. To investigate procedures on prescription and application of biological therapies in 
daily practice.
4. To investigate the occurrence of comorbidities in patients with (severe) psoriasis.
Q uestions
With respect to these objectives, attempt was made to answer the following questions:
41
I. Which differences can be established when comparing the efficacy and safety of 
biological therapies for severe psoriasis in daily clinical practice with the outcomes 
of RCTs?
II. Are treatment outcomes influenced by specific factors, such as patient and treatment 
characteristics, addition or withdrawal of concomitant (systemic) therapies, antibody 
formation and comorbidities?
III. Has the total cost-of-illness of severe psoriasis changed since the introduction of
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biologics? Can the introduction of biological therapies be cost neutral or cost saving 
compared with the period before introduction of biological therapies for certain 
patients?
IV. How are procedures on prescription and application of biological therapies 
implemented in daily practice health care? Which information about physicians’ 
prescription behaviour and treatment efficacy do these data provide?
V. How often do cardiovascular, rheumatological and hepatic comorbidities occur 
in patients with severe psoriasis? What is the relevance of these comorbities for 
systemic treatment of patients?
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CHAPTER 6 
Etanercept and efalizumab treatment for high-need psoriasis. 
Effects and side effects in a prospective cohort study in outpatient 
clinical practice
A bstrac t
Background: Since the beginning of 2005, etanercept and efalizumab are officially 
registered and reimbursed for the treatment of recalcitrant psoriasis in The Netherlands.
Objective: The evaluation of the efficacy, safety and adverse events of etanercept and 
efalizumab treatment in daily practice.
Methods: A  prospective cohort study was carried out for patients treated with etanercept 
or efalizumab between February 2005 and March 2006.
Results: Over the past 13 months, 45 individuals were treated with etanercept and 17 
subjects were treated with efalizumab. The cohort represented a high-need population.
At week 12, 82% of the subjects treated with 2 x 50 mg etanercept per week and 71% of 
the subjects treated with 2 x 25 mg etanercept per week reached a 50% improvement in 
Psoriasis Area and Severity Index relative to baseline. Efficacy of etanercept treatment 
was comparable to the results of clinical trials. For efalizumab, efficacy in responding 
patients was also comparable to clinical trial data, but the percentage of dropouts was 
substantial. During biological treatment, safety was preserved and mainly mild adverse 
events were reported.
Conclusion: Etanercept and efalizumab are effective and safe therapies for patients with 
psoriasis, even for a high-need population. Etanercept was able to sustain the clinical 
improvement throughout 24 weeks, whereas efalizumab was not in 47% of subjects.
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Adapted from: Berends MA, Driessen RJ, Langewouters AM, Boezeman JB, van de Kerkhof 
PC and de Jong EM. Etanercept and efalizumab treatment for high-need psoriasis. Effects 
and side effects in a prospective cohort study in outpatient clinical practice. J.Dermatolog.
Treat. 2007; 18: 76-83.
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In troduction
Etanercept and efalizumab belong to the newest antipsoriatic therapies, known as 
biologics. These drugs became of particular interest for the treatment of psoriasis after 
discovering the high potential combined with assumed fewer side effects than regular 
systemic antipsoriatic therapies.
In September 2004, the European Union approved etanercept and efalizumab for the 
treatment of adult patients with moderate to severe plaque psoriasis who failed to respond 
to, or have a contraindication to, or are intolerant of other systemic therapies. In The 
Netherlands, these pharmaceuticals have been reimbursed by health insurance since 
the beginning of 2005. Etanercept binds specifically to tumor necrosis factor a (TNF-a) 
and blocks its interaction with cell surface TNF-a receptors.1 Efalizumab binds to human 
CD11a, the a-subunit of leukocyte function antigen-1 (LFA-1), thereby inhibiting the 
adhesion of leukocytes to other cell types.2
Many well-designed trials have been performed to study the efficacy of biologics in 
considerable numbers of patients. The use in daily practice, however, is different from the 
setting in which trials are conducted. From February 2005 until March 2006, we started 
with biological therapy in 62 individuals with recalcitrant psoriasis in our outpatient clinic. 
In this report we describe the first year of experience in treating patients in daily clinical 
practice with moderate to severe plaque psoriasis with etanercept and efalizumab. 
Evaluating the efficacy and safety of biological agents in clinical practice rather than 
in clinical trials provides relevant additional information about these new therapeutic 
strategies in the day-to-day care of psoriasis.
Patients and m ethods
Patients
46 Data were collected prospectively, using a standard form at each visit for all patients treated 
with etanercept or efalizumab between February 2005 and March 2006. Patients came 
into consideration for one of these treatments if they had failed to respond to phototherapy, 
methotrexate and ciclosporin in the past, or if they had a contraindication to, or were 
intolerant of one of these treatments. At the same time, patients had to have a minimum 
Psoriasis Area and Severity Index (PASI) of 10 at the time of screening, as stated in the 
guidelines of the Dutch Society of Dermatology and Venereology (Nederlandse Vereniging 
voor Dermatologie en Venereologie, NVDV).
Charts were reviewed for demographics and baseline characteristics, including age, sex, 
existence of psoriatic arthritis, duration of psoriasis, baseline PASI, previous dermatological
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treatments and the number of concomitant non-dermatological drugs.
Protocol
Before treatment, a chest X-ray and a Mantoux skin test were performed to exclude 
tuberculosis. Patients were treated with etanercept or efalizumab, depending on the 
physician's preference. For etanercept, two dosing regimens were used randomly, either 
50 milligram (mg) subcutaneously (SC) twice weekly for 12 weeks, followed by 25 mg SC 
twice weekly for 12 weeks (dosage schedule 1), or 25 mg SC twice weekly for 24 weeks 
(dosage schedule 2). After 24 weeks, patients interrupted etanercept treatment for an 
indefinite period according to the approved European Medicines Agency (EMEA) label. 
Efalizumab was given in a single conditioning dose of 0.7 mg/kilogram (kg) SC, followed 
by 1.0 mg/kg weekly (up to a maximum single dose of 200 mg).
Contraindications for etanercept treatment were an active infection or increased susceptibility 
for infections (including immunocompromised individuals), a history of tuberculosis, the 
existence of a demyelinating disease and pregnancy. Relative contraindications were the 
existence of cardiac decompensation, a blood dyscrasia, a malignancy in recent history, 
the presence of an antinuclear antibody (ANA) positive autoimmune disease or chronic 
exposition to actinic radiation in the past.
Contraindications for therapy with efalizumab were the presence of pustular, guttate 
or erythrodermic psoriasis during screening, a previous malignancy (basal cell 
carcinomas excluded), active infection or increased susceptibility for infections (including 
immunocompromised individuals), active tuberculosis, and pregnancy. Relative 
contraindications were the existence of leukocytosis, lymphocytosis or thrombocytopenia, 
the presence of an ANA positive autoimmune disease or chronic exposition to actinic 
radiation in the past.
Patients were allowed to use topical dermatological therapies during biological treatment.
An effort was made to confine the use of concomitant systemic dermatological therapies 47 
in cases of unsatisfactory effectiveness of etanercept or efalizumab. Termination of other 
non-dermatological drugs was found unnecessary.
Visits were scheduled every 4 weeks during the first 12 weeks, every 6 weeks until week 
24 and every 12 weeks thereafter. At each visit, the PASI and adverse events were 
documented. Furthermore, laboratory tests were conducted, including haematological 
analysis, serum chemistry, urinalysis and ANA. After 12 weeks of therapy, the treatment 
protocol required an improvement in PASI of at least 50% for both etanercept- and 
efalizumab-treated patients. Patients who did not meet this criterion were excluded from 
therapy according to the reimbursement guidelines. In some of these cases, treatment
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with the other available biological agent was started thereafter. The administration of 
etanercept or efalizumab was discontinued if patients developed a serious infection; 
therapy was restarted after recovery. Likewise, therapy was interrupted in cases of elective 
surgical procedures.
Analysis
Data from charts and forms were transported to a database and analysed to define treatment 
efficacy by means of PASI, with primary efficacy endpoints including the achievement of 
an improvement in PASI relative to baseline of at least 50% or 75% (PASI 50 and PASI 
75, respectively). Efficacy analysis of the first 12 weeks of treatment was made according 
to the intention to treat principle. Missing PASI at given time points were imputed using 
the last observation carried forward (LOCF). Because there were large differences in the 
follow-up periods of subjects, efficacy of the next 12 weeks was measured by means of 
a per protocol analysis. Reported adverse events and abnormal laboratory values were 
summarized. If patients received both etanercept and efalizumab treatment, chart analysis 
was performed twice. Multiple occurrences of the same adverse event in a single subject 
were counted once.
Results
Demographics
Over the past 13 months, 45 subjects were treated with etanercept, of whom 28 received 
a dose of 50 mg SC twice weekly for 12 weeks, followed by 25 mg SC twice weekly for 
12 weeks (dosage schedule 1) and 17 received a dose of 25 mg SC twice weekly for 24 
weeks (dosage schedule 2).
Seventeen subjects were treated with efalizumab. Overall, 55% was male, the mean age 
48 was 50.9 years and the mean duration of psoriasis was 21.6 years. Of all the subjects,
18 suffered from psoriatic arthritis. The mean PASI at baseline was 19.8. Patients had 
previously received 4 to 10 different dermatological therapies, with an average of 6.7 
treatments per patient. The mean number of systemic therapies that patients had used 
before the start of biological treatment was 3.3, indicating a high-need population.3 Some 
patients had even used biological agents in the past, mostly in the context of clinical trials. 
These included etanercept, alefacept, efalizumab, infliximab and onercept. The mean 
number of concomitant non-dermatological drugs was 2.2 (Table 1).
Patients were treated for various periods. The overall mean duration of treatment was 26 
weeks (interruptions after 24 weeks or for other reasons excluded), with a range of 5-46
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Table 1. Baseline dem ograph ic  data and d isease characte ris tics .
Etanercept 
Dosage 
schedule 1
Etanercept 
Dosage 
schedule 2
Efalizumab A ll
Age, years
Range 28-71 39-42 27-71 27-71
Mean (±SEM) 49.6 (1.7) 52.9 (2.3) 51.1 (3.2) 50.9 (1.3)
Gender, no. (%)
Male 16 (57) 9 (53) 9 (53) 34 (55)
Female 12 (43) 8 (47) 8 (47) 28 (45)
Psoriasis, no. (%)
With psoriatic arthritis 11 (39) 2 (12) 5 (29) 18 (29)
Without psoriatic arthritis 17 (61) 15 (88) 12 (71) 44 (71)
Duration of psoriasis (years)
Range 3-42 5-54 3-40 3-54
Mean (±SEM) 20.7 (1.9) 28.0 (3.1) 16.8 (2.5) 21.6 (1.5)
Baseline PASI score
Mean (±SEM) 25.1 (2.2) 16.3 (1.2) 14.7 (1.3) 19.8 (1.2)
Previous treatments (no.)
Range, total 4-10 4-9 4-9 4-10
Range, systemic treatments 1-6 2-6 2-5 1-6
Mean, total (±SEM) 6.8 (0.3) 6.4 (0.3) 6.8 (0.3) 6.7 (0.2)
Mean, systemic treatments (±SEM) 3.5 (0.2) 3.0 (0.2) 3.4 (0.3) 3.3 (0.1)
Types of previous treatments used, no. (%)
Topical steroids/ vitamin D analogues 28 (100) 17 (100) 17 (100) 62 (100)
Dithranol 19 (68) 12 (71) 14 (82) 45 (73)
Methotrexate 28 (100) 17 (100) 16 (94) 61 (98)
UVB 25 (89) 14 (82) 15 (88) 54 (87)
PUVA 21 (75) 14 (82) 11 (65) 46 (74)
Acitretin 20 (71) 12 (71) 13 (76) 45 (73)
Ciclosporin 21 (75) 9 (53) 13 (76) 43 (69)
Fumaric acid 15 (54) 6 (35) 7 (41) 28 (45)
Etanercept 2 (7) 3 (18) 3 (18) 8 (13)
Alefacept 2 (7) 2 (12) 4 (24) 8 (13)
Efalizumab 6 (21) 0 (0) 0 (0) 6 (10)
Infliximab 2 (7) 0 (0) 2 (12) 4 (6)
Onercept 1 (4) 2 (12) 0 (0) 3 (5)
Concomitant non-dermatological drugs, no.
Range 0-9 0-6 0-9 0-9
Mean (±SEM) 2.5 (0.5) 1.7 (0.4) 2.1 (0.6) 2.2 (0.3)
Dosage schedule 1, 50 mg SC twice weekly for 12 weeks, followed by 25 mg SC twice weekly; Dosage schedule 
2, 25 mg SC twice weekly; SEM, Standard Error of the Mean; PASI, Psoriasis Area and Severity Index; UVB 
Ultraviolet B; PUVA, Psoralen-Ultraviolet A.
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weeks in the etanercept dosage schedule 1 group, 11-49 weeks in the etanercept dosage 
schedule 2 group and 6-32 weeks in the efalizumab-treated group.
Efficacy
Twenty-three subjects (82%) in the etanercept dosage schedule 1 group, 12 subjects 
(71%) in the etanercept dosage schedule 2 group and 10 subjects (59%) in the efalizumab 
group achieved a PASI 50 at week 12. At the same time, respectively 39%, 24% and 6% 
achieved a PASI 75 (Figure 1).
F igure 1. E fficacy resu lts  a fte r 12 w eeks o f b io log ica l the rapy (in ten tion  to  treat 
analysis).
Dosage schedule 1, 50 mg SC twice weekly for 12 weeks, followed by 25 mg SC twice weekly; Dosage schedule 
2, 25 mg SC twice weekly; PASI, Psoriasis Area and Severity Index; PASI 50, 50% reduction in PASI relative to 
baseline; PASI 75, 75% reduction in PASI relative to baseline.
For 14 subjects in the etanercept dosage schedule 1 cohort, 14 subjects in the dosage 
schedule 2 cohort and 4 subjects in the efalizumab cohort, PASI at 24 weeks of treatment 
were available. After per protocol analysis, data revealed the achievement of a PASI 
50 in respectively 71%, 79% and 100% of these subjects. Nevertheless, these efficacy 
percentages are calculated by dividing on the remaining number of subjects at week 24. 
In the efalizumab cohort, the dropout rate due to lack of efficacy at week 24 was high, i.e.
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eight subjects (47%) (Table 2).
Table 2. E fficacy resu lts  after 18 and 24 weeks o f b io log ica l the rapy (per p ro toco l 
analysis).
Etanercept 
Dosage 
schedule 1
Etanercept 
Dosage 
schedule 2
Efalizumab All
No. of patients at baseline 28 17 17 62
No. of patients with unfinished follow-up
At week 18 10 1 6 17
At week 24 13 0 5 18
No. of dropouts due to lack of efficacy
At week 18 1 2 6 9
At week 24 1 3 8 12
Remaining no. of patients
At week 18 17 14 5 36
At week 24 14 14 4 32
> 50% improvement in PASI, no. (%)
At week 18 15 (88) 11 (79) 5 (100) 31 (86)
At week 24 10 (71) 11 (79) 4 (100) 25 (78)
> 75% improvement in PASI, no. (%)
At week 18 8 (47) 9 (64) 1 (20) 18 (50)
At week 24 7 (50) 8 (57) 1 (25) 16 (50)
< 50% improvement in PASI, no. (%)
At week 18 2 (12) 3 (21) 0 (0) 5 (14)
At week 24 4 (29) 3 (21) 0 (0) 7 (22)
Dosage schedule 1, 50 mg SC twice weekly for 12 weeks, followed by 25 mg SC twice weekly; Dosage schedule
2, 25 mg SC twice weekly; PASI, Psoriasis Area and Severity Index.
For 18 of all the etanercept-treated subjects, a PASI beyond 24 weeks was available. 51 
Analysis of the effect of treatment interruption, after 24 weeks according to EMEA 
guidelines or due to other reasons, on PASI in this group showed that these patients 
encountered a mean increase in PASI of 2.97 (Standard Error of the Mean ±1.07) during 
interruption, with a mean increase of 0.65 per week (Figures 2 and 3). Currently, 12 of 
these subjects have reached a PASI 50 and 8 have achieved a PASI 75. The only subject 
in the efalizumab group, who was treated beyond 24 weeks, has currently achieved an 
improvement in PASI relative to baseline of 69.5%.
Despite a considerable reduction in the severity of disease in many patients, the effects 
of biological therapy were unsatisfactory several times. In these cases, concomitant use
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of other antipsoriatic therapies was necessary. In 91% of all etanercept-treated patients 
and 82% of all efalizumab-treated patients, topical corticosteroids or vitamin D analogues 
were used in addition to biological treatment. Other concomitant therapies included 
methotrexate, dithranol, acitretin and fumaric acid. Five subjects in the etanercept dosage 
schedule 1 cohort, one subject in the etanercept dosage schedule 2 cohort and one patient 
in the efalizumab cohort used one of these therapies.
F igure 2. E ffect o f e tanercept in te rrup tion  at week 24 in 18 sub jects.
PASI, Psoriasis Area and Severity Index.
Side effects
52 In general, etanercept and efalizumab treatment was well tolerated, and mainly mild 
adverse events were reported. The most common side effects reported (with an overall 
incidence of more than 20%) were upper respiratory infections, flu-like symptoms and 
gastrointestinal symptoms. No subjects were diagnosed with tuberculosis, although after 
the marker study period we discovered three patients with possible latent tuberculosis 
who had to be prophylactically treated with isoniazid. Malignancies were found in two 
subjects. One 48-year-old man was diagnosed with an oesophageal carcinoma, as well 
as with three squamous cell carcinomas and Bowen's disease during etanercept therapy. 
Another etanercept-treated patient developed a basal cell carcinoma and a squamous cell 
carcinoma. Both patients were treated with phototherapy in the past.
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Figure 3. Increase in PASI during  trea tm ent in te rrup tion  in 18 sub jects.
PASI, Psoriasis Area and Severity Index.
Infections were reported 38 times. These included upper and lower respiratory infections, 
skin infections, eye infections, urinary tract infections and oral infections. Eye infections 
were seen four times in the etanercept group and none in the efalizumab group (Table 3). 
Etanercept therapy was interrupted 12 times: seven times because of upper or lower 
respiratory infections, twice because of flu-like symptoms and three times due to an elective 
surgical procedure. Efalizumab treatment was only interrupted once, due to the scheduling 
of surgery. Five patients required hospital admission: once because of severe arthralgia in 
combination with a high increase in the C-reactive protein (CRP, 118 milligram/litre [mg/l]) 
value and four times through severe exacerbation of psoriasis. Exacerbations were seen 53 
after abrupt discontinuation of other systemic antipsoriatic treatments before the start of 
biological therapy, and consecutively a poor response on biological treatment; after the 
occurrence of infection during biological therapy, that caused discontinuation of biological 
therapy; or both. Four of the subjects, who needed admission to hospital, were treated with 
efalizumab at that time, including the patient with arthralgia.
Seven efalizumab-treated patients (41%) reported changes in the morphologic pattern 
of psoriasis since the start of treatment. Such morphologic changes did not occur in the 
etanercept cohort.
Routine laboratory monitoring did reveal leukocytosis (white blood cell count > 11 x 109/
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Table 3. Adverse  events.
S4
Etanercept 
Dosage 
schedule 1
Etanercept 
Dosage 
schedule 2
Efalizumab All
Infections, no. (%)
Upper respiratory infections 1S (46) 6 (SS) 2 (12) 21 (S4)
Lower respiratory infections 2 (7) 2 (12) 1 (6) S (B)
Skin infections O (O) 2 (12) 2 (12) 4 (6)
Eye infections2 O (O) 4 (24) O (O) 4 (6)
Urinary tract infections 1 (4) 2 (12) O (O) s (S)
Oral infections O (O) 1 (6) O (O) 1 (2)
(Pre)malignancies, no. (%)
Actinic keratosis 1 (4) 1 (6) 1 (6) s (S)
Squamous cell carcinoma 2 (7) O (O) O (O) 2 (S)
Bowen’s disease 1 (4) O (O) O (O) 1 (2)
Basal cell carcinoma 1 (4) O (O) O (O) 1 (2)
Oesophageal carcinoma 1 (4) O (O) O (O) 1 (2)
Skin reactions, no. (%)
Skin reactions0 6 (21) 4 (24) O (O) 1O (16)
Pruritus 2 (7) S (1B) 4 (24) 9 (1S)
Injection site reactions S (1B) 1 (6) 1 (6) 7 (11)
Oedema 1 (4) 1 (6) 1 (6) s (S)
Hair loss 1 (4) O (O) 1 (6) 2 (S)
Miscellaneous, no. (%)
Flu-like symptomsc S (1B) 4 (24) 6 (SS) 1S (24)
Gastrointestinal symptomsd S (1B) 4 (24) S (29) 14 (23)
Arthralgia S (11) 6 (SS) 2 (12) 11 (1B)
Headache 1 (4) 4 (24) 7 (41) 12 (19)
Otalgia 1 (4) 2 (12) O (O) s (S)
Eye irritation 1 (4) 1 (6) O (O) 2 (S)
Hypoglycaemias O (O) 1 (6) O (O) 1 (2)
Dyspnea O (O) O (O) 1 (6) 1 (2)
Epistaxis O (O) O (O) 1 (6) 1 (2)
Hospital admission O (O) 1 (6) 4 (24) S (B)
Any 2S (B2) 17 (1OO) 14 (B2) S4 (B7)
Dosage schedule 1, 50 mg SC twice weekly for 12 weeks, followed by 25 mg SC twice weekly; Dosage schedule 
2, 25 mg SC twice weekly. aSuch as blepharitis, conjunctivitis; bSuch as drug eruption, prurigo nodularis, 
photodermatosis, mollusca contagiosa, mycosis, urticaria, eczema, pseudofolliculitis barbae; cSuch as myalgia, 
fatigue, chills, sweating; dSuch as nausea, vomiting, diarrhea, abdominal pain, loss of appetite, rectal bleeding.
litre) in 2S patients at one or more moments during therapy. Twelve of these patients 
were in the etanercept cohort (27%) and 11 patients were in the efalizumab group (6S%).
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Fourteen times leukocytosis was combined with an increased CRP (CRP > 10 mg/l): six 
times in the etanercept group and eight times in the efalizumab group. However, only seven 
patients reported clinical signs of infection (etanercept: n = 4, efalizumab: n = 3), principally 
diagnosed as mild upper respiratory infections and skin infections. Thrombocytopenia was 
seen three times, one in every treatment group. No other notable changes in laboratory 
markers were found during therapy.
Current status
At the beginning of March 2006, 48 subjects were still on biological treatment, including 
three subjects who had temporarily discontinued therapy. Of the efalizumab cohort,
47% discontinued therapy because of lack of efficacy. On the contrary, only six subjects 
(13%) terminated etanercept treatment. One of these six subjects (i.e. the patient with the 
oesophageal carcinoma and squamous cell carcinomas) discontinued therapy because of 
these adverse events, diagnosed at week 44.
D iscussion
Our aim was to evaluate the efficacy, safety and adverse events of etanercept and 
efalizumab treatment in the outpatient clinic. Data were obtained from a one-year follow up 
of 62 patients. The cohort represented a high-need population, concerning the treatment 
of psoriasis.
A  total of 82% of the subjects in the etanercept dosage schedule 1 group and 71% of 
the subjects in the etanercept dosage schedule 2 group achieved a PASI 50 at week 
12; 39% and 24%, respectively, achieved a PASI 75 at this point. These efficacy data 
are comparable with the results of several clinical trials.4-6 During the next 12 weeks, the 
efficacy of etanercept treatment remained stable.
Efalizumab efficacy data were much less satisfying. A total of 59% of all subjects achieved 
a PASI 50, but only 6% achieved a PASI 75 at week 12. Furthermore, after 24 treatment 55 
weeks, eight of the 17 efalizumab-treated patients discontinued therapy because of lack 
of efficacy. In addition, four subjects in this cohort needed hospital admission during 
therapy. This is in contrast with efalizumab clinical trial data, which show significant PASI 
improvements in large numbers of patients. 3;7-10
It has to be kept in mind that these data are presumably influenced by the use of 
concomitant antipsoriatic therapies. More than 80% of all subjects needed concomitant use 
of topical steroids or vitamin D analogues, and in seven of all the subjects, the use of other 
systemic antipsoriatic treatments or dithranol was even necessary. It is an important goal 
to investigate further the effect of combining biologics with other antipsoriatic treatments.
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Combining etanercept with methotrexate has already been found to be more effective in 
the treatment of rheumatoid arthritis than etanercept monotherapy.11 
Abrupt cessation of other systemic antipsoriatic treatments before starting with biologics 
could possibly influence the efficacy of these drugs in a negative manner. Likewise, 
interruption of etanercept treatment after 24 weeks, as we did according to the EMEA 
label, appears to elicit a substantial fall in treatment benefits. Taking this into account, 
we recommend a gradual tapering of systemic antipsoriatic treatments before starting 
biological therapy, or partially overlapping biological therapy with conventional systemic 
therapies. In addition, continuing treatment after 24 weeks instead of interrupting therapy 
at that point would be of benefit to the patient.
Both etanercept and efalizumab were well tolerated. Fifty-four patients reported one or 
more side effects, but those were mainly mild. The most frequently reported side effects 
were upper respiratory infections, flu-like symptoms and gastrointestinal symptoms. Eye 
infections were only seen in the etanercept cohort, as well as eye irritation. Recently, 
Taban et al. accomplished a literature review about inflammatory eye disease associated 
with etanercept therapy, and found that ocular inflammation is a potential adverse event 
following the use of etanercept.12 Of significance as well are the nine subjects in the 
etanercept cohort reporting arthralgias. Only two of these subjects suffered from psoriatic 
arthritis. Physical examination of the other subjects by a rheumatologist did not reveal a 
significant arthritis.
Changes in the morphologic pattern of psoriasis since the start of treatment were reported 
by 41% of the efalizumab-treated patients. In some cases this meant the manifestation 
of psoriasis in regions that were not affected earlier; in other cases, the plaque-type 
psoriasis appeared to change in another type, such as guttate or pustular psoriasis. This 
phenomenon was also seen in other trials, although an incidence of 3.2% was mentioned.13 
As leukocytosis is often seen during treatment with efalizumab, it should not be used as 
56 an infection parameter. Therefore, to monitor infections, physicians should pay attention to 
the clinical symptoms of infection reported by patients. Furthermore, as latent tuberculosis 
was found three times in our cohort, we recommend performing tuberculosis screening in 
all patients who are candidates for biological therapy.
In conclusion, prospective cohort monitoring of patients with high-need psoriasis on 
systemic treatments, especially on biologics, is worthwhile. Information about treatment 
with these new drugs in daily clinical practice is important for adjusting treatment schedules 
and guidelines.
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CHAPTER 7 
Psoriasis treatment with etanercept and efalizumab: clinical 
strategies influencing treatment outcome
Abstract
Background: Multiple trials have been conducted in which the safety and efficacy of 
different biological therapies for psoriasis have been studied. However, the treatment 
course in clinical practice is different from the setting in which trials are conducted. 
Objectives: The evaluation of the efficacy, safety and adverse events of etanercept and 
efalizumab treatment in daily practice and the investigation of interfering clinical strategies 
that could be of influence on treatment outcome.
Methods: A prospective cohort consisting of 101 patients with high-need psoriasis was 
followed for two years and analysed. Patients were treated with etanercept or efalizumab 
between February 2005 and May 2007. Efficacy, safety and adverse events were 
investigated. Furthermore, all accompanying factors of which an influence on treatment 
efficacy outcome was suspected were registered, including treatment interruptions, 
dosage adjustments and combinations of therapies.
Results: Etanercept and efalizumab treatment was effective and safe in most patients. 
However, in many cases the treatment course was characterized by unsatisfactory 
efficacy (83%), necessitating combination therapies or dosage adjustments. Treatment 
interruptions occurred in 56% (etanercept 2x50 mg group), 84% (etanercept 2x25 mg 
group) and 10% (efalizumab-treated patients).
Conclusions: Treatment of patients with high-need psoriasis in daily practice is highly 
different from treatment courses in clinical trials. Frequently applied clinical strategies such 
58 as treatment interruptions, dosage adjustments and combinations of treatments influence 
treatment outcome in routine treatment in comparison with randomized controlled trials. 
Information about treatment with these new drugs in daily clinical practice is important for 
adjusting treatment schedules and guidelines.
Adapted from: Driessen RJ, Berends MA, Boezeman JB, van de Kerkhof PC and de Jong 
EM. Psoriasis treatment with etanercept and efalizumab: clinical strategies influencing 
treatment outcome. Br.J.Dermatol. 2008; 158: 1098-106.
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Introduction
In recent years, multiple trials have been conducted in which the safety and efficacy of 
different biological therapies for psoriasis have been studied. Examples of these therapies 
are etanercept, alefacept, efalizumab, infliximab and adalimumab. In Europe, etanercept, 
efalizumab, infliximab and adalimumab are currently approved for the treatment of 
moderate to severe plaque psoriasis. Etanercept and efalizumab are now routinely used 
in outpatient clinical practice. However, the treatment course in clinical practice is different 
from the setting in which trials are conducted. In clinical practice, the aim is to provide an 
optimal treatment for an individual patient. Dose adjustments, treatment interruptions or 
combinations with other antipsoriatic therapies are instrumental to reach this goal. Clinical 
practice, therefore, is principally different from the artificial situation of clinical trials with 
predefined inclusion, exclusion and discontinuation criteria.
From February 2005 (start of reimbursement) all patients with psoriasis who have been 
treated with biologics in the outpatient clinic were followed prospectively. The first analysis 
of the accompanying data was performed after one year. During this period, 62 patients 
were treated with either etanercept or efalizumab. In most cases, biological therapy 
was effective and safe, although the drop-out rate in the efalizumab-treated group was 
substantial (47%).1 After 2.5 years of therapy, a new data analysis of the extended cohort 
was performed. The number of patients treated with biologics increased up to 101.
In this report we describe the experience in treating a cohort of 101 patients with high-need 
psoriasis with etanercept and efalizumab in daily clinical practice during two years. The 
objective of this study is to report efficacy and safety data of etanercept and efalizumab 
in the context of real world practice. Special attention has been paid to frequently used 
clinical strategies to provide the best result for the individual patient, including treatment 
interruptions, dosage adjustments and combinations of therapies.
Patients and methods 59
Patients
Data were collected prospectively, using a standard form at each visit for all patients 
treated with etanercept or efalizumab between February 2005 and May 2007. Patients 
came into consideration for one of these treatments if they had failed to respond to 
phototherapy, methotrexate and ciclosporin in the past, or if they had a contraindication to, 
or were intolerant of, these treatments. At the same time, patients had to have a minimum 
Psoriasis Area and Severity Index (PASI)2 of 10 at the time of screening.
Charts and forms were reviewed for demographics and baseline characteristics, including
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age, sex, existence of psoriatic arthritis and other joint complaints, duration of psoriasis, 
baseline PASI, previous dermatological treatments and concomitant drugs.
Protocol
Before treatment, a chest X-ray and a Mantoux skin test were performed to exclude 
tuberculosis. Patients were treated with etanercept or efalizumab, depending on which 
therapy was most suitable for a patient according to the physician's opinion. For etanercept, 
two dosing regimens were used, either 50 milligram (mg) subcutaneously (SC) twice 
weekly for 12 weeks, followed by 25 mg SC twice weekly for 12 weeks (2x50 mg group), or 
25 mg SC twice weekly for 24 weeks (2x25 mg group). In the beginning of the etanercept 
treatment period, the etanercept label stated to initiate treatment with 25 mg twice weekly; 
later on, insights changed and most patients were initiated on 50 mg etanercept twice 
weekly for 12 weeks. After 24 weeks, patients interrupted etanercept treatment for an 
indefinite period according to the approved European Medicines Agency (EMEA) label. 
Therapy was resumed if needed. Efalizumab was given in a single conditioning dose of
0.7 milligram/kilogram (mg/kg) SC followed by 1.0 mg/kg weekly (up to a maximum single 
dose of 200 mg).
Contraindications for etanercept treatment were an active infection or increased 
susceptibility for infections (including immunocompromised persons), a history 
of tuberculosis, the existence of a demyelinating disease or pregnancy. Relative 
contraindications were the existence of cardiac decompensation, a blood dyscrasia, a 
recent malignancy, the presence of an antinuclear antibody (ANA) positive autoimmune 
disease or chronic exposure to actinic radiation in the past.
Contraindications for therapy with efalizumab were the presence of pustular, guttate or 
erythrodermic psoriasis during screening, a malignancy in the medical history (basal cell 
carcinomas (BCCs) excluded), active infection or increased susceptibility for infections 
60 (including immunocompromised persons), active tuberculosis and pregnancy. Relative 
contraindications were the existence of leucocytosis, lymphocytosis or thrombocytopenia 
or chronic exposure to actinic radiation in the past.
Patients were allowed to use topical dermatological therapies during biological treatment 
if desired. An effort was made to limit the use of concomitant systemic dermatological 
therapies in cases of unsatisfactory effectiveness of etanercept or efalizumab. Termination 
of other non-dermatological drugs was considered unnecessary.
Visits were scheduled every 4 weeks during the first 12 weeks, every 6 weeks until 
week 24 and every 12 weeks thereafter. At each visit, PASI and adverse events were 
documented. Laboratory tests were conducted, including haematological analysis, serum
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chemistry, urinalysis and ANA. After 12 weeks of therapy, the treatment protocol required 
an improvement in PASI of at least 50% for both etanercept- and efalizumab-treated 
patients. Patients who did not meet this criterion were excluded from therapy according to 
the reimbursement guidelines. In some of these cases, treatment with the other available 
biological agent was started thereafter. The administration of etanercept or efalizumab 
was discontinued if patients developed a serious infection; therapy was resumed after 
recovery.
Analysis
All patients treated with etanercept or efalizumab in the outpatient clinic were included 
for analysis. Descriptive statistics were used to reproduce study results as percentages, 
means and standard error of the mean (SEM).
Treatment efficacy was analysed by calculation of the PASI, the percentage improvement 
in PASI from baseline at different time points, and by the number of patients with an 
improvement in PASI relative to baseline of at least 50%, 75% or 90% (PASI 50, PASI 75 
and PASI 90, respectively). Population PASI scores were calculated for weeks 4, 8, 12,
18, 24 and every 12 weeks thereafter, until follow-up data for no fewer than three patients 
in each treatment group were available. Due to logistical reasons the individual visits were 
not always exactly at these fixed time points. If so, the interpolated PASI between most 
nearby visits was included in the analysis.
Measurement of treatment efficacy was done by means of an intention to treat (ITT) 
principle. Furthermore, those patients who responded satisfactorily and therefore could 
be treated for an unrestricted period of time were analysed separately. This analysis is 
designated as 'per protocol' (PP).
Accompanying factors, of which an influence on treatment efficacy outcome was suspected, 
including dose adjustments, concomitant medication and treatment interruptions, were 
considered. Reported adverse events and abnormal laboratory values were summarized. 61 
If patients received etanercept as well as efalizumab treatment, each biological therapy 
was analysed separately.
Results
Demographics
Over the past 27 months, 101 patients were treated with either etanercept or efalizumab.
Overall, 61% of patients were male, the mean age was 49.0 years and the mean duration of 
psoriasis was 21.3 years. Of all patients, 62 reported joint complaints, of which 28 suffered
PART II
from psoriatic arthritis. The mean PASI at baseline was 18.6. Age and sex distribution were 
comparable for each treatment. At baseline, joint complaints were more common in the 
etanercept-treated group than in the efalizumab-treated group. The duration of psoriasis 
was longest in the etanercept 2x25 mg group. Mean baseline PASI was highest for the 
etanercept 2x50 mg treated patients (Table 1).
Table 1. Baseline demographic data and disease characteristics.
Etanercept 
2x50 mg 
(n = 61)
Etanercept 
2x25 mg 
(n = 19)
Efalizumab  
(n = 21)
All
(n = 101)
Age, years
Range 21-72 28-69 27-71 21-72
Mean (±SEM) 48.2 (1.4) 51.5 (2.5) 48.9 (2.7) 49.0 (1.1)
Sex, no. (%)
Male 39 (64) 11 (58) 12 (57) 62 (61)
Female 22 (36) 8 (42) 9 (43) 39 (39)
Psoriasis, no (%)
With joint complaints 39 (64) 13 (68) 10 (48) 62 (61)
With psoriatic arthritis 20 (33) 3 (16) 5 (24) 28 (28)
Without joint complaints 22 (36) 6 (32) 11 (52) 39 (39)
Duration of psoriasis, years
Range 3-42 4-46 3-40 3-46
Mean (±SEM) 20.5 (1.2) 25.6 (2.8) 19.8 (2.4) 21.3 (1.0)
Baseline PASI
Mean (±SEM) 20.1 (1.3) 16.9 (1.4) 15.8 (1.3) 18.6 (0.9)
SEM, Standard Error of the Mean; PASI, Psoriasis Area and Severity Index.
Patients received 3-11 different categories of dermatological therapies before the start 
62 of biological treatment, with an average of 7.0 treatments per patient. The mean number 
of different systemic therapies that patients used before the start of biological treatment 
was 3.4, indicating a 'high-need'3 population. Some patients had used biological agents 
in the past, mostly in the context of clinical trials. These included etanercept, alefacept, 
efalizumab, infliximab and onercept (Table 2).
Eighty patients were treated with etanercept, of whom 61 received a dose of 50 mg SC 
twice weekly for 12 weeks, followed by 25 mg SC twice weekly for 12 weeks (2x50 mg 
group) and 19 received a dose of 25 mg SC twice weekly for 24 weeks (2x25 mg group). 
Twenty-one patients were treated with efalizumab.
Patients were treated for various periods. The overall mean duration of treatment was 58
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weeks, with a range of 6-107 weeks in the etanercept 2x50 mg group, 11-117 weeks in the 
etanercept 2x25 mg group and 6-88 weeks in the efalizumab-treated group.
Table 2. Previous treatments.
Etanercept 
2x50 mg 
(n = 61)
Etanercept 
2x25 mg 
(n = 19)
Efalizumab  
(n = 21)
All
(n = 101)
Topical, no. (%)
Corticosteroid/ Vitamin D analogue 61 (100) 19 (100) 21 (100) 101 (100)
Dithranol 45 (74) 15 (79) 17 (81) 77 (76)
Coal tar 14 (23) 7 (37) 4 (19) 25 (25)
Calcineurin inhibitor3 4 (7) 0 (0) 2 (10) 6 (6)
Light, no. (%)
UVB 53 (87) 17 (89) 16 (76) 86 (85)
PUVA 40 (66) 15 (79) 15 (71) 70 (69)
Systemic, no. (%)
Methotrexate 58 (95) 19 (100) 20 (95) 97 (96)
Ciclosporin 47 (77) 11 (58) 17 (81) 75 (74)
Retinoidsb 43 (70) 14 (74) 15 (71) 72 (71)
Fumaric acid 35 (57) 5 (26) 8 (38) 48 (48)
Etanercept 9 (15) 2 (11) 4 (19) 15 (15)
Alefacept 9 (15) 3 (16) 4 (19) 16 (16)
Onercept 4 (7) 2 (11) 1 (5) 7 (7)
Efalizumab 11 (18) 0 (0) 0 (0) 11 (11)
Infliximab 2 (3) 0 (0) 1 (5) 3 (3)
aTacrolimus, pimecrolimus; bAcitretin, bexarotene, liarozole. UVB, Ultraviolet B; PUVA, Psoralen-Ultraviolet A.
Efficacy
Forty patients (66%) in the etanercept 2x50 mg group, 13 patients (68%) in the etanercept 63 
2x25 mg group and 12 patients (57%) in the efalizumab group achieved a 50% PASI 
reduction at week 12. At the same time, respectively, 20%, 21% and 10% achieved a PASI 
75, and 8%, 5% and 0% achieved a PASI 90 (Figure 1).
The response on etanercept treatment as well as efalizumab treatment levelled out after 
approximately 24 weeks. At that time point, the mean PASI reduction was 59% (SEM
5.0) in the etanercept 2x50 mg group, 60% (SEM 8.4) in the etanercept 2x25 mg group 
and 51% (SEM 8.8) in the efalizumab group, according to the ITT analysis (Figure 2). PP 
analysis shows a mean reduction in PASI of 59% (SEM 5.3), 58% (SEM 8.9) and 58%
(SEM 5.9), respectively, at week 24 (Figure 3).
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Figure 1. Efficacy results after 12 weeks of biological therapy.
PASI 50 PASI 75 PASI 90
PASI, Psoriasis Area and Severity Index; PASI 50, 50% reduction in PASI relative to baseline; PASI 75, 75% 
reduction in PASI relative to baseline; PASI 90, 90% reduction in PASI relative to baseline.
At the beginning of May 2007, 71 patients were still on biological treatment. Of the 
efalizumab cohort, 62% discontinued therapy because of lack of efficacy, adverse events 
or both. On the contrary, 17 patients (21%) have terminated etanercept treatment (Table 
3).
Table 3. Current therapy status.
Etanercept Etanercept Efalizumab All
64 2x50 mg 2x25 mg (n = 21) (n = 1 0 1 )
(n = 61) (n = 19)
Current therapy status, no. (%)
Discontinued due to lack of efficacy 4 (7) 1 (5) 6 (29) 11 (11)
Discontinued due to adverse events 3 (5) 1 (5) 1 (5) 5 (5)
Discontinued due to lack of efficacy and 
adverse events 2 (3) 4 (21) 6 (29) 12 (12)
Dead 2 (3) 0 (0) 0 (0) 2 (2)
Discontinued treatment (total) 11 (18) 6 (32) 13 (62) 30 (30)
Continued treatment 50 (82) 13 (68) 8 (38) 71 (70)
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Figure 2. Treatment efficacy, intention to treat (ITT).
80
Duration of treatment (weeks)
PASI, Psoriasis Area and Severity Index.
Figure 3. Treatment efficacy, per protocol (PP).
PASI, Psoriasis Area and Severity Index.
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Response-modifying strategies
Despite a considerable reduction in the severity of disease in many patients, biological 
therapy did not induce an improvement that was entirely satisfactorily in 84 (83%) of 
all patients. In these cases, concomitant antipsoriatic therapies were started or therapy 
dose was increased temporarily. In 81% of all etanercept-treated patients and 71% of all 
efalizumab-treated patients, topical corticosteroids or vitamin D analogues were used in 
addition to biological treatment. Other concomitant therapies included coal tar, dithranol, 
tacrolimus, methotrexate, ciclosporin, acitretin, prednisone, fumaric acid and mycofenolate 
mofetil (Table 4).
Table 4. Concomitant medication.
Etanercept 
2x50 mg 
(n = 61)
Etanercept 
2x25 mg 
(n = 19)
Efalizumab  
(n = 21)
All
(n = 1 0 1 )
Topical, no. (%)
Corticosteroid/ Vitamin D analogue 49 (80) 16 (84) 15 (71) 80 (79)
Coal tar 5 (8) 3 (16) 4 (19) 12 (12)
Dithranol 3 (5) 2 (11) 1 (5) 6 (6)
Tacrolimus 5 (8) 0 (0) 0 (0) 5 (5)
Systemic, no. (%)
Methotrexate 12 (20) 0 (0) 2 (10) 14 (14)
Ciclosporin 5 (8) 0 (0) 1 (5) 6 (6)
Acitretin 4 (7) 1 (5) 2 (10) 7 (7)
Prednisone 2 (3) 0 (0) 0 (0) 2 (2)
Fumaric acid 1 (2) 0 (0) 0 (0) 1 (1)
Mycofenolate mofetil 1 (2) 0 (0) 0 (0) 1 (1)
Tacrolimus 1 (2) 0 (0) 0 (0) 1 (1)
66 In 11 patients systemic therapies were introduced after the start of biological therapy, 
if biological monotherapy was insufficient. Seventeen patients were already using 
systemic therapies before biological therapy was started, and in 10 of these cases these 
pharmaceuticals were tapered during biological therapy. Patients who used concomitant 
systemic antipsoriatic treatments did not generally present better efficacy results compared 
with the group that did not use concomitant systemic therapies (Figure 4).
In 24 of all etanercept-treated patients who had an unsatisfactory response on therapy, the 
weekly dose was increased to 2x50 mg for varying periods, mostly 2-4 weeks. Patients 
who used higher dosages of etanercept during their treatment period achieved the same 
ultimate PASI reduction but at a higher cumulative dose of etanercept (Figure 5).
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Figure 4. Influence of concomitant systemic therapy on biological treatment efficacy.
PASI, Psoriasis Area and Severity Index.
Figure 5. Influence o f dose increase on etanercept treatment efficacy.
67
PASI, Psoriasis Area and Severity Index.
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Treatment interruptions occurred in 34 (56%) of the etanercept 2x50 mg treated patients, 
16 (84%) of the etanercept 2x25 mg treated patients and two (10%) of the efalizumab- 
treated patients. Etanercept was interrupted predominantly because of adherence to the 
EMEA label at week 24. Other reasons for treatment interruption were adverse events, 
such as infections, problems with distribution of medication or patients' decisions (Table 5). 
For 27 of all etanercept-treated patients, data about the effect of treatment interruption 
after 24 weeks of conforming to EMEA guidelines were available. Analysis of these data 
demonstrated that 19 of these patients encountered an increase in PASI during interruption, 
with a mean PASI increase of 4.0 per patient. The mean duration of interruption was 25 
days (range 3-92 days) (Figure 6).
Table 5. Response-modifying strategies.
Etanercept 
2x50 mg 
(n = 61)
Etanercept 
2x25 mg 
(n = 19)
Efalizumab  
(n = 21)
All
(n = 1 0 1 )
Accompanying factors, no. (%)
Dose increase 21 (34) 3 (16) 0 (0) 24 (24)
Concomitant medication
Topical 49 (80) 17 (89) 15 (71) 81 (80)
Systemic 23 (38) 1 (5) 5 (24) 29 (29)
Treatment interruption
All 34 (56) 16 (84) 2 (10) 52 (51)
More than 2 weeks cumulative 20 (33) 15 (79) 1 (5) 36 (36)
More than 2 weeks consecutive 17 (28) 13 (68) 0 (0) 30 (30)
Adverse events
In general, etanercept and efalizumab treatment was well tolerated, and mainly mild 
adverse events were reported. The most reported adverse events (with an overall incidence
68 of more than 20%) were upper respiratory infections, pruritus, arthralgia, gastrointestinal 
complaints and flu-like symptoms (Table 6).
Infections
Infections were reported 77 times. These included upper and lower respiratory infections, 
skin infections, eye infections, urinary tract infections, gastrointestinal infections and oral 
infections. No patients were diagnosed with tuberculosis during treatment, although, after 
the marker study period, we discovered 4 patients with possible latent tuberculosis who 
had to be treated prophylactically with isoniazid.
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Figure 6. Influence o f etanercept interruption at week 24.
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PASI, Psoriasis Area and Severity Index.
Malignancies
Malignancies were found in 4 etanercept-treated patients. A 48-year-old man was diagnosed 
with an oesophageal carcinoma, as well as with three squamous cell carcinomas (SCCs) 
and Bowen’s disease during etanercept therapy. Another patient developed a BCC as well 
as a SCC. In the other two patients BCCs were diagnosed. All skin malignancies were 
noticed after less than half a year of biological treatment. The patients in question had 
been treated extensively with phototherapy in the past. Furthermore, a female patient had 
to discontinue etanercept treatment because of a cervix carcinoma in situ. No malignancies 
were found in the efalizumab-treated group.
Serious adverse events
Eleven patients required hospital admission during treatment. In 8 of these patients (5 
treated with etanercept and three treated with efalizumab) their psoriasis was aggravated 
and an intensifying of therapy was needed. Psoriasis aggravation was seen after abrupt 
discontinuation of other systemic antipsoriatic treatments before the start of biological 
therapy, and consecutively a poor response on biological treatment; after the occurrence 
of infection during biological therapy, which caused discontinuation of biological therapy; 
or both. One etanercept-treated patient was admitted with pneumonia. Two other admitted
69
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Table 6. Adverse events.
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Etanercept 
2x50 mg 
(n = 61)
Etanercept 
2x25 mg 
(n = 19)
Efalizumab  
(n = 21)
All
(n = 1 0 1 )
Infections, no. (%)
Upper respiratory infections 27 (44) 12 (63) 4 (19) 43 (43)
Skin infections 4 (7) 3 (16) 3 (14) 10 (10)
Lower respiratory infections 3 (5) 2 (11) 1 (5) 6 (6)
Eye infections 1 (2) 4 (21) 1 (5) 6 (6)
Urinary tract infections 2 (3) 3 (16) 0 (0) 5 (5)
Gastrointestinal infections 1 (2) 0 (0) 3 (14) 4 (4)
Oral infections 1 (2) 1 (5) 1 (5) 3 (3)
(Pre)malignancies, no. (%)
Actinic keratosis 2 (3) 1 (5) 2 (10) 5 (5)
Basal cell carcinoma 2 (3) 1 (5) 0 (0) 3 (3)
Squamous cell carcinoma 2 (3) 0 (0) 0 (0) 2 (2)
Bowen’s disease 1 (2) 0 (0) 0 (0) 1 (1)
Esophageal carcinoma 1 (2) 0 (0) 0 (0) 1 (1)
Cervix carcinoma in situ 1 (2) 0 (0) 0 (0) 1 (1)
Skin reactions, no. (%)
Pruritus 12 (20) 8 (42) 7 (33) 27 (27)
Injection site reactions 10 (16) 1 (5) 1 (5) 12 (12)
Oedema 1 (2) 5 (26) 3 (14) 9 (9)
Hair loss 1 (2) 2 (11) 2 (10) 5 (5)
Other 8 (13) 6 (32) 2 (10) 16 (16)
Muscle and joint complaints, no. (%)
Arthralgia 10 (16) 7 (37) 3 (14) 20 (20)
Pain 6 (10) 4 (21) 2 (10) 12 (12)
Muscular pain 2 (3) 1 (5) 3 (14) 6 (6)
Enthesitis 2 (3) 0 (0) 0 (0) 2 (2)
Arthritis 0 (0) 0 (0) 1 (5) 1 (1)
Bursitis 1 (2) 0 (0) 0 (0) 1 (1)
Enthesopathy 0 (0) 1 (5) 0 (0) 1 (1)
Miscellaneous, no. (%)
Flu-like symptoms 15 (25) 7 (37) 6 (29) 28 (28)
Gastrointestinal complaints 13 (21) 5 (26) 5 (24) 23 (23)
Headache 5 (8) 4 (21) 10 (48) 19 (19)
Fatigue 9 (15) 4 (21) 2 (10) 15 (15)
Coughing 5 (8) 2 (11) 3 (14) 10 (10)
Eye complaints 3 (5) 5 (26) 2 (10) 10 (10)
Dead 2 (3) 0 (0) 0 (0) 2 (2)
Any 55 (90) 19 (100) 20 (95) 94 (93)
Represented are numbers and percentages of patients having at least one 
category.
adverse event in a predefined
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patients suffered from severe joint complaints; both were being treated with efalizumab at 
that moment.
Two female patients of our cohort died of sudden cardiac arrest during etanercept 
treatment. One had a history of hypertension and stroke; the other suffered from chronic 
obstructive pulmonary disease.
Dermatological adverse events
Dermatological adverse events are represented in Table 7. Pruritus, injection site reactions 
and skin infections (including erysipelas, mycosis, folliculitis, herpes zoster and wound 
infections) were reported most frequently.
Miscellaneous
Two patients reported vision impairment during etanercept treatment. Because optic 
neuritis was suspected, etanercept therapy was discontinued and patients were referred 
to an ophthalmologist or neurologist. In neither patient could the diagnosis be confirmed.
Besides vision impairment, other eye complaints were common. These included eye 
infections, such as chalazion and conjunctivitis, and other complaints, such as dryness, 
redness and irritation of the eyeball (Table 6).
Laboratory abnormalities
Routine laboratory monitoring revealed a newly developed leucocytosis (white blood cell 
count > 11x109/litre [l]) in 12 patients (15%) on etanercept therapy and 19 patients (90%) 
on efalizumab therapy. In these cases, a concurrent increase in C-reactive protein was 
monitored in three and 10 patients, respectively. A significant leucopenia (white blood cell 
count < 4x109/l) was found in one etanercept-treated patient. Three efalizumab-treated 
patients (14%) and 8 etanercept-treated patients (10%) developed a thrombocytopenia 
(platelet count < 150x109/l). In 18 (23%) patients on etanercept and 5 (24%) patients on 71 
efalizumab, alanine amino transferase values increased above 45 units/litre (U/l) during 
treatment. Other laboratory changes were pre-existent or were considered clinically 
insignificant.
Discussion
The aim of the present prospective cohort study was to evaluate the efficacy, safety and 
adverse events of etanercept and efalizumab treatment in the outpatient clinic and to 
investigate accompanying factors that influenced treatment outcome. We present data 
from a 27-month follow-up of 101 patients treated with etanercept or efalizumab.
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Table 7. Dermatological adverse events.
Etanercept 
2x50 mg 
(n = 61)
Etanercept 
2x25 mg 
(n = 19)
Efalizumab  
(n = 21)
All
(n = 1 0 1 )
Dermatological conditions, no (%)
Pruritus 12 (20) 8 (42) 7 (SS) 27 (27)
Injection site reactions 10 (16) 1 (5) 1 (5) 12 (12)
Skin infections 4 (7) S (16) S (14) 10 (10)
Oedema 1 (2) 5 (26) S (14) 9 (9)
Hair loss 1 (2) 2 (11) 2 (10) 5 (5)
Actinic keratosis 2 (S) 1 (5) 2 (10) 5 (5)
Basal cell carcinoma 2 (S) 1 (5) 0 (0) S (S)
Morphological changes in psoriasis 2 (S) 0 (0) 1 (5) S (S)
Drug eruption 0 (0) 1 (5) 1 (5) 2 (2)
Urticaria 1 (2) 1 (5) 0 (0) 2 (2)
Squamous cell carcinoma 2 (S) 0 (0) 0 (0) 2 (2)
Bowen’s disease 1 (2) 0 (0) 0 (0) 1 (1)
Black hairy tongue 1 (2) 0 (0) 0 (0) 1 (1)
Eczema 1 (2) 0 (0) 0 (0) 1 (1)
Photodermatosis 0 (0) 1 (5) 0 (0) 1 (1)
Itchy dermatitis 0 (0) 1 (5) 0 (0) 1 (1)
Perineurioma 0 (0) 1 (5) 0 (0) 1 (1)
Papillomatous lesion 1 (2) 0 (0) 0 (0) 1 (1)
Prurigo 0 (0) 1 (5) 0 (0) 1 (1)
Grover’s disease 1 (2) 0 (0) 0 (0) 1 (1)
Leg ulcer 1 (2) 0 (0) 0 (0) 1 (1)
The cohort represented a high-need population: only patients with a PASI of at least 10 who 
did not respond sufficiently to phototherapy, methotrexate and ciclosporin were included. 
Safety and efficacy of biologics in randomized controlled trials (RCTs) and initial experiences 
with biologics in clinical practice are described in literature.S-15 RCTs in which etanercept 
and efalizumab were investigated show a mean PASI reduction between approximately 
50% and 60% at week 12. In the present study, comparable efficacy results are found for 
etanercept-treated patients. In the efalizumab-treated group, efficacy results for week 12 
are lower. Moreover, PASI 75 and PASI 90 responses are less high than RCT data for both 
etanercept- and efalizumab-treated patients.S;5-10;12;14;15 A few explanations for this can be 
given.
Firstly, the present population differs from study populations used in RCTs in many respects. 
The cohort is composed only of patients who were not responsive or contraindicated to 
three systemic therapies. Secondly, it may be the fact that a certain number of the patients
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making the transition from conventional therapy to biological treatment without washout do 
not have a representative baseline PASI, and that they are starting from a point of partial 
response. Thirdly, the individualized approach of permitting combination treatments and 
dose adjustments makes comparison with RCTs difficult. Furthermore, data about patients 
with extremely poor response on therapy have great impact on all (ITT) efficacy results. 
Nevertheless, it is possible that there actually is a discrepancy between efficacy of biologics 
in real life practice versus RCTs. Additional reasons for this could be non-compliance or 
inadequate use of medication.
According to the represented efficacy data, it may be concluded that the higher dose 
of etanercept is equally or less effective than etanercept 25 mg twice weekly. However, 
based on practical clinical experience, this seems not to be the case. Several explanations 
for the lower efficacy results for the 2x50 mg etanercept group can be given. First of all, 
mean baseline PASI was highest for the etanercept 2x50 mg group (Table 1), reflecting a 
severely affected subgroup. Secondly, patients initially treated with 2x50 mg etanercept 
used more different types of antipsoriatic therapies in history (Table 2), reflecting a 
degree of therapy resistance. Furthermore, the mean follow-up period was longer for the 
etanercept 2x25 mg group than for the 2x50 mg group. This may imply that some 2x50 
mg treated patients require treatment for a longer time to achieve the maximum response 
on therapy.
The response on biological treatment in this cohort showed a maximum effect after
approximately 6 months. For this reason we believe that efficacy in daily practice can best
be analysed after half a year, in contrast to the current guidelines of reimbursement, for
which an analysis after 12 weeks is demanded. A study by Krueger et al. demonstrated
that patients with psoriasis who initially had an incomplete response or did not respond
to etanercept treatment in RCTs had meaningful improvement with continued treatment.16
The etanercept dose was increased temporarily in 24 of 80 cases. This indicates that the
use of 2x25 mg weekly may not be sufficient throughout the whole treatment period for a 73
high-need psoriasis cohort. No influence of these dosage adjustments was seen on safety
parameters.
Interruption of etanercept treatment after 24 weeks, as carried out according to the EMEA 
label, appears to elicit a substantial fall in treatment benefits. Taking this into account, 
continuing treatment after 24 weeks instead of interrupting therapy at that point would be 
of benefit to the patient.
In routine practice, combination treatment may imply a classical drug to which a biologic 
is added subsequently, or the reverse: a biologic with subsequent combination with a 
classical drug. Further studies on various combination schedules are indicated. In this
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study, a combination of therapies did not lead to increased toxicity or altered safety profiles 
during the time they were applied.
Both etanercept and efalizumab were well tolerated. Ninety-four patients reported one 
or more adverse events, but those were mainly mild. Two female patients died of a 
sudden cardiac arrest during the treatment follow-up period, but this was presumably 
not related to the use of etanercept, according to the opinion of the general practitioner. 
Common adverse events were upper respiratory infections, pruritus, joint complaints, 
gastrointestinal complaints and flu-like symptoms. Thirty-seven patients reported muscle 
and joint complaints: 30 of these patients already had such complaints before biological 
treatment was started.
As optic neuritis is a potential serious side effect of etanercept, special attention needs to 
be paid to all patients with vision impairment.17 In our patients with complaints of reduced 
vision, no signs of demyelinating disease were found. Apart from vision impairment, other 
eye complaints occurred in our cohort as well. Taban et al. undertook a literature review 
about inflammatory eye disease associated with etanercept therapy, and found that ocular 
inflammation is a potential adverse event following the use of etanercept.18 
Skin malignancies were seen in low frequencies in this cohort. All were recorded in the first 
6 months of treatment with biologics. Therefore, it is more likely that these malignancies 
are caused by previous antipsoriatic therapies such as ciclosporin and phototherapy than 
biologics. To reduce actinic overexposure, the eligibility criteria for use of biologics should 
state a failure to respond to either phototherapy or ciclosporin.
In conclusion, prospective cohort monitoring of patients with high-need psoriasis on 
systemic treatments, especially on biologics, is worthwhile. The course of treatment in 
general practice is highly different from treatment schedules in clinical trials, and it is worth 
noting that clinical trials on selected healthy individuals lack external validity in some cases. 
Frequently applied clinical strategies such as treatment interruptions due to concomitant 
74 illnesses or protocol definitions, dosage adjustments and combination of treatments 
influence treatment outcome in routine treatment in comparison with RCT research data. 
Therefore, information about treatment with these new drugs in daily clinical practice is 
important for adjusting treatment schedules and guidelines.
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CHAPTER 8 
Three-year registry data on biological treatment for psoriasis: the 
influence of patient characteristics on treatment outcome
Abstract
Background: The course of biological treatment in clinical practice may be highly 
different from treatment schedules in clinical trials. Treatment modifications and patient 
characteristics may influence treatment safety and efficacy. So far, long-term results from 
the use of biological treatment in clinical practice are lacking.
Objectives: To report short- and long-term efficacy and safety data on biologics, especially 
etanercept, used in daily clinical practice. Special attention has been paid to patient 
characteristics that may have influenced the response to therapy.
Methods: Prospectively collected registry data of all patients with psoriasis treated with 
biologics in the Radboud University Nijmegen Medical Centre Department of Dermatology 
outpatient clinic were used for analysis. Patient and treatment characteristics were 
surveyed. Efficacy and safety of etanercept for up to three years were analysed. Moreover, 
the influence of patient characteristics on etanercept treatment response was studied.
Results: The analysed cohort, consisting of 118 patients, went through 142 treatment 
episodes in total. Patients treated with biologics had an extensive medical history. 
Optimization of biological treatment was established in various ways, including treatment 
switches and introduction of concomitant therapies. Short-term etanercept efficacy 
analysis showed a mean Psoriasis Area and Severity Index (PASI) improvement at week 
24 of 59.7%. No significant influence of gender, age, baseline PASI, body mass index, 
number of previous systemic therapies or duration of psoriasis was found on week 24 
efficacy results, although trends were discernible. The efficacy of etanercept remained 77 
stable for up to 156 weeks. Long-term daily practice treatment with etanercept was only 
occasionally accompanied by major safety concerns.
Conclusions: The current study demonstrates that etanercept is able to improve psoriasis 
symptoms for a considerable time, and that serious side effects are infrequent. The 
influence of patient characteristics on treatment response is limited.
Adapted from: Driessen RJ, Boezeman JB, van de Kerkhof PC and de Jong EM. Three-year 
registry data on biological treatment for psoriasis: the influence of patient characteristics 
on treatment outcome. Br.J.Dermatol. 2009; 160: 670-5.
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Introduction
The safety and efficacy of biological treatments for psoriasis have been thoroughly studied 
in well designed clinical trials. Results of these trials founded the approval of four different 
biologics for psoriasis by the European Union: etanercept, efalizumab, infliximab and 
adalimumab. Now that biological therapies are accepted as a regular therapeutic option 
for psoriasis, knowledge about the use of these therapies in daily practice is growing. This 
has given rise to the compilation of new guidelines for the management of psoriasis.1-5 
Recently, we performed a study in which the experience in treating a cohort of 101 patients 
with high-need psoriasis with etanercept and efalizumab in daily clinical practice during 
two years was described. In that study, we focused on different biological therapies, 
including treatment modifications which were suspected to influence treatment efficacy 
outcome. The course of biological treatment in general practice proved highly different 
from treatment schedules in clinical trials.6
In addition to treatment modifications induced by physicians, patient characteristics may 
also influence treatment safety and efficacy. Clinical trials make use of predefined inclusion, 
exclusion and discontinuation criteria, which leads to the selection of specific, in general 
'healthy', patient categories. In clinical practice, however, an attempt is made to provide 
an optimal treatment for each individual patient, even though many have comorbidities, 
co-medication and an extensive psoriasis treatment history.
In the current report we describe the experience in treating a cohort of 118 patients with high­
need psoriasis with biologics in daily clinical practice for up to three years. The objective of 
this study is to report short- and long-term efficacy and safety data on biologics, especially 
etanercept, in the context of real-world practice. Data are analysed from the perspective 
of individual patients. Special attention has been paid to patient characteristics that may 
have influenced the response to therapy.
78 Patients and methods
Patients
Data were extracted from a prospective observational cohort registry, including all patients 
with psoriasis treated with biologics between February 2005 and May 2008. Patients came 
into consideration for biological treatment if they had failed to respond to phototherapy, 
methotrexate and ciclosporin in the past, or if they had a contraindication to, or were 
intolerant of these treatments. At the same time, patients had to have a minimum Psoriasis 
Area and Severity Index (PASI)7 of 10 at the time of screening.
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Protocol
Before treatment, a chest X-ray and a purified protein derivative skin test were performed 
to exclude tuberculosis. A general blood screening, including haematological analysis, 
serum chemistry and antinuclear antibodies (ANA), was performed in each patient.
Patients were treated with a biologic that was most suitable in the physician's opinion.
As etanercept and efalizumab have been approved and reimbursed since the start of 
2005, and consequently most experience is gained with these therapies, these drugs were 
preferred as initial treatment. Infliximab was used for patients with very severe psoriasis, 
who were unresponsive to etanercept or efalizumab. Adalimumab was approved, but not 
reimbursed, in December 2007. Therefore, adalimumab has been prescribed only in a few 
cases up until now.
Absolute contraindications for biological treatment were a known hypersensitivity to the 
constituents of the drug to be prescribed, an active infection or increased susceptibility 
for infections (including immunocompromised persons), a history of tuberculosis, 
and pregnancy. Furthermore, antitumor necrosis factor-a therapies (etanercept, 
infliximab, adalimumab) were contraindicated in patients with a demyelinating disease. 
Contraindications specific for therapy with efalizumab were the presence of pustular, 
guttate or erythrodermic psoriasis during screening and a history of malignancy (basal 
cell carcinomas excluded). Relative contraindications for biological treatment were 
cardiac decompensation, a blood dyscrasia, a recent history of malignancy (absolute 
contraindication for efalizumab), the presence of ANA-positive autoimmune disease or 
chronic exposure to actinic radiation in the past.
Patients were allowed to use topical dermatological therapies during biological treatment 
if desired. An effort was made to limit the use of concomitant systemic dermatological 
therapies in cases of unsatisfactory effectiveness of biological treatment. Termination of 
other non-dermatological drugs was considered unnecessary.
Ideally, visits were scheduled every 4 weeks during the first 12 weeks, every 6 weeks 79 
until week 24 and every 12 weeks thereafter. Each visit, PASI and adverse events were 
documented. After 12 weeks of therapy (or 8 weeks for infliximab), the treatment protocol 
required an improvement in PASI of at least 50% for all treated patients. Patients who 
did not meet this criterion were excluded from therapy according to the reimbursement 
guidelines. In some of these cases, treatment with another available biological agent was 
started thereafter. The administration of a biologic was discontinued if patients developed 
a serious infection; therapy was restarted after recovery.
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Analysis
All patients with psoriasis treated with biologics in the Radboud University Nijmegen 
Medical Centre Department of Dermatology outpatient clinic were included for analysis. 
Descriptive statistics were used to reproduce study results as percentages and mean ± 
standard error of the mean (SEM).
Patient characteristics were surveyed, including age, gender, duration of psoriasis, PASI at 
first screening, duration of follow-up, number of biological treatment episodes and therapy 
status at analysis. General medical history was categorized by organ system or, in cases 
of high prevalence, by disease. Treatment characteristics, including nature of treatment, 
number of different treatment episodes, duration of treatment episodes and concomitant 
or intervening systemic therapies were outlined. The number of patients actively treated 
with biologics and the number of dropouts were counted.
As most patients of the current cohort were treated with etanercept, and most short- 
and long-term data were available from this group, efficacy analysis in this study was 
performed for etanercept-treated patients only. In the previous article, a maximal treatment 
response was observed after 24 weeks of therapy. Therefore, to study short-term efficacy 
of etanercept and the influence of patient characteristics on treatment response, only 
etanercept-treated patients of whom efficacy data of at least 24 weeks were available 
were included for analysis. Patients were stratified by gender, age, baseline PASI, body 
mass index (BMI), number of previous systemic therapies and duration of psoriasis. Mean 
percentage PASI improvement at week 24 was calculated for the entire group as well as 
for subgroups by means of interpolation. The number of patients with an improvement 
in PASI relative to baseline of at least 50%, 75% or 90% (PASI 50, PASI 75 and PASI 
90, respectively) at week 24 was counted. To demonstrate the magnitude of differences 
between subgroups, an independent samples t-test was performed using SPSS 14.0.2 for 
windows (SPSS Inc., Chicago, IL, U.S.A.). All tests are two-tailed. P < 0.05 was considered 
80 statistically significant.
Long-term treatment efficacy was analysed by calculation of the absolute decrease in 
PASI. In this analysis, only patients treated with etanercept for at least 72 weeks were 
included. Mean weekly etanercept dosage was reflected. Mean population PASI values 
were calculated by interpolation of data, considering week 4, 8, 12, 18, 24 and every 12 
weeks thereafter as fixed time points. Interpolation was performed until data about no 
fewer than 6 patients were available.
Adverse events of all patients treated with biologics were outlined. Represented were 
numbers of patients having at least one adverse event in a predefined category. Serious 
adverse events were defined as malignancies or adverse events that were immediately
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life threatening, caused persistent disability, required hospital admission, or resulted in a 
patient's death.
Results
Patient characteristics
Between February 2005 and May 2008, 118 patients were treated with a biologic for at 
least one consecutive period. Mean ± SEM age of patients was 47.3 ± 1.0 years. Sixty-four 
percent of patients were male. Patients had had psoriasis for a mean ± SEM of 22.4 ± 0.9 
years. Mean ± SEM PASI at first screening was 17.5 ± 0.8. Mean ± SEM duration of patient 
follow up in the registry was 1.7 ± 0.1 years. Fifteen percent of all patients were treated 
with more than one biologic.
At analysis in May 2008, 88 (75%) of all patients were still on biological therapy. The 
remaining 25% were lost to follow up, had discontinued therapy due to adverse events, 
lack of efficacy or desire to become pregnant, or had died (Table 1).
Table 1. Patient characteristics.
Patient characteristics n = 118
Agea (years), mean ± SEM 47.3 ± 1.0
Gender, no. (%)
Male 76 (64)
Female 42 (36)
Duration of psoriasis3 (years), mean ± SEM 22.4 ± 0.9
PASIa, mean ± SEM 17.5 ± 0.8
Follow-up duration (years), mean ± SEM 1.7 ± 0.1
Biological treatment episodes, no. (%)
One 100 (85)
Two 14 (12)
More than two 4 (3)
Therapy status at analysis, no. (%)
Active 88 (75)
Lost to follow up 11 (9)
Discontinued due to AE and lack of efficacy 6 (5)
Discontinued due to AE 5 (4)
Discontinued due to lack of efficacy 5 (4)
Death 2 (2)
Discontinued due to desire to become pregnant 1 (1)
aAt first screening. SEM, Standard Error of the Mean; PASI, Psoriasis Area 
and Severity Index; AE, Adverse Event.
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Patients treated with biologics had an extensive medical history. More than 40% of all 
patients had undergone surgery for different reasons. A great proportion of patients had an 
unfavourable cardiovascular risk profile, considering the high prevalence of hypertension 
(36%), hyperlipidaemia (19%), diabetes (14%) and cardiological disease (14%). In 
addition, mean BMI was 28.8 kilograms/meters squared (kg/m2), and 44 (37%) patients 
were obese (defined as BMI > 30 kg/m2).
Treatment characteristics
The analysed cohort, consisting of 118 patients, went through a total of 142 treatment 
episodes. Mean ± SEM duration of a treatment episode was 1.8 ± 0.1 years. Eighty 
percent of patients were treated with etanercept only. Additionally, 9 patients were initially 
treated with efalizumab, but switched to etanercept later on. Another 10 patients were 
treated with efalizumab as well, of whom 4 were treated with etanercept before, and one 
was treated with infliximab thereafter. Four other patients went through more than two 
biological treatment episodes. One patient was initially treated with etanercept, followed 
by efalizumab, but due to lack of efficacy of both treatments infliximab was initiated. 
Another patient was treated with, respectively, etanercept and efalizumab as well, but 
preferred retreatment with etanercept. Likewise, one patient was treated with efalizumab, 
etanercept and retreated with efalizumab thereafter. A patient with very severe, therapy- 
resistant psoriasis underwent 5 different treatment episodes, including infliximab, 
efalizumab, etanercept, infliximab and adalimumab, respectively (Table 2).
Concomitant or intervening systemic therapies were introduced or maintained in 30 
patients. These comprised methotrexate (n = 17), ciclosporin (n = 9), acitretin (n = 9), 
fumaric acid (n = 2), mycophenolate mofetil (n = 1), tacrolimus (n = 1), ultraviolet (UV) B 
(n = 1) and Psoralen-UVA (PUVA) (n = 1). Concomitant therapies were used to prevent 
patients from rebound or to improve treatment efficacy. Although unconventional, PUVA 
82 was used in a patient during a 10-month interruption period of infliximab. UVB was used to 
bridge a transition period from efalizumab to etanercept in another patient.
Short-term efficacy of etanercept and the influence of patient characteristics on treatment 
response
To evaluate the influence of patient characteristics on etanercept treatment response, 90 
(81%) patients with available week 24 efficacy data were included for analysis. Mean 
PASI improvement at week 24 was 59.7%. PASI 50, PASI 75 and PASI 90 at week 24 
was achieved by, respectively, 62 (69%), 35 (39%) and 16 (18%) patients. No significant 
influence of gender, age, baseline PASI, BMI, number of previous systemic therapies or
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duration of psoriasis was found on week 24 efficacy results. Differences between efficacy 
data were most pronounced for subgroups stratified by baseline PASI above 20, BMI 
above 30 kg/m2 and psoriasis duration longer than 20 years. Patients with a baseline PASI 
above 20 showed a greater mean percentage PASI reduction than patients with a baseline 
PASI below 20 (67.6% versus 54.9%, p = 0.072). Furthermore, obese patients tended to 
demonstrate a lower efficacy response compared with patients with BMI beneath 30 kg/ 
m2 (53.0% versus 63.4%, p = 0.146). A psoriasis duration of longer than 20 years was 
associated with a mean percentage PASI reduction of 64.1% at week 24, whereas patients 
with a shorter duration of psoriasis before biological treatment showed a mean percentage 
PASI reduction of 54.6% (p = 0.170) (Table 3). Obviously, patients with psoriasis duration 
of longer than 20 years were older than patients with a shorter psoriasis history (67.6 
versus 54.9 years).
Table 2. Treatment characteristics.
Treatment characteristics n = 118
Nature of treatment, no. (%)
Etanercept only 94 (80)
Efalizumab, followed by etanercept 9 (8)
Efalizumab only 5 (4)
Etanercept, followed by efalizumab 4 (3)
Infliximab only 1 (1)
Efalizumab, followed by infliximab 1 (1)
Miscellaneous 4 (3)
Number of treatment episodes
Etanercept 112
Efalizumab 24
Infliximab 5
Adalimumab 1
All 142
Duration of treatment episodes3 (years), mean ± SEM
Etanercept 1.6 ± 0.1
Efalizumab 1.0 ± 0.2
Infliximab 0.7 ± 0.3
Adalimumab 1.0
All 1.8 ± 0.1
aData are influenced by duration of follow-up and therapy status. SEM, 
Standard Error of the Mean.
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Long-term efficacy of etanercept
Efficacy results of a 156-week etanercept treatment period are represented in Figure 1. Of 
all 111 etanercept-treated patients, 63 (57%) were treated for longer than 72 weeks. Mean 
PASI at baseline for this group was 16.6. Mean weekly dosage of etanercept was 60.4 
milligram. After 24 weeks of treatment, an absolute decrease in PASI of approximately 
10 points was established (interpolated mean week 24 PASI: 7.2). This effect remained 
stable during the next 132 weeks. At analysis, 9 patients of the surveyed subgroup had 
discontinued etanercept treatment as a result of lack of efficacy (n = 4), adverse events 
(n = 4) or both (n = 1). Furthermore, 6 patients were lost to follow up and one patient had 
temporarily interrupted etanercept therapy due to a desire to become pregnant.
Figure 1. Efficacy o f three-year etanercept treatment.
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PASI, Psoriasis Area and Severity Index; SEM, Standard Error of the Mean.
Serious adverse events
Serious adverse events occurred in 22 patients. Fifteen patients were admitted to the 
hospital at least once. In total, 23 periods of hospital admission were required, i.e. as a 
result of an exacerbation of psoriasis (etanercept, n = 10; efalizumab, n = 4; infliximab, n 
= 3; adalimumab, n = 1), muscle and joint complaints (efalizumab, n = 2), cerebrovascular 
accident (etanercept, n = 1), pneumonia (etanercept, n = 1) and infusion reaction (infliximab, 
n = 1). Psoriasis exacerbations occurred as a result of erysipelas during etanercept
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treatment (n = 1), inefficacy of efalizumab (n = 4), prolonged infliximab interruption period 
(n = 1), or for no apparent reason (n = 12).
Table 3. Mean Psoriasis Area and Severity Index reduction at week 24 stratified by 
patient characteristics.
Patient characteristics  
(n = 90)
No. of patients (%) PASI reduction (%), 
mean ± SEM
P-value
Gender
Male 59 (66) 61.6 ± 4.1 0.456
Female 31 (34) 56.1 ± 6.1
Age, years
> 50 44 (49) 58.4 ± 5.2 0.717
s 50 46 (51) 60.9 ± 4.9
Baseline PASI
> 20 34 (38) 67.6 ± 4.9 0.072
s 20 56 (62) 54.9 ± 4.6
Body mass index, kg/m2
> 30 32 (36) 53.0 ± 6.7 0.146
s 30 58 (64) 63.4 ± 3.8
Previous systemic treatments, no.
> 5 32 (36) 62.2 ± 5.9 0.588
s 5 58 (64) 58.3 ± 4.3
Psoriasis duration, years
> 20 48 (53) 64.1 ± 4.2 0.170
s 20 42 (47) 54.6 ± 5.6
PASI, Psoriasis Area and Severity Index; SEM, Standard Error of the Mean.
Eight episodes of malignancies were found in 6 patients, and included basal cell carcinomas 
(etanercept, n = 3), squamous cell carcinomas (etanercept, n =2; efalizumab, n = 1), 
breast cancer (etanercept) and an oesophageal carcinoma (etanercept). Two female 85 
patients died of a sudden cardiac arrest during etanercept treatment. One had a history 
of hypertension and stroke, and the other had chronic obstructive pulmonary disease.
Whether the cardiac arrests were induced by a preceding myocardial infarction is unclear.
Mild adverse events were of the same nature as outlined in the previous study,6 and are 
therefore not represented.
Discussion
The aim of the current prospective observational cohort study was to present short- and 
long-term efficacy and safety data on biological treatment for patients with high-need
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psoriasis in daily practice, and to investigate the influence of patient characteristics on 
therapy response. As most patients were treated with etanercept, and most long-term data 
were available from this group, efficacy analyses focused on etanercept therapy. In the 
current study, daily practice efficacy and safety results of etanercept treatment for up to 
three years were represented.
Long-term efficacy analysis showed a mean PASI improvement of approximately 57% after 
24 weeks of etanercept treatment. Efficacy results may be overestimated, as only patients 
with available long-term efficacy data were included for analysis. The effect remained stable 
during the next 132 weeks of treatment, which leads to the conclusion that etanercept has 
the potential to improve psoriasis symptoms for a considerable time. However, although 
patients encountered a significant PASI improvement, an absolute PASI of approximately 
7.0 remained. For patients expecting their psoriasis to be cleared by biological therapy, 
such a residual psoriasis could be a major disappointment. Moreover, a significant PASI 
residue makes addition of other topical or systemic antipsoriatic treatments necessary in 
some cases. Notifying patients about the chance that their psoriasis will not entirely be 
cleared by biological treatment is therefore essential.
Long-term daily practice treatment with etanercept was only occasionally accompanied 
by major safety concerns. Whether these are related to the use of etanercept is unclear, 
but a direct role for biologics on the incidence of serious adverse events seemed unlikely 
in most cases. Results of an integrated safety analysis showed that there were no signs 
of dose-related or cumulative toxicity over time with etanercept treatment for up to 144 
weeks.8 In the current study, etanercept retained an apparently positive safety profile for 
up to 156 weeks.
No significant influence of gender, age, baseline PASI, BMI, number of previous systemic 
therapies or duration of psoriasis was found on week 24 efficacy results, although 
trends were discernible. Patients with a baseline PASI above 20 showed a greater mean 
86 percentage PASI reduction than patients with a baseline PASI below 20. This can be 
explained by the phenomenon called 'regression to the mean', as outlined by Wolfe et 
al.9 According to Hick and Feldman, this is caused by 'eligibility creep', the tendency for 
patients to have higher measured severity at initial assessment visits when eligibility is 
determined.10 Obese patients tended to demonstrate lower efficacy response compared 
with patients with BMI beneath 30 kg/m2. Recently, Clark and Lebwohl concluded from a 
literature analysis that etanercept may have compromised efficacy in heavier individuals.11 
Efficacy of etanercept was lower in patients with psoriasis duration shorter than 20 years 
compared with patients with a longer psoriasis duration. The hypothesis that an extensive 
systemic treatment history might lead to resistance for newly described systemic therapies
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seems thus rejected. In contrast, some patients with psoriasis may be more resistant to 
systemic treatments than others, which leads to fast switches in systemic treatments, and 
consequently a shorter medication history until eligibility for biological treatment.
Patients treated with biologics had an extensive medical history, especially in the field of 
cardiovascular diseases. Although not investigated in the current study, the impact of these 
comorbidities (obesity excluded) on the course of biological treatment seems indifferent 
in daily practice. However, concurrent medical complaints related to pre-existing diseases 
may be wrongfully interpreted as side effects of biological treatment, sometimes leading 
to discontinuation of medication. Reviewing general health before and during biological 
therapy is therefore required.
In conclusion, this three-year analysis of biological treatment in patients with psoriasis 
shows that etanercept is able to produce a sustained efficacy in long-term clinical therapy 
up to 156 weeks. During long-term treatment, serious side effects are infrequent, and the 
influence of patient characteristics on treatment outcome is limited. As long-term efficacy 
and safety data of biological therapies are difficult to gain from randomized controlled 
trials, continuous, prospective registration of patient and treatment data in daily practice 
is essential.
87
PART II
References
1. Gottlieb A, Korman NJ, Gordon KB et al. Guidelines of care for the management 
of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and 
guidelines of care for treatment with an emphasis on the biologics. J.Am.Acad. 
Dermatol. 2008; 58: 851-64.
2. Menter A, Gottlieb A, Feldman SR et al. Guidelines of care for the management of 
psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of 
care for the treatment of psoriasis with biologics. J.Am.Acad.Dermatol. 2008; 58: 
826-50.
3. Griffiths CE, laccarino L, Naldi L et al. Psoriasis and psoriatic arthritis: immunological 
aspects and therapeutic guidelines. Clin.Exp.Rheumatol. 2006; 24: S72-S78.
4. Nast A, Kopp I, Augustin M et al. German evidence-based guidelines for the 
treatment of Psoriasis vulgaris (short version). Arch.Dermatol.Res. 2007; 299: H I-  
38.
5. Smith CH, Anstey AV, Barker JN et al. British Association of Dermatologists 
guidelines for use of biological interventions in psoriasis 2005. BrJ.Dermatol. 2005; 
153: 486-97.
6. Driessen RJ, Berends MA, Boezeman JB et al. Psoriasis treatment with etanercept 
and efalizumab: clinical strategies influencing treatment outcome. BrJ.Dermatol. 
2008; 158: 1098-106.
7. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. 
Dermatologica 1978; 157: 238-44.
8. Pariser D, Yang Y, Stevens S et al. Short- and long-term safety profiles of etanercept 
in patients with psoriasis: An integrated analysis. J.Am.Acad.Dermatol. 2008; 58 
Suppl 2: AB121.
9. Wolfe F, Michaud K, Dewitt EM. Why results of clinical trials and observational 
88 studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and
interpretive issues. Ann.Rheum.Dis. 2004; 63 Suppl 2: ii13-ii17.
10. Hick J, Feldman SR. Eligibility creep: a cause for placebo group improvement in 
controlled trials of psoriasis treatments. J.Am.Acad.Dermatol. 2007; 57: 972-6.
11. Clark L, Lebwohl M. The effect of weight on the efficacy of biologic therapy in 
patients with psoriasis. J.Am.Acad.Dermatol. 2008; 58: 443-6.
CHAPTER 9
CHAPTER 9 
Etanercept combined with methotrexate for high-need psoriasis 
Abstract
Background: For some high-need psoriatic patients, the efficacy of etanercept monotherapy 
is insufficient. In these cases it might be indicated to combine etanercept with other 
conventional treatments.
Objectives: To provide daily practice safety and efficacy data for etanercept and 
methotrexate combination therapy.
Methods: Data were extracted from an existing database, which contains prospective 
safety and efficacy data of all patients who were treated with etanercept in clinical practice.
A case was defined as a patient using etanercept and methotrexate simultaneously for an 
indefinite period during follow-up. For all cases, baseline data, Psoriasis Area and Severity 
Index (PASI), adverse events and laboratory values were investigated. Furthermore, the 
influence of introduction and discontinuation of methotrexate on these parameters was 
analysed.
Results: Fourteen patients with simultaneous use of etanercept and methotrexate were 
selected. In 6 patients, methotrexate was introduced after etanercept to avoid further 
psoriasis deterioration, which resulted in an improvement of psoriasis in 4 of these patients.
Eight patients were on methotrexate therapy before start of etanercept. Discontinuation 
of methotrexate in 6 of these patients resulted in a decrease in PASI improvement in 5 
patients. Etanercept combined with methotrexate was well tolerated, and only mild adverse 
events were reported. No clinically significant changes in laboratory parameters occurred. 
Conclusions: Results show that combining etanercept with methotrexate is reasonable 
when efficacy of etanercept monotherapy is insufficient, or when rapid deterioration of 89 
psoriasis after abrupt discontinuation of methotrexate is expected. Laboratory values 
and adverse events were not different from what would have been expected when using 
methotrexate alone.
Adapted from: Driessen RJ, van de Kerkhof PC, de Jong EM. Etanercept combined with 
methotrexate for high-need psoriasis. BrJ.Dermatol. 2008; 159: 460-3.
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Introduction
Psoriasis is a common skin disease, affecting people in different ways, varying from a 
limited number of small erythematosquamous plaques to lesions covering large body 
surface areas. Some severely affected patients have been designated as 'high need', 
defined by failure of at least two conventional systemic therapies due to lack of efficacy, 
intolerance or contraindication.1 These patients are eligible for biological treatment, such 
as etanercept. Etanercept is a human tumor necrosis factor (TNF) receptor p75 Fc fusion 
protein that blocks interaction of TNF-a with cell surface TNF receptors.2 Etanercept has 
been proven highly effective for the treatment of psoriasis.3 For some high-need patients, 
however, efficacy of etanercept monotherapy is insufficient. In these cases it might be 
indicated to switch to an alternative biological therapy or to combine etanercept with 
other conventional treatments. So far, however, no evidence-based data are available 
on efficacy and safety of combinations of biologics with other systemic therapies for 
psoriasis. The concomitant use of etanercept and methotrexate has already been studied 
for rheumatoid arthritis. In these studies, the combination of etanercept and methotrexate 
was significantly more effective than methotrexate or etanercept alone.4-7 For psoriasis, no 
such studies have been performed yet.
In this report we describe our experience in treating 14 high-need psoriatic patients with 
a combination of etanercept and methotrexate. The aim of this report is to provide daily 
practice safety and efficacy data for etanercept and methotrexate combination therapy.
Patients and methods
Data were extracted from an existing database. This database contains prospective, daily 
practice safety and efficacy data of all patients who were treated with etanercept at the 
Radboud University Nijmegen Medical Centre Department of Dermatology from February 
2005. Patients were eligible for etanercept treatment if they had failed to respond to 
90 phototherapy, methotrexate and ciclosporin in the past, or if they had a contraindication to, 
or were intolerant of these treatments. At the same time, patients had to have a Psoriasis 
Area and Severity Index (PASI)8 of at least 10 at the time of screening.
In general, etanercept was given at a dosage of 50 milligram (mg) subcutaneously (SC) 
twice weekly for 12 weeks, followed by 25 mg SC twice weekly. Contraindications for 
etanercept treatment were an active infection or increased susceptibility for infections 
(including immunocompromised persons), a history of tuberculosis, the existence of a 
demyelinating disease and pregnancy. Relative contraindications were the existence of 
cardiac decompensation, a blood dyscrasia, a malignancy in recent history, the presence 
of an antinuclear antibody (ANA)-positive autoimmune disease or chronic exposure to
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actinic radiation in the past.
Visits were scheduled every 4 weeks during the first 12 weeks, every 6 weeks until week 
24 and every 12 weeks thereafter. Each visit, PASI and adverse events were documented. 
Laboratory tests were conducted, including haematological analysis, serum chemistry, 
urinalysis and ANA.
For this study, a case was defined as a patient using etanercept and methotrexate 
simultaneously for an indefinite period during follow-up. This implied either cases in which 
methotrexate was added to etanercept because of unsatisfactory response to etanercept 
monotherapy, or cases in which methotrexate was used and etanercept was started 
afterwards. The latter treatment schedule was obeyed to prevent severely affected patients 
from rebound after discontinuation of methotrexate. When etanercept was introduced 
successfully, an attempt was made to taper methotrexate.
For all cases, baseline data, PASI scores, adverse events and laboratory values were 
investigated retrospectively. Furthermore, the influence of introduction and discontinuation 
of methotrexate on these parameters was analysed.
Results
In total, 14 patients were treated simultaneously with etanercept and methotrexate. Six of 
these patients initially started on etanercept, and methotrexate was introduced later in the 
course of treatment due to insufficient efficacy of etanercept monotherapy (patients 1-6).
In the other 8 patients, etanercept was introduced while patients were on methotrexate 
(patients 7-14). Patient 9 was treated with etanercept 25 mg twice weekly during the 
entire treatment period, in contrast to all other patients, who had initially been treated with 
etanercept 50 mg twice weekly for 12 weeks.
Baseline characteristics are represented in Table 1. Concomitant methotrexate dosages 
ranged from 2.5 to 35.0 mg per week (a maximum of 35.0 mg was used by a patient who 
accidentally raised the methotrexate dosage up to 14 tablets). The mean weekly dosage 91 
ranged from 7.5 to 21.4 mg in this group.
The influence of introduction of methotrexate during etanercept therapy on efficacy 
parameters is shown in Figure 1. In 6 patients (patients 1-6), methotrexate was introduced 
to avoid further psoriasis deterioration. This immediately resulted in an improvement of 
psoriasis, and therefore, better treatment efficacy outcomes in 4 of these patients (patients 
2-4 and 6). Patient 1 preferred to cease etanercept shortly after the introduction of 
methotrexate to be able to start another antipsoriatic treatment. For patient 5, high-dose 
methotrexate was necessary to reverse the worsening of psoriasis. The mean duration of 
combination therapy was 40.8 weeks (range 6.0-73.9) (Figure 1).
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Table 1. Baseline demographic data and disease characteristics.
Patient Age
(yrs)a
Gender Psoriatic
arthritis
Duration of Baseline 
psoriasis PASI 
(yrs)a
MTX weekly  
dosage, mean 
(mg)
MTX weekly  
dosage, 
range (mg)
1 36 Male No 14 10.6 7.5 7.5
2 33 Female No 4 31.8 14.2 15.0-12.5
3 50 Male No 39 19.0 15.6 10.0-35.0
4 42 Female No 24 18.3 9.7 7.5-10.0
5 45 Female Yes 25 19.8 18.8 15.0-25.0
6 49 Female No 23 45.2 8.5 2.5-10.0
Mean 1 6 43 - - 22 24.1 12.4 -
7 52 Male Yes 21 15.9 9.0 5.0-10.0
8 53 Male No 21 17.0 15.0 15.0
9 39 Male No 18 16.2 8.4 7.5-10.0
10 51 Female No 21 27.3 13.0 7.5-17.5
11 45 Male No 27 27.8 16.3 10.0-22.5
12 50 Male No 11 5.9 10.3 7.5-20.0
13 25 Male No 8 16.8 21.4 2.5-22.5
14 38 Male No 22 20.8 7.5 5.0-10.0
Mean 7-14 44 - - 19 18.5 12.6 -
aAt start of etanercept. Yrs, years; PASI, Psoriasis Area and Severity Index; MTX, methotrexate; Mg, milligram.
Figure 1. Influence o f introduction o f methotrexate on efficacy results.
92
Labels indicate patient number and moment of introduction of methotrexate. introduction of methotrexate 15 mg/ 
week. ** Introduction of methotrexate 25 mg/week. PASI, Psoriasis Area and Severity Index.
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Patients 7-14 were on methotrexate therapy before start of etanercept. Methotrexate was 
discontinued in 6 of these patients (patients 7, 9, 10, 12-14). This resulted in a decrease 
in PASI improvement in 5 patients (patients 7, 9, 10, 12 and 13). For patient 8, efficacy of 
etanercept in combination with methotrexate was disappointing, and for this reason both 
therapies were ceased. Methotrexate tapering is still ongoing for patient 11. The mean 
period of treatment overlap was 42.7 weeks (range 1.6-99.4) (Figure 2).
Figure 2. Influence o f withdrawal o f methotrexate on efficacy results.
120
100
Labels indicate patient number and moment of withdrawal of methotrexate. In patient 8, both etanercept and 
methotrexate were ceased. Methotrexate tapering is still ongoing for patient 11. PASI, Psoriasis Area and Severity 
Index. For more detailed figures, please see original article (Br.J.Dermatol. 2008; 159: 460-3).
Etanercept combined with methotrexate was well tolerated, and only mild adverse events 93 
were reported. Five patients had gastrointestinal complaints that possibly were related 
to the use of methotrexate, including the patient who used 35.0 mg of methotrexate. 
Diagnosed infections included folliculitis, herpes labialis and two urinary tract infections.
Other infection-like symptoms, such as sore throat, common cold and influenza, were 
reported 12 times. Two patients showed actinic keratoses. No malignancies were seen, 
especially no skin malignancies.
Laboratory results demonstrated liver function abnormalities (increase in alanine 
aminotransferase, aspartate aminotransferase, Y-glutamyltransferase or lactate 
dehydrogenase) in 5 patients. For three of these patients a relationship with the concomitant
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use of methotrexate was suspected, but discontinuation of methotrexate was unnecessary 
in these cases. All other laboratory abnormalities were considered clinically insignificant.
Discussion
This case series shows efficacy and safety results of combination treatment of 14 patients 
with high-need psoriasis with etanercept and methotrexate in daily practice. Results show 
that combining etanercept with methotrexate is reasonable when efficacy of etanercept 
monotherapy is insufficient, even when methotrexate is introduced half way through the 
etanercept treatment course. Furthermore, overlapping with methotrexate while introducing 
etanercept treatment is useful when deterioration of psoriasis after abrupt discontinuation 
of methotrexate is expected. Laboratory values and adverse events for etanercept therapy 
combined with methotrexate are not different from what would have been expected when 
using methotrexate alone.
The improvement of efficacy results after introduction of methotrexate or the decrease 
in efficacy after discontinuation of methotrexate could be explained by the individual 
effects of methotrexate. However, all patients included in this report had been treated with 
methotrexate in the past, and this had been unsuccessful or unsatisfactory in all cases. 
Combination of etanercept and methotrexate has been proven more effective than 
methotrexate or etanercept alone for the treatment of rheumatoid arthritis.4-7 This is 
probably due to the additive effect of etanercept and methotrexate, as both therapies 
intervene in the pathogenesis of rheumatoid arthritis in different manners.9-11 Methotrexate 
was first introduced as an antiproliferative agent that inhibits the synthesis of purines and 
pyrimidines. Nowadays, it has become clear that many of the anti-inflammatory effects of 
methotrexate are mediated by adenosine.9 As the mechanism with which methotrexate 
induces the anti-inflammatory effect is different from that of etanercept, an additive effect 
of methotrexate on etanercept could be expected in psoriasis as well.
94 Risk profiles of etanercept and methotrexate are essentially different and no interactions 
between these drugs have been described. Use of methotrexate is associated with 
potentially serious side effects such as bone marrow toxicity, hepatotoxicity and 
nephrotoxicity, whereas use of etanercept is not.21112 However, combining medicines that 
act on different components of the immune system could theoretically result in massive 
immune suppression, and consequently an increased risk for infections and malignancies. 
Furthermore, long-term use of methotrexate can lead to persistent organ damage as liver 
fibrosis, although this is relatively infrequent.13 This case series did not reveal serious 
infections, malignancies or other serious adverse events, not even in those patients who 
had combination therapy for a long period of time.
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Whether the combination of etanercept and methotrexate is more effective for the treatment 
of psoriasis than etanercept or methotrexate alone needs further double-blind, controlled 
investigation in large groups of patients. Also, controlled trials are required to investigate 
safety issues of etanercept and methotrexate combination therapy. The present study 
describes the first case series in which combination of etanercept and methotrexate in 
patients with high-need psoriasis is evaluated.
95
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CHAPTER 10 
Extent and clinical consequences of antibody formation against 
adalimumab in patients with plaque psoriasis
Abstract
Objectives: To investigate the extent antibodies to adalimumab are formed in patients with 
plaque psoriasis and to study whether these antibodies have clinical consequences. Also, 
to examine the relationship between antibodies to adalimumab and adalimumab trough 
titers.
Design: Prospective observational cohort study.
Setting: Two Dutch dermatology departments in university hospitals.
Patients: All consecutive patients starting a regimen of adalimumab for chronic plaque 
psoriasis. Patients were screened and fulfilled the Dutch reimbursement criteria for 
adalimumab to treat psoriasis.
Intervention: Adalimumab treatment (per label).
Main outcome measure: The titer of antibodies to adalimumab, the adalimumab trough 
concentration, and the Psoriasis Area and Severity Index at weeks 12 and 24.
Results: Antibodies to adalimumab were detected in 13 of 29 patients (45%) during 24 
weeks of treatment. Differences in response rates among patients with low, high and 
no titers of antibodies to adalimumab were significant at weeks 12 and week 24 (p =
0.04 and p < 0.001, respectively). The median adalimumab trough concentrations varied 
significantly among patients with low, high and no titers of antibodies to adalimumab (1.30 
[range, 0.01-5.50], 0.0 [range 0.0-0.0], and 9.6 [range 0.0-22.6] mg/l, respectively; p <
0.001). At week 24, the median adalimumab trough concentrations differed significantly 
among good responders, moderate responders and non-responders (9.7 [range 0.0-22.6], 97 
8.9 [range 3.2-12.6], and 0.0 [range 0.0-13.3] mg/l, respectively; p = 0.01).
Conclusion: Antibodies to adalimumab are associated with lower serum adalimumab 
trough concentrations and with non-response or loss of response to adalimumab in 
patients with plaque psoriasis.
Adapted from: Lecluse LL, Driessen RJ, Spuls PI, de Jong EM, Stapel SO, van Doorn 
MB, Bos JD, Wolbink GJ. Extent and clinical consequences of antibody formation against 
adalimumab in patients with plaque psoriasis. Arch. Dermatol. 2010; 146: 127-32.
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Introduction
Antibodies to adalimumab have been associated with non-response or loss of initial 
response to adalimumab in a substantial portion of patients with rheumatoid arthritis and 
Crohn's disease.1-4 Adalimumab is a fully humanized monoclonal immunoglobulin (Ig)G1 
antibody and tumor necrosis factor a (TNF-a) antagonist; its indication was extended for 
treatment of moderate to severe chronic plaque psoriasis in 2008. Treatment of psoriasis 
with adalimumab has shown promising results in phase III trials.56 Some patients with 
plaque psoriasis do not respond to adalimumab, or they no longer respond to adalimumab 
treatment despite initial good results. The mechanism of antibody formation is assumed 
to have a role in these patients. Because adalimumab, with other biological agents, 
represents the end of the therapeutic spectrum for treatment-resistant moderate to severe 
plaque psoriasis, it is important to identify factors that may impair the clinical response. 
Further research may then lead to treatment optimization.
The objectives of this study were to investigate the extent antibodies to adalimumab are 
formed in patients with plaque psoriasis and to study whether these antibodies have clinical 
consequences. Another objective was to examine the relationship between antibodies to 
adalimumab and adalimumab trough titers. Therefore, we evaluated adalimumab trough 
concentration and concentration of antibodies to adalimumab relative to clinical response 
in a cohort of patients with plaque psoriasis and up to 24 weeks of adalimumab treatment.
Patients and Methods
Patients
This prospective observational cohort study in The Netherlands consisted of all consecutive 
patients with plaque psoriasis starting a regimen of adalimumab at the Departments of 
Dermatology of the Academic Medical Center in Amsterdam and the Radboud University 
98 Nijmegen Medical Centre in Nijmegen. Patients were treated with adalimumab 40 mg 
every other week after an initial dose of 80 mg and a dose of 40 mg the week thereafter. 
In patients with an inadequate response as judged by the treating physician, the dosing 
interval of adalimumab could be reduced to once weekly. The study was approved by 
the medical ethics committees of both hospitals and all patients gave written informed 
consent.
Clinical response
Disease severity was assessed at baseline, at week 12, and at week 24 using the Psoriasis 
Area and Severity Index (PASI), which is the most commonly used outcome measure in
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trials of antipsoriatic agents.7 Response was measured as the percentage improvement 
in PASI compared with baseline. Patients were classified as non-responders (< 50% 
improvement in PASI compared with baseline [< PASI 50]), moderate responders (> PASI 
50 to < PASI 75 improvement), or good responders (> PASI 75 improvement). The PASI 
assessment was performed before serum sample analysis.
Measurement of adalimumab concentrations
Blood was drawn at an adalimumab trough concentration (just before administration of 
adalimumab) 12 and 24 weeks after initiation of treatment. The samples were frozen and 
analysed when all sampling was completed. The laboratory had no access to clinical data 
at the time of analysis. Adalimumab trough concentrations were measured by enzyme- 
linked immunosorbent assay (ELISA), based on the principle that adalimumab is captured 
through its ability to bind tumor necrosis factor. Adalimumab trough concentrations were 
quantified as described previously.2 Adalimumab binding was assessed by incubation 
with biotinylated rabbit IgG directed to the adalimumab idiotype. The detection limit of the 
assay is approximately 0.001 milligram/liter (mg/l).
Measurement of antibodies against adalimumab
Concentrations of antibodies to adalimumab were measured using a radioimmunoassay.
The assay measures specific high-avidity IgG antibodies to adalimumab by an antigen- 
binding test as described previously.2 Because the presence of adalimumab interferes with 
the assay, concentrations of antibodies to adalimumab in patients with high concentrations 
of adalimumab are underestimated or undetectable. Therefore blood was drawn at the 
adalimumab trough concentration. The antibody test was considered positive when the 
concentration of antibodies to adalimumab exceeded 12 arbitrary units/milliliter (AU/ml), 
which was previously shown to be the mean +6 standard deviations of the pretreatment 
values.2 In a previous study, the serum concentrations of antibodies to adalimumab showed 99 
two clusters, which could be separated at a cutoff value of 100 AU/ml.2 In our cohort, the 
concentrations of antibodies to adalimumab also naturally formed two clusters; therefore, 
we used the same cutoff points for titers of antibodies to adalimumab. A concentration 
between 12 and 100 AU/ml was considered a low titer of antibodies to adalimumab, and a 
concentration above 100 AU/ml was considered a high titer of antibodies to adalimumab.
Statistical analysis
For differences between groups, we used independent samples t-test, chi-square test, the 
Mann-Whitney U test, or Kruskal-Wallis test, as appropriate. The threshold for significance
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was set at p < 0.05. To analyse clinical response in patients with and without antibodies to 
adalimumab after 24 weeks of treatment for patients who stopped treatment, we used the 
last observation carried forward method.
Results
Patient characteristics
Most patients in the cohort were male (69% [20 of 29]), with a mean age of 44 years 
(Table 1). The mean disease severity on the PASI at baseline was 15.5, and the mean 
disease duration was 22 years. One patient scored only 3 on the PASI at baseline 
because she had switched from etanercept, to which her psoriasis responded, but her 
arthritis did not. Patients did not respond to a mean of 4.2 previous systemic therapies, 
including phototherapy. Among all patients, 17% (5 of 29) were also diagnosed as having 
psoriatic arthritis. At baseline, one patient used concomitant fumaric acid, one patient used 
concomitant acitretin, and three patients used concomitant methotrexate (mean dosage, 
12 milligram/week). Most patients used concomitant topical therapies.
There were no significant differences between patients with and without antibodies to 
adalimumab in mean age, proportion of male sex, PASI at baseline, body mass index, 
proportion of patients with psoriatic arthritis, or number of previous systemic therapies. 
Table 1 gives the patient characteristics of the total cohort, and separated for patients with 
or without antibodies to adalimumab.
Clinical response
At week 12, 14 of 28 patients (50%) were moderate responders, 9 (32%) were good 
responders and 6 (21%) had even reached 90% improvement compared with baseline 
(data are missing for one patient). Twenty-seven of 29 patients were still receiving 
100 adalimumab at week 24.
Two patients discontinued receiving adalimumab because of its ineffectiveness as decided 
by the treating dermatologist after 14 and 16 weeks. At week 24, 16 of 29 patients (53%) 
were moderate responders, 10 (34%) were good responders, and 4 (14%) had reached 
90% improvement compared with baseline. At week 24, half of the non-responders had 
reached 40% improvement compared with baseline.
Most patients who were good responders at week 12 (n = 9) were still good responders 
at week 24 (n = 7). Likewise, most of the non-responders at week 12 (n = 14) remained 
non-responders at week 24 (n = 8).
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Table 1. Clinical characteristics o f patients at baseline.
Antibodies to adalimumab
Characteristic
Total cohort 
(n = 29)
Patients with 
(n = 13)
Patients w ithout 
(n = 16)
Age, mean (SD), years 44 (11) 47 (13) 42 (10)
Male sex, no. (%) 20 (69) 8 (62) 12 (75)
Disease duration, mean, years 22 25 20
Psoriasis Area and Severity Index, mean 15.5 16.2 14.9
Body mass index3 29 30 28
Diagnosed as having psoriatic arthritis, no (% ) 5 (17) 3 (23) 2 (13)
Concomitant methotrexate, no (%) 3 (10) 0 (0) 3 (19)
Previous systemic therapies, no. (% )
Methotrexate 28 (97) 12 (92) 16 (100)
Ciclosporin 19 (66) 9 (69) 10 (63)
UVB 27 (93) 12 (92) 15 (94)
PUVA 19 (66) 9 (69) 10 (63)
Etanercept 20 (69) 12 (92) 13 (81)
Infliximab 2 (7) 1 (8) 1 (6)
Efalizumab 8 (28) 5 (38) 3 (19)
Adalimumab 0 (0) 0 (0) 0 (0)
Mean no. of previous therapies 4.2 4.6 3.9
No data differed significantly between patients with and without antibodies to adalimumab except for the 
proportion of patients previously treated with etanercept (p = 0.02). Last observation carried forward method 
was used in two patients; if applicable. aCalculated as weight in kilograms divided by height in meters squared. 
SD, Standard Deviation; UVB, Ultraviolet B; PUVA, Psoralen-Ultraviolet A.
Concentrations of antibodies to adalimumab
During 24 weeks of follow-up, antibodies to adalimumab were detected in 13 of 29 patients 
(45%). Seven patients had antibodies to adalimumab at week 12, and another 6 patients 
at week 24. At week 12, 2 of 25 patients (8%) had a low titer of antibodies to adalimumab 
(range, 13-21 AU/ml), and 5 (20%) had a high titer of antibodies to adalimumab (range, 101 
340-7300 AU/ml). At week 24, 6 of 29 patients (21%) had a low titer of antibodies to 
adalimumab (range, 15-54 AU/ml), and 7 (24%) had a high titer of antibodies to adalimumab 
(range, 1640-55700 AU/ml).
One patient with a high titer at week 12 (474 AU/ml) had a low titer at week 24 (30 AU/ml); 
he received adalimumab every week from weeks 8 through 24 and was treated with oral 
prednisone after week 12 for asthma. All other patients had increasing titers of antibodies 
to adalimumab over time. The three patients who took concomitant methotrexate did not 
develop antibodies to adalimumab.
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Adalimumab trough concentrations
Adalimumab trough concentrations ranged from undetectable to 22.6 mg/l. In patients 
receiving adalimumab 40 mg every other week, the median adalimumab trough 
concentrations were 8.2 (range, 0.0-17.0) mg/l at week 12 and 4.8 (range, 0.0-22.6) mg/l 
at week 24. In Figure 1, the course of adalimumab trough concentrations is shown over 
24 weeks in patients with and without antibodies to adalimumab. The median adalimumab 
trough concentrations varied significantly among patients with low, high, and no titers of 
antibodies to adalimumab (1.30 [range, 0.01-5.50], 0.0 [range, 0.0-0.0], and 9.6 [range, 
0.0-22.6] mg/l, respectively; p < 0.001).
Figure 1. Median adalimumab trough concentrations fo r patients with low, high and 
no titers o f antibodies to  adalimumab.
The median adalimumab trough 
concentrations were measured at weeks 
12 and 24 for patients with low, high and 
no titers o f antibodies to adalimumab. At 
weeks 12 and 24, the differences among 
the three groups were statistically 
significant (p = 0.001 and p < 0.001, 
respectively). For patients with high titers 
o f antibodies to adalimumab, a positive 
adalimumab trough concentration could 
probably have been obtained shortly 
after baseline. The adalimumab trough 
concentration at baseline is assumed 
to be 0 based on previous studies2 and 
the fact that no patient had received 
adalimumab before baseline.
Increased dosing frequency of adalimumab
The adalimumab dosing interval was shortened in two patients at week 12 and in another 
seven patients between weeks 12 and 24 because of ineffectiveness as decided by the 
treating dermatologist. In these nine patients receiving adalimumab every week, the 
median adalimumab trough concentration was 1.7 (range, 0.0-13.3) mg/l at week 24. 
Adalimumab trough concentrations did not differ significantly between patients who used 
adalimumab every week versus every other week (p = 0.54).
One patient was treated with adalimumab approximately once every 25 days between
High titer of antibodies (n = 7) 
Low titer of antibodies (n = 6)
No titer of antibodies (n = 16)
Baseline Week 12 Week24
CHAPTER 10
weeks 12 and 24. This patient had no health care insurance and paid out of pocket for 
treatment. His adalimumab trough concentration was undetectable (without antibodies to 
adalimumab).
Clinical response and concentrations of antibodies to adalimumab 
Among patients with a good response on the PASI at week 12, only one had detectable 
antibodies to adalimumab (13 AU/ml). Similarly, among patients with a moderate response, 
only one patient had detectable antibodies to adalimumab (21 AU/ml). At week 24, both 
patients had increased titers of antibodies to adalimumab and no longer responded to 
adalimumab treatment. Among patients with a good response on the PASI at week 24, 
there was again only one patient with detectable antibodies to adalimumab (41 AU/ml). 
Two patients who were moderate responders had detectable antibodies to adalimumab 
at week 24 (15 and 19 AU/ml). All patients with high titers of antibodies to adalimumab at 
weeks 12 or 24 were non-responders. However, not all non-responders had high titers of 
antibodies to adalimumab (Figure 2). Differences in response rates among patients with 
low, high and no titers of antibodies to adalimumab were significant at weeks 12 and week 
24 (p = 0.043 and p < 0.001, respectively). Twelve of 17 patients (71%) without antibodies 
to adalimumab improved their response on the PASI between weeks 12 and 24, as 
opposed to 1 of 7 patients (14%) of patients with antibodies to adalimumab. Differences 
between responses at weeks 12 and 24 were not significant for either group.
Clinical response and adalimumab trough concentration
At week 12, non-responders had lower adalimumab trough concentrations than good 
responders (4.2 [range, 0.0-16.0] versus 11.0 [range, 1.0-17.0] mg/l; p = 0.046). The 
median adalimumab trough concentration in moderate responders (4.4 [range, 1.0­
10.0] mg/l) was not significantly different compared to the other groups. At week 24, the 
median adalimumab trough concentrations differed significantly among good responders, 
moderate responders, and non-responders (9.7 [range, 0-22.6], 8.9 [range, 3.2-12.6] and
0.0 [range, 0.0-13.3] mg/l, respectively; p = 0.01) (Figure 3). Data from a patient with a 
typical antibody response are shown in Figure 4; as the level of antibodies to adalimumab 
increased, the PASI increased and the adalimumab trough concentration decreased.
Discussion
In this study, we have shown that antibodies to adalimumab are formed in a large portion 
of patients with plaque psoriasis; at the end of the study, 45% (13 of 29) of patients had 
developed antibodies to adalimumab. High titers of antibodies to adalimumab were
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Figure 2. Percentages o f non-responders, moderate responders, and good 
responders fo r patients with low, high and no titers o f antibodies to adalimumab at 
week 24.
■ Good responder ■ Moderate responder ■ Non-responder
No (n = 16) Low (n = 6) High (n = 7)
Titers of antibodies to adalimumab
The difference among the three groups was statistically significant (p < 0.001).
particularly associated with undetectable adalimumab trough concentrations. We 
also showed that high titers of antibodies to adalimumab and low adalimumab trough 
concentrations were associated with impaired treatment outcome.
Response rates to adalimumab in this study are surprisingly lower than those in phase III 
trials56, in which 53% and 71% of patients were good responders after 12 and 16 weeks, 
respectively, compared with 32% (9 of 28) of patients in our cohort after 12 weeks. At 
104 week 24, the percentages of good responders for the two phase III trials were 64% and 
70%, compared with 35% (10 of 29) in our cohort. This might be the result of selected 
populations in phase III trials versus the 'normal' population with psoriasis having more 
comorbidities and concomitant medication.8 However, another factor may be the selection 
of patients in our cohort since they were treated in tertiary psoriasis referral centers, and 
some had previously failed other systemic therapies.
Twelve of 13 patients (92%) who developed antibodies to adalimumab had previously 
been treated with etanercept versus 8 of 16 patients (50%) who did not develop antibodies 
to adalimumab, which was a significant difference. This is a notable finding that needs 
further investigation. However, the test for antibodies to adalimumab is specific, and cross-
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Figure 3. Adalimumab trough concentrations at week 24 fo r the different response 
levels on the Psoriasis Area and Severity Index (PASI).
p < 0.001
I---------------------------------------------------------- 1
p = 0.001 
I--------------------------1
p = 0.006 
I---------------------------- 1
_ L  S
---------------- T-----------------------------------------------T-----------------------------------------------T-------------------------------
Good responder Moderate responder Non-responder
(n = 10) (n = 6) (n = 13)
The two outliers in the non-responder group (asterisks) were included in the analyses.
linking is unlikely. Furthermore, neutralizing antibodies to etanercept have not been 
demonstrated to date. As shown in patients receiving infliximab who develop antibodies to 
infliximab9, we assume that adalimumab and antibodies to adalimumab form complexes. 
These complexes may be removed by the liver and the spleen. This would explain the 
undetectable serum adalimumab trough concentrations in patients with high titers of 
antibodies to adalimumab compared with the clearly detectable serum adalimumab trough 
concentrations in patients without antibodies to adalimumab.
Removal of the therapeutic agent by the formation of complexes would explain why all 
patients with high titers of antibodies to adalimumab were non-responders. It has been 
speculated that dose escalation may overload the capacity of the immune system to 
produce antibodies to adalimumab or may lead to immunological tolerance.10
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Figure 4. Data from  a good responder at 12 weeks who developed a high tite r of 
antibodies to  adalimumab after week 12 and lost most response to treatment.
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PASI, Psoriasis Area and Severity Index.
The proportion of our patients who developed antibodies to adalimumab is higher than 
that in other studies. In a phase III trial of patients treated with adalimumab for psoriasis
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that analysed antibody formation, only 8.8% of patients tested positive for antibodies to 
adalimumab.6 However, patients may have been tested for antibodies even if they had 
received only one dose of adalimumab. Furthermore, no specific details about the methods 
of antibody testing were given.
In a study by Bartelds et al.,17% of patients with adalimumab-treated rheumatoid arthritis 
developed antibodies to adalimumab after 28 weeks.2 That study used the same assay and 
had practically the same set-up as in the present study. An explanation for the difference 
in results might be concomitant methotrexate use. Among patients with rheumatoid 
arthritis who used concomitant methotrexate, the percentage of patients with antibodies to 
adalimumab was significantly lower than the percentage of patients without antibodies to 
adalimumab (p = 0.003). Of the patients using concomitant methotrexate (mean dosage, 
19.4 mg/week), 12% developed antibodies to adalimumab versus 38% of patients 
receiving adalimumab monotherapy. Furthermore, concomitant low-dose methotrexate 
has been shown to reduce immunogenicity associated with infliximab treatment for 
rheumatoid arthritis.11 In our cohort, only three patients used concomitant methotrexate; 
none of these patients developed antibodies to adalimumab. However, the sample number 
is too small to statistically analyse the effect of methotrexate on development of antibodies 
to adalimumab in our cohort.
Another factor in antibody formation may be related to patient genetics.10 Further 
investigation of this theory is needed. Also requiring more study is the finding of non­
responders to adalimumab therapy without evidence of antibody formation against 
adalimumab. The non-response of these patients cannot be explained based on current 
knowledge.
We analysed few patients in our study. However, the small sample size should not be 
considered a limitation because the data analysis demonstrated statistically significant 
differences. Nevertheless, multiple regression analysis with a larger cohort could detect 
factors that might affect antibody formation, such as concomitant methotrexate use and 
dosing interval changes.
In conclusion, antibodies to adalimumab are associated with lower serum adalimumab 
trough concentrations and with non-response or loss of response to adalimumab in patients 
with plaque psoriasis. We recommend testing for antibodies to adalimumab when patients 
lose response to adalimumab or do not respond at all, since spontaneous improvement 
is unlikely in the presence of high titers of antibodies to adalimumab. Further research is 
needed to identify risk factors for antibody development and factors affecting antibody 
development. Investigations are also needed to study how the effect of antibodies to 
adalimumab can be minimized.
107
PART II
108
References
1. Bartelds GM, Wolbink GJ, Stapel S et al. High levels of human anti-human 
antibodies to adalimumab in a patient not responding to adalimumab treatment. 
Ann.Rheum.Dis. 2006; 65: 1249-50.
2. Bartelds GM, Wijbrandts CA, Nurmohamed MT et al. Clinical response to 
adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab 
concentrations in rheumatoid arthritis. Ann.Rheum.Dis. 2007; 66: 921-6.
3. West RL, Zelinkova Z, Wolbink GJ et al. Immunogenicity negatively influences the 
outcome of adalimumab treatment in Crohn's disease. Aliment.Pharmacol.Ther 
2008; 28: 1122-6.
4. Wolbink GJ, Vis M, Lems W et al. Development of antiinfliximab antibodies and 
relationship to clinical response in patients with rheumatoid arthritis. Arthritis 
Rheum. 2006; 54: 711-5.
5. Gordon KB, Langley RG, Leonardi C et al. Clinical response to adalimumab 
treatment in patients with moderate to severe psoriasis: double-blind, randomized 
controlled trial and open-label extension study. J.Am.Acad.Dermatol. 2006; 55: 
598-606.
6. Menter A, Tyring SK, Gordon K et al. Adalimumab therapy for moderate to severe 
psoriasis: A randomized, controlled phase III trial. J.Am.Acad.Dermatol. 2008; 58: 
106-15.
7. Ashcroft DM, Wan Po AL, Williams HC et al. Clinical measures of disease severity 
and outcome in psoriasis: a critical appraisal of their quality. Br.J.Dermatol. 1999; 
141: 185-91.
8. Lecluse LL, Naldi L, Stern RS et al. National registries of systemic treatment for 
psoriasis and the European 'Psonet' initiative. Dermatology 2009; 218: 347-56.
9. Van der Laken CJ, Voskuyl AE, Roos JC et al. Imaging and serum analysis of 
immune complex formation of radiolabelled infliximab and anti-infliximab in 
responders and non-responders to therapy for rheumatoid arthritis. Ann.Rheum. 
Dis. 2007; 66: 253-6.
10. Wolbink GJ, Aarden LA, Dijkmans BA. Dealing with immunogenicity of biologicals: 
assessment and clinical relevance. Curr.Opin.Rheumatol. 2009; 21: 211-5.
11. Maini RN, Breedveld FC, Kalden JR et al. Therapeutic efficacy of multiple intravenous 
infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with 
low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998; 41: 
1552-63.
ECONOMIC IMPACTOF PSORIASIS AND PSORIASISTREATMENT
o
O
IIA Ib V C l
ECOI/IOIAIIC
b V K l  III
CHAPTER 11
CHAPTER 11 
The economic impact of high-need psoriasis in daily clinical 
practice before and after the introduction of biologics
Abstract
Background: Although costs of biologics are high, effective treatment of patients with 
psoriasis may reduce the total health care costs, as it may limit the need for hospitalization.
Objective: To investigate the economic impact of psoriasis, including direct costs, before 
and after the introduction of biologics, with special focus on hospitalized patients, treatment 
effectiveness and patient satisfaction with medication.
Methods: A descriptive retrospective cohort study including 67 patients with high-need 
psoriasis was performed. Direct costs were investigated for the biological and pre- 
biological treatment period. Direct costs for a subgroup of hospitalized patients were 
analysed separately. Patient satisfaction with biological treatment was measured using 
the Treatment Satisfaction Questionnaire for Medication (TSQM) version II. Effectiveness 
of biological therapy was investigated by means of the Psoriasis Area and Severity Index 
(PASI).
Results: Mean total direct costs were €10,146.- per patient per year (PPPY) in the pre- 
biological treatment period, compared to €17,712.- PPPY in the biological treatment 
period. For 6 patients in the cohort, introduction of biologics lead to a reduction of direct 
costs, as these patients did not need long hospitalizations. Treatment with biologics led 
to a 66.4% decrease in PASI from 19.0 at start of biological therapy to 6.4 at analysis.
Patient's satisfaction with biologics was high, indicated by a mean TSQM score of 77.8. 
Conclusions: Introduction of biological therapies may have cost-neutral or cost-saving 
effects for patients who otherwise require long hospitalization periods. Treatment with 111 
biologics proved effective and was accompanied by a high satisfaction for the patients.
Adapted from: Driessen RJ, Bisschops LA, Adang EM, Evers AW, van de Kerkhof PC, de 
Jong EM. The economic impact of high-need psoriasis in daily clinical practice before and 
after the introduction of biologics. Br.J.Dermatol. 2010 Feb 15. [Epub ahead of print]
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Introduction
Psoriasis is a common chronic skin disease, which impairs patients' quality of life to a 
large extent.1 Several studies have indicated that psoriasis also has a relevant economic 
impact, generated by the expenditures for different treatments, diagnostic procedures, 
medical consultations and productivity losses.2'6 The economic impact of psoriasis seems 
to be larger as the severity of psoriasis increases.7 Recently, a cost-of-illness study in Italy 
revealed that the sum of direct and indirect costs for patients with severe psoriasis was 
€11,434.40 on average per year. As this study was performed before the introduction of 
biological therapies, none of the patients included had received such a therapy.3 
Since the beginning of 2005, biological therapies have been introduced for the treatment 
of moderate to severe psoriasis, including etanercept, efalizumab, infliximab, adalimumab 
and recently ustekinumab. These therapies have been proven highly effective, as they 
significantly improve patients' skin symptoms as well as quality of life.8-10 
As a consequence of the high costs of biologics, strict reimbursement criteria for biological 
treatment are formulated in many countries. Nevertheless, direct medication costs 
for the treatment of immune-mediated diseases, have risen excessively since then. In 
The Netherlands, both etanercept and adalimumab are in the top 10 most expensive 
pharmaceuticals as well as in the top 10 pharmaceuticals with the biggest cost rise in 
2008.11 However, effective treatment of patients with psoriasis may reduce other direct 
health care costs, as it potentially limits the need for labour-intensive and time-consuming 
treatments and hospital admissions. A longitudinal cohort study by Bhosle et al. showed 
that the introduction of a biologic resulted in a significant reduction in health care service 
utilization compared to the period before biological treatment.12
In the current retrospective cohort study, the economic impact of psoriasis before and after 
the introduction of biologics was investigated. In contrast to most other pharmacoeconomic 
112 studies, this study was performed in a real life care setting. Direct costs for both the 
biological and pre-biological treatment period were calculated for the same patients with 
high-need psoriasis. The current study focussed specifically on direct costs for a subgroup 
of hospitalized patients. Furthermore, biological treatment effectiveness and patient 
satisfaction with biological therapies was evaluated.
Patients and methods
Setting and population
A retrospective cohort analysis comprised all patients with psoriasis treated with biologics
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at the Radboud University Nijmegen Medical Centre Department of Dermatology between 
February 2005 and February 2009. Patients were eligible for biological treatment if they 
had failed to respond to phototherapy, methotrexate and ciclosporin in the past, or if they 
had a contraindication to, or were intolerant of these treatments. At the same time, patients 
had to have a minimum Psoriasis Area and Severity Index (PASI)13 of 10 at the time of 
screening.
Outcome measures
Charts were reviewed from the very first hospital visit for psoriasis up to the final hospital visit 
(this latter taking place between October 2008 and February 2009) for demographic data, 
topical and systemic medication history, number of diagnostic procedures, and number 
and duration of in- and outpatient hospital visits. Episodes of clinical trial participation 
were not included. Measures that were determined before initiation of biological treatment 
were considered as belonging to the pre-biological treatment period; measures that were 
determined after this date were considered as belonging to the biological treatment period. 
The end of the biological treatment period was defined as the final documented hospital 
visit for psoriasis. At this visit, patients were asked to fill out the Treatment Satisfaction 
Questionnaire for Medication (TSQM) version II. The TSQM is a generic measure of 
treatment satisfaction for medication, including questions on effectiveness, side effects, 
convenience and global satisfaction, generating scores ranging from 0 (extremely 
dissatisfied) to 100 (extremely satisfied).14
Efficacy of treatment in the biological therapy period was represented by the percentage 
decrease in PASI from baseline (start of biological therapy) at the final visit, and by the 
percentage of patients who achieved a 50% and 75% reduction in PASI (PASI 50 and 
PASI 75, respectively) relative to baseline. These measures were already prospectively 
collected in the light of a registry including the same patients.
Analysis
As costs for biological treatment are generally higher in the initial treatment phase compared 
with the maintenance phase, only patients who were treated with biologics for at least one 
year, and for whom data for at least one year of the pre-biological treatment period were 
available were included for analysis. Direct costs were calculated for both the biological 
and pre-biological treatment period by multiplying the quantity of medication used, the 
number of diagnostic procedures, and the number and duration of hospital visits by prices 
published by the Dutch Health Care Insurance Board (College Voor Zorgverzekeringen).15 
Costs for topical therapies were estimated by multiplying the number of prescriptions by
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the price of 60 grams of ointment. Emollients or over-the-counter (OTC) medicines were 
not included for analysis. Costs for ultraviolet (UV) therapies were calculated on the basis 
of a standard monthly price for treatment with a mean frequency of twice per week.16 
The calculation of travelling expenses was performed through multiplication of the mean 
number of hospital visits a year by the travelling distance, multiplied by a fixed amount of 
€0.19 per kilometre. For each systemic therapy, the mean daily dose (MDD) in milligrams 
(mg) was determined. As the yearly expenses for biological treatment matched with the 
expenses for approximately 30 hospital admission days, the direct costs for patients who 
were admitted for more than 30 days per year on average in the pre-biological treatment 
period were analysed separately.
All costs were presented as mean costs (in €) per patient per year (PPPY). Values were 
represented as mean (range; 95% confidence interval [CI]). Statistical analysis was carried 
out using descriptive statistics.
Results
Patient and treatment characteristics
In total, 140 charts of patients treated with biologics were reviewed. Of these charts, 67 
were suitable for analysis, as patients were followed for at least one year before and after 
the introduction of biologics. Forty-four patients were male and 23 were female. Mean age 
at the start of the biological treatment period was 47.9 (range 21.7-71.8; 95% CI 45.1-50.7) 
years. Mean follow-up duration was 6.6 (range 1.0-35.5; 95% CI 5.1-8.2) years of the pre- 
biological treatment period and 2.6 (range 1.0-4.5; 95% CI 2.4-2.8) years of the biological 
treatment period. Mean PASI at start of the biological treatment period was 19.0 (range 
5.9-45.2; 95% CI 16.8-21.2).
Of all patients, 64 were treated with etanercept, 20 with efalizumab, 12 with adalimumab, 
114 and 4 with infliximab (Table 1). Forty-two patients were treated with only one biologic, 
mostly etanercept; 19 were treated with two different biologics; 6 were treated with three or 
four different biologics. The final biological therapy before analysis comprised etanercept 
in 48 patients, adalimumab in 12 patients, efalizumab in 6 patients, and infliximab 
in one patient. Conventional systemic therapies included methotrexate, ultraviolet B 
(UVB), acitretin, ciclosporin, fumaric acid, psoralen-ultraviolet A (PUVA), hydroxyurea, 
mycofenolate mofetil and tacrolimus.
Mean daily dose of each therapy used is reflected in Table 1. With regard to biological 
therapies, this was 8.8 mg for etanercept, 17.9 mg for efalizumab, 3.8 mg for adalimumab, 
and 11.2 mg for infliximab (after extrapolation of the costs).
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Table 1. Nature and costs o f system ic therapies (daily clinical practice use).
Pre-biological 
treatm ent period
Biological 
treatm ent period
Number
of
patients
Mean costs 
/patient 
/yeara (€)
Number
of
patients
Mean costs 
/patient 
/yeara (€)
MDD
(mg)
Conventional systemic therapies
Methotrexate 57 97 14 120 2.2
UVBb 39 1,105 12 1,105 -
Acitretin 34 804 7 691 36.7
Ciclosporin 34 3,099 S 2,301 26S.6
Fumaric acid 25 205 4 95 476.6
PUVAb 11 1,160 2 1,160 -
Hydroxyurea 0 0 1 221 912.7
Mycofenolate mofetil 0 0 1 4,464 2595.7
Tacrolimus 0 0 1 2,180 2.5
Biological therapies
Etanercept 0 0 64 15,329 S.S
Efalizumab 0 0 20 12,576 17.9c
Adalimumab 0 0 12 16,642 3.S
Infliximabd 0 0 4 26,650 11.2
aCalculated as total costs/ total period of actual drug use. bCosts for UV therapies were calculated on the basis 
of a standard monthly price for treatment in a mean frequency of twice per week. cCalculated on the basis of 
one ampoule of 125 milligrams per week. dCosts for infliximab were calculated by extrapolation of the costs for a 
year of therapy (actual treatment period was 157 days on average), and do not include costs for administration 
of infliximab. MDD (mg), Mean Daily Dose (milligram); UVB, Ultraviolet B; PUVA, Psoralen-Ultraviolet A.
Direct costs
Direct costs are outlined in Table 2. Mean total direct costs were €10,146.- (range 715­
51,375; 95% CI 7,614-12,678) PPPY in the pre-biological treatment period, compared with 
€17,712.- (range 7,508-99,750; 95% CI 15,004-20,421) PPPY in the biological treatment 115 
period. This implies a significant mean rise in direct costs of €7,566.- PPPY The rise in 
direct costs was mainly attributable to the expenses for biological therapies, i.e. €13,843.- 
(range 6,534-22,727; 95% CI 13,212-14,474) PPPY on average. The number of day care 
and hospital admission days per year was reduced by 94% (5.1 versus 0.3) and 64%
(14.9 versus 5.4), respectively, after the introduction of biologics. Direct costs related to 
day-care admission decreased significantly during biological therapy (€1,167.- [range 
0-6,903; 95% CI 827-1,506] PPPY versus €60.- [range 0-830; 95% CI 13-107] PPPY).
When each patient was included for analysis, direct costs for hospitalization did not differ 
significantly. However, when excluding cost data on patient 10, which were much higher
Table 2. Direct costs.
Pre-biological treatm ent period Biological treatm ent period
Volume3 Costs" Volum e1 Costsb
Treatment prescriptions
Topical therapies 21.7 138 (5-436; 113-163) 6.7 74 (0-261; 61-88)
Conventional systemic therapies 1.1 607 (12-3,345; 438-775) 0.3 89 (0-2,343; 12-167)
Biological therapies 0.0 0 (0-0; -) 1.3 13,843 (6,534-22,727; 13,212-14,474)
Diagnostic procedures
Laboratory 14.9 164 (20-1,203; 123-204) 20.4 176 (70-1,019; 146-206)
Radiology 0.7 29 (0-129; 23-35) 0.3 12 (0-102; 6-17)
Skin/ liver biopsies 0.3 38 (0-286; 25-51) 0.4 34 (0-378; 18-50)
Medical consultations
Consultations of physician 7.6 757 (0-1,808; 677-837) 7.0 696 (179-1,825; 619-772)
Day-care admission days 5.1 1,167 (0-6,903; 827-1,506) 0.3 60 (0-830; 13-107)
Hospital admission days 14.9 7,098 (0-43,465; 4,675-9,522) 5.4 2,584 (0-75,801; 232-4,936)
Travelling expenses oo oo 168 (0-1,196; 125-210) 765.8' 146 (8-634; 117-174)
Total direct costs 10,146 (715-51,375; 7,614-12,678) 17,712 (7,508-99,750; 15,004-20,421)
3Mean volume per patient per year. bCosts are presented as means (in €) per patient per year (range; 95% confidence interval). Mean number of kilometres.
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than for other patients (Table 3), a significant difference could be established (pre-biological 
treatment period: €6,738.- [range 0-43,465; 95% CI 4,384-9,092], biological treatment 
period: €1,475.- [range 0-21,517; 95% CI 564-2,385].
Direct costs for subgroup of hospitalized patients
As the yearly expenses for biological treatment matched with the expenses for 
approximately 30 hospital admission days, direct costs for patients who were admitted 
for more than 30 days per year on average in the pre-biological treatment period were 
analysed separately. This subgroup comprised 12 patients. Median number of hospital 
admission days was 53.0 PPPY in the pre-biological treatment period, compared with 5.3 
PPPY in the biological treatment period. For 6 of the 12 patients the mean direct costs 
per year declined after the introduction of biologics, as a consequence of the reduction 
in hospital admission days. Five patients who were admitted for more than 30 days per 
year on average in the pre-biological treatment period were not admitted during biological 
therapy (Table 3). Patient 10 had an extremely severe therapy resistant psoriasis, and was 
admitted frequently, even during biological therapy.
Table 3. Direct costs fo r patients w ith hospital admission > 30 days.
Pre-biological treatment period B iological treatment period
Patient no. Number o f daysa Direct costsb Number o f daysa Direct costsb
1 54.2 31,215 0.0 12,770
2 58.6 30,888 3.6 17,336
3 33.3 18,985 0.0 16,404
4 30.6 18,880 0.0 19,567
5 91.3 51,375 0.0 15,037
6 62.1 31,514 45.2 35,190
7 73.1 36,235 7.2 18,321
8 31.5 19,319 18.4 24,340
9 34.6 18,785 0.0 21,810
10 64.9 35,493 159.2 99,750
11 51.6 26,761 23.6 28,332
12 51.7 27,371 7.0 25,222
Median of 12 
patients 53.0 29,130 5.3 20,689
aMean number of hospital admission days per patient per year. bMean costs (in €) per patient per year.
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Patient satisfaction with biological therapy
Patients were highly satisfied with their biological therapies, reflected by the mean TSQM 
score for global satisfaction of 77.8 (range 0.0-100.0; 95% CI 72.3-83.4). Categorised 
TSQM questions on effectiveness, side effects and convenience showed a mean score of 
71.3 (range 0.0-100.0; 95% CI 64.5-78.2), 95.5 (range 0.0-100.0; 95% CI 91.9-99.1) and 
80.2 (range 50.0-100.0; 95% CI 76.5-83.9), respectively.
Effectiveness of biological treatment
The mean PASI at the start of the biological treatment period was 19.0 (range 5.9-45.2; 
95% CI 16.8-21.2). This decreased to a score of 6.4 (range 0.0-26.6; 95% CI 5.1-7.6), 
indicating a mean improvement of 66.4%. Seventy-three percent of patients (n = 49) 
reached a PASI 50; forty-three percent (n = 29) reached a PASI 75.
Discussion
The current retrospective cohort study of the economic impact of psoriasis in a real life care 
setting shows that the direct costs, related to the treatment of high-need psoriasis in daily 
clinical practice, are significantly higher during the biological treatment period than during 
the period before. Although the direct costs for biological therapy were high (€13,843.- 
PPPY), there was a large decrease in costs for medical consultations during biological 
treatment, ultimately resulting in a mean rise in direct costs of €7,566.- PPPY (Table 2). 
The number of day care and hospital admission days in this period decreased by 94% and 
64%, respectively. For 6 of the 67 patients in the cohort, introduction of biologics led to a 
reduction of direct costs, as these patients no longer needed long-term hospitalization.
In accordance with previous studies, the introduction of biologics was accompanied by 
a distinct improvement of psoriasis signs, as reflected by a mean decrease in PASI of 
118 66.4%. Moreover, patients appeared to be highly satisfied with biological treatment, as the 
TSQM score for global satisfaction was 77.8.
The outcomes are the results from an analysis of daily clinical practice data in patients 
with severe, classical-therapy resistant (high-need) psoriasis treated in a tertiary referral 
hospital with biologics for more than one year. Cost proportions may be different for 
patients with milder psoriasis and for treatment in primary or secondary care settings, as 
treatment schedules may be different.
In the current study, the MDD for etanercept was 8.8 mg, i.e. 61.6 mg per week. Based 
on the mean follow-up duration of 2.6 years, the mean weekly etanercept dosage would 
normally be 54.4 mg, according to the dosage schedule of 50 mg twice weekly for 12
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weeks followed by a dose of 25 mg twice weekly or 50 mg once weekly. The mean dosage 
of 61.6 mg per week equals this standard dosage regimen plus a dose increase from 50 
mg to 100 mg for 20 weeks. So, in the current cohort the used etanercept dosage, and 
therefore the expense for biological therapy, is considerably higher than in randomized 
controlled trials. In a previous study we found that 35.5% of the patients, who were of the 
same cohort as that analysed currently, were obese.17 This may lead to an increase in the 
medication doses required for adequate therapy, and thus in medication costs.
Costs related to psoriasis comorbidities, such as psoriatic arthritis, were not included in 
the current analysis. In addition, OTC medicines were not taken into account, although a 
study by Javitz et al. revealed that the direct costs for OTC medication in psoriasis care are 
substantial.18 Direct costs may in fact be higher, though, both for the period before and the 
period after the introduction of biologics. Furthermore, specific OTC products may have 
antipsoriatic effects, thereby influencing 'biological' treatment effectiveness.
The design of the present study has certain limitations. Firstly, the retrospective design 
could give rise to inaccuracies during analysis. Obviously, a prospective study would have 
given more reliable data. It would be of great value if treatment effectiveness, quality of 
life and cost measures could be taken into account in prospective registries on systemic 
treatments for psoriasis in daily practice.
Secondly, only patients who received biologics for at least one year were included for 
analysis. For patients who did not continue treatment for at least one year, biological 
treatment may have been ineffective or not tolerated, which may influence the outcomes.
However, only five of all 140 patients discontinued therapy before the period of one year as 
a result of ineffectiveness or intolerance. Other patients were lost to follow-up, or started 
biologics shortly before the analysis was performed.
Thirdly, the causality of biological treatment in the shifts of different cost aspects after the 
introduction of biological therapies is difficult to establish, as carryover effects may have 
taken place. 119
In conclusion, treatment of patients with psoriasis with biologics in daily practice is clinically 
effective with a substantial PASI decrease. It results in a rise in direct costs of €7,566.- 
PPPY on average. A small subgroup of patients who demonstrate a significant reduction in 
hospital admissions after the introduction of biologics even show a reduction in direct costs 
in this period. So, introduction of biological therapies for psoriasis may have cost-neutral 
or cost-saving effects for patients who otherwise require long hospitalizations. Additionally, 
treatment with biologics was accompanied by a high patient satisfaction.
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Analysis of three-year national reimbursement application data on 
etanercept and efalizumab for psoriasis
Abstract
Background: Since September 2004, etanercept and efalizumab are approved by the 
European Union for the treatment of adult patients with moderate to severe plaque 
psoriasis. To obtain approval for reimbursement of these therapies, patients need to fulfil 
specific diagnostic, disease activity, and response criteria.
Objective: Aim of this analysis was to evaluate three-year Dutch reimbursement application 
data, which were applied for treatment of psoriasis with etanercept or efalizumab. 
Methods: All applications for approval of treatment with etanercept and efalizumab between 
January 2005 and January 2008 were included. Data were analysed descriptively with 
regard to application characteristics, patient characteristics, disease activity measures, 
medication history, and response on therapy.
Results: Analysis was performed of 2,306 received applications, which included 1,197 
patients with 1,327 initial treatment applications. 1,254 of all initial treatment applications 
and 812 of all follow-up applications were approved. According to the application data 
concerning medication history, phototherapy was used by most patients, followed by 
ciclosporin and methotrexate. A 50% reduction in Psoriasis Area and Severity Index after 
12 weeks of treatment was achieved by 69.0% of all patients with an approved initial 
treatment application for etanercept, and by 50.0% of all patients with an approved initial 
treatment application for efalizumab.
Conclusions: The present analysis demonstrates that, as a consequence of strict 
adherence to reimbursement criteria, only 0.4% of Dutch patients with psoriasis are treated 
with etanercept or efalizumab. The question arises whether it is indicated to broaden these 
criteria, in particular considering the long-term and presumably safe control of psoriasis 
by biologics.
Adapted from: Driessen RJ, de Jong EM, de Rie MA, Salemink GW, van de Kerkhof PC. 
Analysis of 3-year national reimbursement application data on etanercept and efalizumab 
for psoriasis. Br. J. Dermatol. 2008; 159: 760-1.
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Introduction
The past years have witnessed great advances in our knowledge of the pathogenesis of 
psoriasis, which has catalysed the development of targeted biological treatments, such as 
etanercept and efalizumab.1 Etanercept is a human tumor necrosis factor (TNF) receptor 
fusion protein, which competitive inhibits TNF-binding to its cell surface receptors and 
thereby inhibits the biological activity of TNF.2 Efalizumab is a recombinant humanized 
monoclonal antibody that inhibits the binding of lymphocyte function-associated antigen 1 
(LFA-1) to intercellular adhesion molecule 1 (ICAM-1), which interferes with T lymphocytes 
adhesion to other cell types.3
Since September 2004, etanercept and efalizumab are approved by the European Union for 
the treatment of adult patients with moderate to severe plaque psoriasis. As a consequence 
of the expense of these biological therapies, patients need to fulfil specific criteria to obtain 
approval for reimbursement in many countries. In The Netherlands, patients with psoriasis 
are considered for reimbursement of the cost of treatment with etanercept or efalizumab 
if they are unresponsive, intolerant or have contraindications to phototherapy, ciclosporin 
and methotrexate. Furthermore, a minimum Psoriasis Area and Severity Index (PASI)4 of 
10 is required at the time of screening. A PASI between 8 and 10 in combination with a 
Skindex-295 of at least 35 is accepted as well. After 12 weeks of therapy, a PASI reduction 
of at least 50% (PASI 50) is necessary to demonstrate effectiveness of the prescribed drug 
and to get approval for long-term treatment and reimbursement.
Evaluation of these diagnostic, disease activity and response criteria in The Netherlands 
occurs centrally by a subcommittee of an independent foundation (LAndelijke Beoordeling 
Aanvragen Geneesmiddelen [National Evaluation of Applications of Drugs], LABAG). This 
committee is appointed by health insurance companies and comprises representatives of 
dermatologists, rheumatologists, health insurance companies and the government.
Since the beginning of 2005, etanercept and efalizumab are reimbursed by Dutch health 
126 insurance companies for the treatment of patients with psoriasis. Therefore, reimbursement 
application data of three years are available at the moment.
Aim of this analysis was to evaluate three-year Dutch reimbursement application data, 
including diagnostic, disease activity, and response criteria, which were applied for 
treatment of psoriasis with etanercept or efalizumab.
Patients and methods
Requests for reimbursement of etanercept or efalizumab were made by dermatologists 
filling out an application form, which was submitted to the national committee (LABAG).
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This application form contained patient's demographic data, specific questions about 
phototherapy, methotrexate and ciclosporin use in history, baseline and follow-up PASI, 
and Skindex-29.
All applications for approval of treatment with etanercept and efalizumab between January 
2005 and January 2008, submitted to LABAG, were included. Data were analysed 
descriptively with regard to application characteristics, patient characteristics and disease 
activity measures of involved patients, medication history, and response on therapy. 
Patient characteristics and medication history were analysed from the patient perspective. 
Response on therapy was analysed from the treatment perspective.
Application characteristics
The number of received application forms and the number of patients concerned was 
calculated. The percentage of approved initial and follow-up treatment applications was 
computed.
Patient characteristics
Patient characteristics included gender, age at application, and baseline PASI.
Medication history
Analysis of medication history comprised whether phototherapy, methotrexate and 
ciclosporin were used in history and the reason for treatment failure. According to the 
Dutch guideline, only patients with plaque psoriasis are eligible for biological therapies.
Response on therapy
To be eligible for treatment with etanercept or efalizumab, patients must be unresponsive, 
intolerant or have contraindications to phototherapy, ciclosporin and methotrexate. 
Response failure of phototherapy was defined as a less than 50% clearance of psoriasis 
after twice weekly treatment for 10 weeks. Response failure of ciclosporin was defined 
as a less than 50% clearance of psoriasis after treatment with a daily dosage of 3-5 
milligrams/ kilogram for 16 weeks. Response failure of methotrexate was defined as a less 
than 50% clearance of psoriasis after treatment with a weekly dosage of 22.5 milligrams 
for 16 weeks. Patients may not have reached the required maximum therapy dose as a 
consequence of contraindications or intolerance.
In some cases, it was difficult to distinguish contraindications and side effects. For 
example, actinic damage is a side effect of phototherapy, but also an (acquired) relative 
contraindication for phototherapy or ciclosporin treatment. In these cases, the reason for
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treatment failure was defined as “adverse event AND contraindication”.
To study the response of therapy after three months, only patients with initial application 
approval were enclosed. PASI 50 response was calculated by comparing the number 
of approved applications for continuation after twelve weeks with the number of initial 
applications. Furthermore, the mean percentage improvement in PASI from baseline 
was calculated for each treatment in two ways. First, treatment efficacy was analysed 
for all patients with approved initial applications. In case of missing follow-up application 
forms and hence missing PASI, treatment was considered insufficient and the baseline 
PASI was carried forward to week 12 (although side effects could have been a reason for 
discontinuation of therapy as well). Second, mean percentage improvement in PASI from 
baseline was determined for 'responding' patients, i.e. patients with approved initial and 
follow-up applications.
Results
Application characteristics
From January 2005 to January 2008, 2,306 application forms were received by LABAG. 
These concerned 1,327 initial treatment applications (etanercept 1,014, efalizumab 313). 
From patient perspective, this comes down to 1,197 patients, including 884 patients 
with an application for etanercept, 183 patients with an application for efalizumab and 
130 patients with two applications: one for etanercept and one for efalizumab. The last 
mentioned group failed to respond to the first applied biological therapy, and an application 
for an alternative biologic was submitted. In 62.3% (81) of the patients in this group, the 
first applied therapy was efalizumab; for 37.6% (49) the first submitted application was 
etanercept.
In 2005, 571 initial treatment applications were received, compared to 429 and 327 in 
128 2006 and 2007, respectively. When analysing the number of received initial applications 
per month, no specific seasonal pattern was recognizable. In total, 1,254 (94.5%) of all 
initial treatment applications were approved by LABAG.
Patient characteristics
Of all patients, 729 (60.9%) were male, 452 (37.8%) were female, and of 16 (1.3%) the 
gender was not mentioned. Mean ± standard error of the mean (SEM) age was 49.0 ±
0.4 years (range 16.9-86.6). Mean baseline PASI at patients' initial application was 22.5. 
Skindex-29 was applied only for 21 patients (1.7%). The mean Skindex-29 was 48.5. Date 
of primary diagnosis of psoriasis was not registered on the application forms, so disease
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duration could not be calculated.
Medication history
Medication history and reason for treatment failure are presented in Table 1. According to 
the application forms, most people used phototherapy in history (1141, 95.3%). Ciclosporin 
was used at the required dosage and duration by 826 (69.0%) of all patients; methotrexate 
was only used at the required dosage and duration by less than half of the patients (531, 
44.4%). Response on phototherapy was insufficient in 79.0% of all cases. On the contrary, 
ciclosporin and methotrexate had side effects or were contraindicated in more than 65% 
of the patients.
Table 1. Medication history o f individual patients and reason fo r treatment failure.
All patients, 
no. (%)
Insufficient, 
no. (%)
AE,
no. (%)
AE and CI, 
no. (%)
CI,
no. (%)
Unknown, 
no. (%)
Phototherapy 1197 (100.0) 946 (79.0) 81 (6.8) 41 (3.4) 71 (5.9) 58 (4.8)
Yesa 1141 (95.3) 935 (78.1) 69 (5.8) 36 (3.0) 52 (4.3) 49 (4.1)
Noa 56 (4.7) 11 (0.9) 12 (1.0) 5 (0.4) 19 (1.6) 9 (0.8)
C iclosporin 1197 (100.0) 331 (27.7) 195 (16.3) 483 (40.4) 112 (9.4) 76 (6.3)
Yesa 826 (69.0) 327 (27.3) 151 (12.6) 291 (24.3) 7 (0.6) 50 (4.2)
Noa 371 (31.0) 4 (0.3) 44 (3.7) 192 (16.0) 105 (8.8) 26 (2.2)
Methotrexate 1197 (100.0) 282 (23.6) 340 (28.4) 399 (33.3) 68 (5.7) 108 (9.0)
Yesa 531 (44.4) 242 (20.2) 97 (8.1) 118 (9.9) 8 (0.7) 66 (5.5)
Noa 666 (55.6) 40 (3.3) 243 (20.3) 281 (23.5) 60 (5.0) 42 (3.5)
Percentages are calculated by dividing by the total number of patients (1197). aYes/No are answers to specific 
questions on medication history: ‘Did the patient receive treatment with phototherapy twice weekly for 10 
weeks?’ ‘Did the patient receive treatment with ciclosporin at a daily dosage of 3-5 mg/kg for 16 weeks?’ ‘Did the 
patient receive treatment with methotrexate at a weekly dosage of 22.5 mg for 16 weeks?’ AE, Adverse Events; 
CI, Contraindication. 129
Response on therapy
In total, 1,254 of all initial treatment applications and 812 of all follow-up applications were 
approved by LABAG. The remaining 442 follow-up applications were not received or were 
rejected, mainly as a result of a < 50% decrease in PASI at week 12.
Age, gender, and baseline PASI were comparable for each treatment group. A PASI 
50 response was achieved by 69.0% of all patients with an approved initial treatment 
application for etanercept, and by 50.0% of all patients with an approved initial treatment 
application for efalizumab. The mean reduction in PASI relative to baseline at week 12
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was 53.1% for etanercept, compared with 35.5% for efalizumab, after carrying forward 
the baseline PASI to week 12 in case of missing follow-up PASI. When analysing only 
'responding' patients, mean reduction in PASI relative to baseline was 75.0% and 68.3% 
for etanercept and efalizumab, respectively (Table 2).
Table 2. Response on therapy o f patients with approved initia l treatment application.
All approved applications 
(n =1254)
Applications o f responding 
patients" (n = 812)
Etanercept 
(n = 972)
Efalizumab 
(n = 282)
Etanercept 
(n = 671)
Efalizumab 
( n =141)
Baseline PASI, mean ± SEM (range) 22.6 ± 0.4 
(1.8-72.0)
21.7 ± 0.6 
(0.9-63.3)
23.2 ± 0.4 
(3.0-68.3)
22.1 ± 0.8 
(8.2-56.4)
Follow-up PASI, mean ± SEM (range) 10.6 ± 0.3 
(0.0-72.0)
14.0 ± 0.7 
(0.0-63.3)
5.8 ± 0.2 
(0.0-70.8)
7.0 ± 0.5 
(0.0-35.3)
PASI reduction relative to baseline 53.1% 35.5% 75.0% 68.3%
PASI 50 responseb Etanercept 69.0%
Efalizumab 50.0%
aResponding patients are defined as patients with approved initial and follow-up applications. bCalculated as 
number of responding patient divided by total number of patients in each treatment group. PASI, Psoriasis Area 
and Severity Index; SEM, Standard Error of the Mean; PASI 50, 50% reduction in PASI relative to baseline.
Discussion
This report presents three-year Dutch diagnostic, disease activity, and response criteria 
data, which were applied for reimbursement of treatment of psoriasis with etanercept 
or efalizumab. Analysed application forms comprised data of 1,197 patients, who were 
potentially eligible for biological therapy. As the estimated number of persons suffering 
from psoriasis in The Netherlands is 300,000, this is only 0.4% of the Dutch psoriasis 
population. Moreover, approximately 15% to 20% (i.e. 45,000 to 60,000) of psoriatic 
130 patients have a moderate to severe psoriasis that may require systemic therapy.6 Converted 
to these numbers, only 2% to 3% of patients with psoriasis requiring systemic treatment 
seemed eligible for biological therapy. Obviously, the number of patients using biological 
treatment will increase in the following years, although the number of new applications per 
year declined during the studied period. Nevertheless, the request for biological therapy is 
evidently made for merely a small percentage of patients with psoriasis.
Only 5.5% of all initial applications were rejected by LABAG. This validates the conclusion 
that dermatologists are familiar with the demanded criteria for reimbursement of biological 
therapies.7 Three times more applications were received for etanercept than efalizumab. 
Apparently, dermatologists have a preference for etanercept as first-choice biological
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therapy. The fact that etanercept is approved for the treatment of psoriatic arthritis as well, 
whereas efalizumab is not, might account for this.8 Furthermore, according to the presented 
data, the efficacy of etanercept is superior to efalizumab. However, the presented data are 
unsuitable for objective comparison between etanercept and efalizumab. For this purpose, 
a randomized controlled trial is needed.
Epidemiologic literature states that psoriasis is equally common in males and females.9 In 
the current analysis, however, 60.9% of all patients was male and 37.8% was female. This 
gender difference could be explained by the fact that women of childbearing potential will 
less frequently be treated with systemic medication of which data about the influence on 
pregnancy are limited. On the other hand, male patients may suffer from a more severe 
psoriasis than women, as studies show that plaque thickness is associated with male 
gender.1011 Mean baseline PASI was slightly higher than baseline data of randomized 
clinical trials.12
According to the application data concerning medication history, phototherapy was used 
by most patients, followed by ciclosporin and methotrexate. The relatively infrequent 
use of ciclosporin and methotrexate may have resulted from the fact that many patients 
actually did receive these therapies, but did not completely fulfil the required criteria for 
dosage and treatment duration. Remarkably, methotrexate was only used by fewer than 
half of the patients. This may be due the fact that patients did not reach the required 
dosage of 22.5 mg per week because of side effects at lower dosage. Another explanation 
may be that many patients with psoriasis requiring systemic treatment are successfully 
treated with methotrexate, and consequently do not need biological therapy. The latter 
explanation may also clarify why the request for biological therapy is made for merely a 
small percentage of patients with moderate to severe psoriasis.
As expected, response on phototherapy was insufficient in most cases, whereas reasons 
for failure of ciclosporin and methotrexate were mostly side effects or contraindications.
However, questions about medication history seemed to be misinterpreted many times. 131 
Data, therefore, were less suitable for analysing the medication history exactly, although the 
documentation was sufficient for decision-making by LABAG. Furthermore, distinguishing 
contraindications and side effects was difficult.
A PASI 50 response was achieved by 69.0% of all patients with an approved initial 
treatment application for etanercept, and by 50.0% of all patients with an approved initial 
treatment application for efalizumab. These results are slightly lower than randomized 
controlled trial data (etanercept 76%, efalizumab 55%)12, but comparable to the results 
of a daily practice cohort studies, in which the efficacy, safety and adverse events of 
etanercept and efalizumab treatment in daily practice were evaluated.1314
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Overall, the mean reduction in PASI relative to baseline at week 12 was 53.1% for 
etanercept and 35.5% for efalizumab. However, in this analysis treatment efficacy is 
underestimated, as the baseline PASI was carried forward to week 12 in case of missing 
follow-up PASI. The analysis of only responding patients leads to an overestimation of 
treatment efficacy (etanercept 75.0%, efalizumab 68.3%), so the real values should be 
somewhere in between the results of both analyses.
The present analysis demonstrates that, as a consequence of strict adherence to 
reimbursement criteria, only 0.4% of Dutch patients with psoriasis are treated with 
etanercept or efalizumab. The question arises whether it is indicated to broaden these 
criteria, in particular considering the long-term and presumably safe control of psoriasis 
by biologics.
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CHAPTER 13
Analysis of four-year Dutch reimbursement application data of 
biological therapies for psoriatic arthritis
Abstract
Objectives: To get the approval for reimbursement of biological therapies for psoriatic 
arthritis (PsA), patients need to fulfil specific criteria in many countries. Aim of this study 
was to evaluate the four-year Dutch reimbursement application data, including diagnostic, 
disease activity and response criteria, which were applied for treatment of PsA with 
biologics.
Methods: All initial and follow-up applications for approval of treatment with biologics were 
included for investigation. Data were analysed descriptively with regard to application 
characteristics, patient characteristics and response to therapy.
Results: In the period studied, 3723 application forms of 1991 patients were received. This 
concerned 2118 initial treatment applications and 1605 follow-up applications. Of all initial 
treatment applications, 2003 (94.6%) were approved. The major part of all applications 
concerned requests for etanercept (59.1%), followed by adalimumab (38.2%). Patients 
were suffering from polyarthritis in most cases (63.1%). Methotrexate was used by nearly 
all patients, but only 55.8% had used the required dosage of 25 mg/week. Approximately 
79.4% of all patients had met the response criteria after three months of treatment. The 
mean number of affected joints declined from 7.7 at first application to 1.4 at follow-up. 
The initial visual analogue scale (VAS) score indicated by patients decreased from 71.2 
to 24.1 at follow-up. The VAS score indicated by physicians decreased from 66.0 to 18.4. 
Conclusions: Biologics are expensive, but highly effective in the treatment of PsA. Careful 
134 compilation of treatment and reimbursement criteria is important for patients as well as for 
physicians and health insurance companies.
Adapted from: Driessen RJ, de Jong EM, Salemink GW, Burer JH, van de Kerkhof PC, van 
den Hoogen FH. Analysis of 4-year Dutch reimbursement application data of biological 
therapies for psoriatic arthritis. Rheumatology (Oxford) 2010; 49: 588-91.
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Introduction
Psoriatic arthritis (PsA) is a seronegative inflammatory joint disease associated with 
psoriasis. Mild PsA can be successfully treated with nonsteroidal anti-inflammatory drugs 
(NSAIDs) or intra-articular corticosteroid injections. In case of severe PsA, synthetic or 
biological disease-modifying antirheumatic drugs (DMARDs), or combinations of these 
therapies are needed to alleviate signs and symptoms, and to inhibit structural joint 
damage.1
Currently, three anti-tumor necrosis factor a (TNF-a) agents are registered for the treatment 
of PsA, including adalimumab, etanercept and infliximab. Biologics are expensive and 
therefore in many countries criteria are developed that patients need to fulfil to get approved 
for reimbursement of these therapies. Nevertheless, a recent pharmacoeconomic study 
on PsA showed that anti-TNF-a therapy is cost-effective in short-term clinical practice.2 
In The Netherlands, the reimbursement criteria for biological treatment for PsA as well as for 
other rheumatological indications are formulated by the Dutch Society for Rheumatology 
(Nederlandse Vereniging voor Reumatologie), and subsequently authorized by the Health 
Care Insurance Board (College Voor Zorgverzekeringen). Which criteria are applicable 
is dependent on the type of PsA. At joint count, at least two inflamed joints should be 
found. Patients are eligible for reimbursement of biological treatment if they are not 
responsive to methotrexate in a dosage of at least 25 milligram (mg)/week, or if they 
have a contraindication or intolerance for this therapy. Secondly, the global assessment of 
disease activity, measured on the basis of a visual analogue scale (VAS) of 0-10, should 
be at least 4 according to the physician as well as the patient. Thirdly, the arthritis should 
be persistent despite local (intra-articular) therapy. In case of polyarticular PsA (5 or more 
joints affected), there should be at least 5 tender and 5 swollen joints, or a mutilating 
arthritis should be present. After three months of therapy, patients should have met the 
response criteria, implying a diminution of number of painful or swollen joints, in at least 
one affected joint in case of an oligoarticular PsA, or in at least 20% of the affected joints 
in case of a polyarticular PsA. Disease activity measures on psoriasis are left out of 
consideration.
From February 2004 to March 2008, evaluation of these diagnostic, disease activity 
and response criteria in The Netherlands occurred centrally by a subcommittee of an 
independent foundation (LAndelijke Beoordeling Aanvragen Geneesmiddelen [LABAG], 
National Evaluation of Applications of Drugs). This committee was appointed by health 
insurance companies and comprises representatives of rheumatologists, dermatologists, 
paediatricians, health insurance companies and the government. Applications for 
biological therapies for PsA could only be submitted by physicians with experience in
135
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treating patients with PsA.
Aim of this study was to evaluate the four-year Dutch reimbursement application data, 
including diagnostic, disease activity and response criteria, which were applied for 
treatment of PsA with biological therapies.
Patients and methods
Requests for reimbursement of biologics were made by rheumatologists filling out an 
application form, which was submitted to the national committee (LABAG). This application 
form contained the patient's demographic data, questions about the number of affected 
joints, specific questions about methotrexate use and dosage in history, type of PsA and 
VAS scores on global disease activity of patients and physicians. After three months 
of therapy, a second, identical form was filled out and submitted for evaluation of the 
response criteria.
All initial and follow-up applications for approval of treatment with biologics submitted to 
LABAG between February 2004 and March 2008 were included for investigation. Data were 
analysed descriptively with regard to application characteristics, patient characteristics and 
response to therapy. Patient characteristics were analysed from the patient perspective. 
Response to therapy was analysed from the treatment perspective.
Application characteristics
The number of received application forms and the number of patients concerned were 
calculated. The percentage of approved initial and follow-up treatment applications was 
computed.
Patient characteristics
Patient characteristics included gender, age at very first application, type of PsA, baseline 
136 VAS scores and medication history with regard to methotrexate use.
Response to therapy
The assumption was made that rheumatologists did not submit a follow-up application 
when there was insufficient response or side effects to biological therapy. Therefore, the 
percentage of patients meeting the response criteria after three months of therapy was 
calculated by dividing the number of approved follow-up applications by the number of 
approved initial applications. Furthermore, the response to therapy was represented by 
the decline in the number of affected joints and the reduction in VAS scores of patients 
and physicians.
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Results
Application characteristics
In the period studied, 3723 application forms were received by LABAG. This concerned 
2118 initial treatment applications and 1605 follow-up applications. Of all initial 
treatment applications, 2003 (94.6%) were approved, 51 (2.4%) were rejected because 
reimbursement criteria were not fulfilled, 47 (2.2%) could not be taken into consideration due 
to insufficient data, 10 (0.5%) were withdrawn by physicians before approval, three (0.1%) 
were considered as reflecting no reason to treat, two (0.1%) had no decision status, one 
(0.0%) received no follow-up advice and one (0.0%) received a neutral advice, meaning 
that direct consultation of the health insurance company by the prescribing physician was 
required. Of the 1605 follow-up applications, 1591 (99.1%) met the response criteria and 
were approved, 7 (0.4%) did not meet the response criteria and thus were rejected, 5 
(0.3%) were withdrawn, one (0.1%) was considered as reflecting no reason to treat and 
one (0.1%) could not be taken into consideration due to insufficient data.
Of the 2118 initial treatment application forms, 1251 (59.1%) concerned an application for 
etanercept, 810 (38.2%) for adalimumab, 7 (0.3%) for infliximab, one (0.0%) for anakinra 
and in 49 (2.3%) forms the medication requested for was not discernible. The number 
of applications for infliximab was low, as this biologic, in contrast to etanercept and 
adalimumab, was not fully reimbursed by health insurance companies in The Netherlands.
Patient characteristics
Initial and follow-up application forms comprised 1991 patients. Of all patients, 1075 
(54.0%) were males, 868 (43.6%) were females, and for 48 (2.4%) the gender was not 
mentioned. Mean age at first application was 47.9 (range 8.7-85.1; standard error of 
the mean (SEM) 0.3) years. According to the application forms, patients had different 
types of PsA, including polyarthritis (n = 1256, 63.1%), oligoarthritis (n = 641, 32.2%), 
mutilating arthritis (n = 57, 2.9%), polyarthritis as well as mutilating arthritis (n = 19, 1.0%), 
oligoarthritis as well as mutilating arthritis (n = 5, 0.2%) or the type of PsA was unclear (n =
13, 0.7%). At first application, the mean number of affected joints was 7.7 (range 0.0-62.0; 
SEM 0.1). Mean VAS score indicated by patients was 71.2 (range 9.0-100.0; SEM 0.3); 
mean VAS score indicated by physicians was 66.0 (range 8.0-100.0; SEM 0.3). Of all 1991 
patients, 1945 (97.7%) used methotrexate in history, of whom 1085 had used the required 
dosage of methotrexate of 25 mg/week. In the other 860 patients, this dosage was not 
reached as a consequence of side effects at lower dosages of methotrexate. The mean 
maximum dosage of methotrexate used was 20.9 (range 5.0-50.0; SEM 0.1) mg/week.
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Response to therapy
A total of 2003 of all initial treatment applications and 1591 of all follow-up applications 
were approved by LABAG, indicating that approximately 79.4% (1591 out of 2003) of all 
patients had met the response criteria after three months of treatment. From the data it is 
unclear whether biological treatment was withdrawn because of unresponsiveness to the 
treatment, side effects or other reasons. Categorized for different biological therapies, the 
percentage of patients meeting the response criteria came down to approximately 80.1% 
(966 out of 1206) for patients treated with etanercept and approximately 83.3% (622 out of 
747) of patients treated with adalimumab.
The mean number of affected joints declined from 7.7 (range 0.0-62.0; SEM 0.1) at first 
application to 1.4 (range 0.0-28.0; SEM 0.1) at follow-up, corresponding with an 81.8% 
decline in the number of affected joints in three months. The initial VAS score indicated 
by patients decreased from 71.2 (range 9.0-100.0; SEM 0.3) to 24.1 (range 0.0-95.0; 
SEM 0.4) at follow-up, i.e. a reduction of 66.2%. Likewise, the VAS score indicated by 
physicians decreased from 66.0 (range 8.0-100.0; SEM 0.3) to 18.4 (range 0.0-90.0; SEM
0.3; 72.1% reduction).
Discussion
This report represents the four-year Dutch national diagnostic, disease activity and response 
criteria data, which were applied for reimbursement of treatment of PsA with biologics. 
Analysed application forms comprised data of 1991 patients, who were potentially eligible 
for biological therapy. A previous analysis of three-year Dutch reimbursement application 
data, which were applied for treatment of psoriasis with etanercept or efalizumab, 
concerned 1197 patients.3 Thus, relatively more requests for biological treatment are made 
for PsA than for moderate to severe psoriasis. Several explanations for this can be given. 
First of all, PsA may be more prevalent than moderate to severe psoriasis, although the 
138 exact prevalence of PsA is unknown. Data about the prevalence of inflammatory arthritis 
in patients with psoriasis vary from 6 to 42%.4 Secondly, rheumatologist may be more 
inclined than dermatologists to prescribe systemic therapies, including biologics. Thirdly, 
the criteria for (initial) reimbursement of biologics may be easier to meet for PsA than 
for moderate to severe psoriasis, as only one systemic drug that must have been used 
in history (i.e. methotrexate) is specified. The criteria only encompass disease activity 
measures specific for PsA and do not include severity measures on psoriasis. Besides, the 
reimbursement criteria do not incorporate frequently used measures such as C-reactive 
protein (CRP) or Disease Activity Score in 28 joints (DAS-28).5 Finally, PsA may be more 
disabling than psoriasis, necessitating intensive systemic therapy.
CHAPTER 13
A high percentage of all initial and follow-up applications (94.6% and 99.1%, respectively) 
were approved, indicating that rheumatologists are familiar with the demanded criteria 
for reimbursement of biological therapies. The major part of all applications concerned 
requests for etanercept, followed by adalimumab. This is very likely related to the different 
moments of approval of reimbursement by health insurance companies of etanercept and 
adalimumab in The Netherlands, as etanercept has been reimbursed since December 2003 
and adalimumab since October 2005. Likewise, as infliximab was not fully reimbursed, the 
number of applications for this pharmaceutical was low.
The patients considered were predominantly male (54.0%) and were suffering from 
polyarthritis in most cases (63.1%). The latter is in agreement with literature, which says 
that polyarthritis is the most common type of PsA in patient with established disease.6 In 
the current study, the mean number of affected joints was 7.7. Methotrexate was used by 
nearly all patients, but only 55.8% had used the required dosage of 25 mg/week.
Global disease activity, indicated on a VAS, was assessed higher by patients than by 
physicians at both moments of evaluation. In a publication by Nicolau et al. on discrepancy 
in the perception of rheumatoid arthritis disease activity between patient and physician, 
the same difference was established in the majority of patients.7
Interestingly, approximately 80% of all patients had met the response criteria after three 
months of treatment. This is much higher than the response percentages calculated by 
using the application data on biological therapies for psoriasis.3 Like the initial criteria for 
reimbursement of biologics, the response criteria may also be easier to meet for PsA than 
for psoriasis. Nevertheless, in randomized controlled trials on biological therapies for PsA, 
the American College of Rheumatology 20% improvement criteria (ACR20) response after 
12 weeks, which roughly resembles the Dutch response criteria, was far below 80%.8 Data 
from large registries may be valuable to establish the efficacy of biological therapies for 
PsA in daily practice.9;10
In conclusion, biologics are expensive but highly effective therapies for different immune- 
mediated diseases, including PsA. Currently, biological therapies are indicated exclusively 
for severely affected patients. Careful compilation of treatment and reimbursement criteria 
is of importance for patients as well as for physicians and health insurance companies. 
The Dutch protocol for reimbursement of biologics for PsA, with diagnostic, disease activity 
and response criteria, has facilitated that every rheumatologist could prescribe biologics 
for PsA. Moreover, it has increased the confidence between rheumatologists and health 
insurance authorities. Hence, the central evaluation of the criteria for reimbursement of 
treatment with biologics in The Netherlands by LABAG could be ceased in April 2008.
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CHAPTER 14
Appropriate infliximab infusion dosage and monitoring: 
results of a panel meeting of rheumatologists, dermatologists and
gastroenterologists
Abstract
Background: Infliximab, an anti-tumor necrosis factor biological agent, is currently indicated 
and reimbursed for rheumatoid arthritis, ankylosing spondylitis, Crohn's disease (both adult 
and paediatric), ulcerative colitis, psoriatic arthritis and plaque psoriasis. Development of 
national and international guidelines for rheumatology, gastroenterology and dermatology 
was mostly based on clinical studies and expert opinion.
Objective: To compare available guidelines and local protocols for rheumatology, 
dermatology and gastroenterology regarding dosage of infliximab, synergy of infliximab 
with concomitant medication and monitoring of vital signs during infliximab administration.
Methods: Current international, national and local guidelines on the use of infliximab 
were reviewed and compared, differences and shortcomings were identified, and optimal 
treatment schedules were discussed during an expert panel meeting (July 2008) of clinical 
experts and researchers from the three departments of a Dutch university hospital.
Results: Recommended dosages of infliximab are not equal for different indications. Loss 
of response to infliximab is a common problem encountered within the three medical 
specialties, but indicators for adjustments in treatment schedules are lacking in all 
guidelines. Monitoring of vital signs (blood pressure, pulse, temperature) during infusion 
with infliximab is common practice and recommended by some guidelines. In our experience 
and confirmed by literature on inflammatory bowel disease, routine measurement of vital 
signs is not of any value in predicting or recognizing acute infusion reactions.
Conclusion: Different indications encompass different dosing schedules for infliximab. 141 
National and internal guidelines do not provide advices regarding loss of response.
Routine measurement of vital signs during infusion is not valuable in detecting acute 
infusion reactions and should only be performed in case of an acute infusion reaction.
These topics need to be studied in future studies and covered in future guidelines.
Adapted from: De Vries HS, van Oijen MG, Driessen RJ, de Jong EM, Creemers MC,
Kievit W, de Jong DJ. Appropriate infliximab infusion dosage and monitoring: results of a 
panel meeting of rheumatologists, dermatologists and gastroenterologists. Accepted for 
publication, Br. J. Clin. Pharmacol.
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Introduction
Rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriatic arthritis, ankylosing 
spondylitis, and psoriasis are chronic inflammatory diseases. Although the exact causes 
of these diseases remain unknown, over the past two decades major advances have 
been made in understanding the inflammatory processes. It is likely that in each of these 
diseases the innate and adaptive immune system are activated, with subsequent production 
of pro-inflammatory cytokines like tumor necrosis factor a (TNF-a).1-3 Antibodies against 
TNF-a have been developed for the treatment of several chronic inflammatory diseases, 
including the monoclonal antibodies infliximab and adalimumab. Infliximab, a chimeric 
(partly human, partly murine) monoclonal antibody, is the only intravenously administered 
anti-TNF antibody indicated and reimbursed for all of the following diseases: rheumatoid 
arthritis, ankylosing spondylitis, Crohn's disease (both adult and paediatric), ulcerative 
colitis, psoriatic arthritis and plaque psoriasis.
National and international guidelines and consensus statements on the use of infliximab 
have been developed for each of the three medical specialties involved in the treatment 
with infliximab (i.e. gastroenterology, rheumatology and dermatology) and reflect the 
current use in clinical practice.
In many centres like ours, the care for patients receiving infliximab is combined for 
patients with autoinflammatory disorders. This emphasizes the need for a combination 
of guidelines for the treatment with infliximab for patients with these disorders within the 
involved medical specialities.
Methods
This paper is the product of an expert panel meeting, held by the authors in July 2008. The 
purposes of this meeting were as follows:
• To identify similarities and differences within international, national and local 
guidelines and additional consensus statements from the medical specialties 
currently using infliximab as anti-TNF therapy, with regards to:
o Indications for infliximab 
o Dosage for initial and maintenance therapy 
o Monitoring of vital signs during infusion with infliximab
o Synergetic effects with concomitant medication use
• To discuss the following topics: optimal dosage of infliximab, monitoring of vital 
signs and use of concomitant medication.
• To discuss the optimal strategy in patients who lost response to infliximab. 
Members of the panel were selected, based on each member's clinical and/ or
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research experience on the use of infliximab, from the Departments of Rheumatology, 
Gastroenterology and Dermatology from our university hospital. Members from each 
medical field performed a literature search in their own discipline by searching the 
MEDLINE database until July 2008, using the keyword “infliximab”, limiting their search 
to practical guidelines and consensus statements. Additionally, the National Guideline 
Clearinghouse, a public resource for evidence-based clinical practice guidelines of the 
Agency for Healthcare Research and Quality in the United States (http://www.guideline. 
gov) was searched on guidelines related to infliximab. Furthermore, (local) Dutch guidelines 
from the medical specialties not accessible by MEDLINE but used in clinical practice were 
reviewed. Regarding these guidelines and consensus statements, we limited ourselves 
to the previous identified topics, namely indication, dosage, monitoring, synergy and loss 
of response (i.e. secondary inefficacy). Results were presented and discussed during the 
panel meeting. Additionally, hiatuses within guidelines and consensus statements were 
discussed.
Results 
Indication
Infliximab was first approved for patients with Crohn's disease in 1998. Approval for other 
indications followed in the subsequent years (Figure 1). In general, patients not responding 
to conventional therapy and having a moderate to high level of disease activity are eligible 
for treatment with a biologic like infliximab.
Gastroenterology
Both the international consensus statements of the American Gastroenterological 
Association (AGA) and the European Crohn's and Colitis Organisation (ECCO) as well 
as national guidelines agree that treatment with infliximab is appropriate for patients with 
inflammatory bowel disease experiencing corticosteroid dependency, glucocorticoid and/ 
or immunomodulative treatment refractoriness or active fistula associated with Crohn's 
disease.4-7 Especially patients with Crohn's disease with extraintestinal manifestations and 
fistulising disease are eligible for treatment with infliximab.48
Rheumatology
The international consensus statement on biologics for the treatment of rheumatoid 
arthritis, which is updated nearly every year, does not provide criteria on which patients 
should be treated with antibodies against TNF-a, like infliximab.9 National guidelines,
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however, do provide such criteria.
Patients should have failed on at least one (Swedish, French and Japanese guidelines) or 
two (British and Dutch guidelines)10111 disease-modifying antirheumatic drugs (DMARDs), 
including methotrexate in an adequate dosage, and should have a disease activity 
measured by the Disease Activity Score using 28 joint counts (DAS28)12 of > 5.1 (British 
guidelines).13-15 However, according to the Swedish guidelines no specific disease activity 
is required for starting with biologics.15 The consensus statement of the American College 
of Rheumatology (ACR) recommends starting with anti-TNF therapy like infliximab in 
case of 1) high disease activity (DAS28 > 5.1) for 3 to 6 months; or 2) high disease 
activity for less than three months in combination with features of a poor prognosis (e.g. 
functional limitation, extra-articular disease, rheumatoid factor positivity, bony erosions by 
radiography); 3) moderate disease activity (DAS28 > 3.2 and < 5.1) for > 6 months and 
inadequate response to monotherapy with methotrexate in combination with features of 
poor prognosis.16
Figure 1. International approval o f infliximab fo r autoinflammatory disorders.
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Dermatology
Few guidelines and consensus statements on the use of infliximab exist for patients with 
plaque psoriasis. According to the international consensus statement by Reich et al. 
patients with psoriatic arthritis in association with skin symptoms or moderate to severe
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psoriasis who have failed two or more systemic therapies are eligible for treatment with 
biologics. Furthermore, patients with a Psoriasis Area and Severity Index (PASI) of at 
least 20 or patients with an improvement of less than 50% on this scale with previous 
(non-)biological treatment, were eligible for treatment with infliximab.17 The guideline of 
the British Association of Dermatologists state that patients should have severe disease, 
defined as a PASI of 10 or more (or a body surface area of 10% or greater where PASI is 
not applicable) and a Dermatology Life Quality Index > 10. Secondly, patients should be 
unresponsive or intolerant to standard therapy.18 In The Netherlands, patients are eligible 
for biological therapies if they have a PASI of at least 10, and have failed to respond to 
phototherapy, methotrexate and ciclosporin in the past, or have a contraindication to, or 
are intolerant of these treatments.19
Dosage
The first randomized clinical trial with infliximab (by that time called cA2) in patients with 
rheumatoid arthritis randomized patients over a single dose of 1 milligram/kilogram (mg/ 
kg) bodyweight, 10 mg/kg bodyweight and placebo.20 In this study, a dosage dependent 
response was observed. A subsequent study comparing the effect of multiple infusions 
with infliximab in patients with rheumatoid arthritis compared 1 mg to 3 mg and 10 mg 
per kilogram bodyweight, showing the best results with the latter two.21 Furthermore 
it was shown that the median duration of response to the lowest dosage (i.e. 1 mg/kg 
bodyweight) lasted three weeks, compared to 5 and 8 weeks with dosages of 3 and 10 
mg/kg bodyweight, respectively.22
Additional studies, performed in patients with Crohn's disease, compared a single dose of
5 mg, 10 mg, or 20 mg per kilogram bodyweight, administered over a two-hour period. In 
this trial, patients receiving 5 mg/kg had the best response to infliximab.23 An open-label 
trial in patients with Crohn's disease, which was performed earlier, compared doses of
1 mg, 5 mg, 10 mg, and 20 mg per kilogram. The group receiving 1 mg/kg had a more 
transient response than the groups given the higher doses.24
One of the first case reports of patients with psoriasis treated with infliximab reported a 
significant response with 5 mg/kg bodyweight, and the first randomized trial in patients 
with psoriasis showed significant responses to 5 mg/kg and 10 mg/kg bodyweight.
Gastroenterology
With regard to dosing of infliximab in inflammatory bowel disease, international and national 
consensus statements/guidelines recommend a dosage of 5 mg/kg body weight, given in 
a 0-2-6- weeks induction regimen and followed by maintenance dosing every 8 weeks.45
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The ECCO statement provides the same dosage schedule, since 5 mg/kg body weight has 
been shown effective in large placebo controlled trials.7 25 Primary non-response can be 
determined after two doses.4 However, the Dutch guidelines recommend to determine the 
treatment effect 8 weeks after the third infusion since optimal effect will then be obtained.5 
When patients attenuate response, dosage can be increased to 10 mg/kg bodyweight or 
the interval between infusions can be shortened up to 4 weeks.57
Rheumatology
In case of patients with rheumatoid arthritis, the standard dosage of infliximab administered 
recommended by most guidelines is 3 mg/kg bodyweight in an induction regimen at weeks
0, 2, and 6, and every 8 weeks thereafter.10;13;14 Some of the national and international 
guidelines do not explicitly state that infliximab should be administered at 3 mg/kg 
bodyweight, but rather assume that clinicians will administer this 'standard dosage'.9;11;16 
As it is for patients with inflammatory bowel disease, attenuation of response should be 
treated with increasing the dosage or shortening the dosing intervals, together with the 
addition or substitution of another DMARD, according to the international consensus 
statement.9 The Japanese guideline, however, does not allow any increment of dosage 
or shortening of the interval, and quite a few guidelines do not give recommendations 
regarding this topic.111416 The NICE guideline is most explicit in its recommendation, 
recommending increasing the dose of infliximab stepwise by approximately 1.5 mg/kg, up 
to a maximum of 7.5 mg/kg every 8 weeks, or alternatively administration of 3 mg/kg as 
often as every 4 weeks.10
Dermatology
The guidelines on the treatment of psoriasis with biologics from the American Academy of 
Dermatology, The British Association of Dermatologists and the international consensus 
146 panel of dermatology experts advises to dose infliximab in a 5 mg/kg infusion schedule at 
weeks 0, 2, and 6, followed by maintenance treatment every 6 to 8 weeks.17;18;26 The British 
guidelines, however, state that no studies have been performed to establish the optimal 
dose or frequency of repeated infusions required in order to achieve disease control.18 The 
dermatology guidelines give no recommendation regarding how to manage attenuated 
response to infliximab.
Synergy
Repeated administration of infliximab has been associated with immunogenicity, i.e. the 
formation of antibodies to infliximab (ATI, also known as HACA; human anti-chimeric
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antibodies). The concomitant use of immunosuppressants may increase the efficacy of 
infliximab, partially because it prevents the development of ATI, and partially by other 
mechanisms currently unknown.27-29
Gastroenterology
The international ECCO guideline has been very clear and advocates that every patient 
receiving infliximab should receive an immunomodulator (i.e. azathioprine, methotrexate 
or 6-mercaptopurine) in order to prevent development of ATI that in turn may reduce 
efficacy and increase the risk for side effects.7 The consensus statement of the AGA 
strongly recommends co-administration with immunosuppressive therapy as well.4 The 
Canadian guidelines are most clear by recommending that all patients should receive 
concomitant immunosuppressants, even if they failed to respond to immunomodulators 
in the past.6 The Dutch national guideline recommends initiation of immunosuppressants 
prior to infliximab in order to reduce the formation of antibodies.5
Rheumatology
Nearly all efficacy studies with infliximab in patients with rheumatoid arthritis have been 
performed in patients receiving concomitant methotrexate.21 Therefore, all international, 
national and local guidelines recommend concomitant treatment with methotrexate in case 
of starting treatment with any anti-TNF-a agent, including infliximab.13;16
Dermatology
The American Academy of Dermatology does not recommend concomitant prescription 
of low-dose methotrexate, although some dermatologists do so to decrease the formation 
of antibodies.26 The international consensus statement on the treatment of psoriasis 
with infliximab does not provide guidelines on the use of concomitant medication during 
treatment with infliximab.17 According to the British guidelines, concomitant systemic 
therapies may be indicated for some patients with very severe or unstable psoriasis, 
although doses should be minimized.18
Monitoring o f vital signs
As a foreign protein-derived agent administered intravenously over a two-hour infusion 
period, infliximab can cause infusion reactions. Formation of ATI may increase the risk of 
infusion reactions.2728 These infusion reactions can be categorized as acute or delayed. 
An acute infusion reaction is defined as any adverse event occurring during infusion or 
within a period of 24 hours after infusion.2730 Severity can vary from mild to severe life
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threatening, and symptoms may include nausea, flushing, dizziness, dyspnea, chest pain 
and hypotension or hypertension. Delayed infusion reactions are defined as reactions 
occurring from 24 hours to 14 days after treatment with infliximab and symptoms may 
include arthralgia, rash, myalgia and fatigue.27;30
In randomized controlled trials with infliximab, vital signs (blood pressure, body temperature 
and pulse) were monitored vigorously. Monitoring body temperature at baseline is 
performed to rule out fever possibly based on infection and monitoring during infusion is 
performed while concerns exist about developing fever during an acute infusion reaction. 
The monitoring of blood pressure and pulse is based on the concern that during infusion 
with infliximab an anaphylactic shock could develop with typical hypotension.
Gastroenterology
Study protocols with infliximab in patients with inflammatory bowel disease and some 
experts state that 30 minutes prior to infusion, every 30 minutes during infusion, and up till 
two hours after infusion, vital signs (blood pressure, body temperature and pulse) should 
be monitored.31 Randomized controlled trials in patients with inflammatory bowel disease 
reported incidences of acute infusion reactions ranging from 9 to 17%.2532 In clinical 
practice the overall incidence of acute infusion reactions with infliximab is approximately 4 
to 10%.3033 None of the international or national guidelines state that during infusion vital 
signs should be monitored. However, it is common practice to monitor vital signs during 
infusion with infliximab.
Rheumatology & Dermatology
As it is the case for gastroenterology, current practice in rheumatology and dermatology 
is to monitor vital signs of patients during infusion with infliximab. However, none of the 
guidelines give specific recommendations regarding monitoring of vital signs.
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Interpretation
With the exception of patients treated for rheumatoid arthritis who are treated with a dosage 
of 3 mg/kg bodyweight, all patients who are treated with infliximab receive a dosage of 5 
mg/kg bodyweight (Table 1). To our knowledge, however, studies comparing response 
rates between dosing schedules of 3 mg/kg and 5 mg/kg in patients with inflammatory 
bowel disease, rheumatoid arthritis or psoriasis have not been performed. The optimal 
concentration of infliximab may still need to be established. In view of this, several recent 
studies in patients with rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing 
spondylitis and psoriasis have shown that trough serum concentrations of infliximab
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correlate with the clinical response to infliximab.34'38 The implication of this might be that 
in the near future, dosage of infliximab will be individualized based on the trough serum 
concentration, thereby optimizing clinical response and cost effectiveness.
Table 1. Dosage regimen o f infliximab fo r d ifferent autoinflammatory disorders.
RA AS PsA CD UC PCD Ps
Dose 3 mg/kg 5 mg/kg 5 mg/kg 5 mg/kg 5 mg/kg 5 mg/kg 5 mg/kg
Induction therapy 
(weeks)
0, 2, 6 0, 2, 6 0, 2, 6 0, 2, 6 0, 2, 6 0, 2, 6 0, 2, 6
Maintenance 
therapy (weeks)
8 6 8 8 8 8 8
RA, Rheumatoid Arthritis; AS, Ankylosing Spondylitis; PsA, Psoriatic Arthritis; CD, 
Ulcerative Colitis; PCD, Pediatric Crohn's Disease; Ps, Psoriasis.
Crohn's Disease; UC,
Regarding attenuation of response, the guidelines of each specialty recommend dosage 
increase or interval shortening or changing to another biological therapy. However, there 
is no clear recommendation which option should be chosen in which subset of patients. 
Pharmacokinetic modelling of infliximab in patients with rheumatoid arthritis showed that 
interval reduction might be more effective in raising serum infliximab concentrations than 
dosage increase.38 Flendrie et al. observed in an open-label study a more pronounced 
efficacy in patients with rheumatoid arthritis receiving interval reduction, compared to 
patients receiving a dosage increase.39 These observations need to be studied in large 
randomized trials.
With the exception of ankylosing spondylitis, the need of concomitant administration of 
immunosuppressants during treatment with infliximab has been stressed by most of the 
guidelines throughout the different specialties, since it appears to prevent the development 
of ATI.27-29 However, benefits and risks of combined strategies should be balanced carefully 
as the evidence for increased risks of combined therapies is growing. In patients with 
inflammatory bowel disease treated with infliximab an increased risk for serious infections 
was observed.40;41
Monitoring of vital signs during infusion with infliximab is based on strict regulations during 
clinical trials and is still advocated in some treatment algorithms and guidelines.630 31 
We recently showed that scheduled monitoring of vital signs during infusion did neither 
indicate nor predict development of acute infusion reactions. When baseline vital signs 
from patients with and without acute infusion reactions were compared, no significant 
differences were observed. Furthermore, during an acute infusion reaction, vital signs did 
not show a significant change compared to baseline.42
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Conclusions and recommendations
Different indications encompass different dosing schedules. Several studies have shown 
a correlation between trough serum concentration of infliximab and clinical response. 
Future studies are needed to study the concentration-effect relationship of infliximab as 
a necessary step before therapeutic drug monitoring can be recommended in guidelines. 
National and internal guidelines do not provide advices regarding loss of response. 
Although some evidence exists that interval reduction might be more effective in raising 
serum infliximab concentrations than dosage increase, large randomized trials are needed 
to observe whether or not interval reduction is superior to dosage increase and in which 
subset of patients, in order to be able to give guidance regarding loss of response in clinical 
guidelines. With regard to concomitant medication, efforts should be made to establish a 
reasonable time interval in which concomitant medication should be decreased.
Routine scheduled measurements of vital signs during infusion is not valuable in detecting 
acute infusion reactions and should only be performed in case of an acute infusion reaction. 
We recommend administering infliximab at an infusion unit under supervision of trained 
personnel. This approach enables direct interventions immediately after a patient reports 
symptoms. Baseline assessment of patients, including vital signs, should still be performed 
as normal clinical practice to rule out possible infections or other contraindications for 
infusion with infliximab. As stressed out by a recent quality appraisal of clinical practice 
guidelines and consensus statements on the use of biological agents in rheumatoid 
arthritis, guidelines should be explicit in their guidance43, which has implications for the 
development of future guidelines.
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CHAPTER 15
Cardiovascular risk factors in high-need psoriasis patients and its 
implications for biological therapies
Abstract
Background: The associations between psoriasis and cardiovascular risk factors are 
reported to be stronger as psoriasis severity increases. This makes studying cardiovascular 
risk factors in patients with high-need psoriasis, eligible for biological therapy, interesting. 
Objective: To survey the prevalence of cardiovascular risk factors in patients with high­
need psoriasis and to compare these data to patients with other dermatological diseases. 
Furthermore, the implications of these findings for treatment with biologics were outlined. 
Methods: The prevalence of cardiovascular risk factors was investigated in a high-need 
psoriatic patient cohort and compared with patients with other skin diseases who filled out 
a questionnaire about the presence of cardiovascular risk factors.
Results: A significantly higher prevalence of obesity, smoking, and hypertension 
was found for the cohort of patients with high-need psoriasis compared with non­
psoriatic controls. Striking differences were found with respect to body mass 
index and obesity, as 35.5% of all patients with high-need psoriasis were obese. 
Conclusions: Patients with high-need psoriasis show a high prevalence of cardiovascular 
risk factors, and may consequently be predisposed to cardiovascular diseases. As 
this is relevant for therapy management in daily clinical practice, especially biologics, 
cardiovascular risk should be evaluated for each patient with high-need psoriasis before 
and during systemic treatment.
Adapted from: Driessen RJ, Boezeman JB, van de Kerkhof PC and de Jong EM. 
Cardiovascular risk factors in high-need psoriasis patients and its implications for biological 
therapies. J.Dermatolog.Treat. 2009; 20: 42-7.
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Introduction
High-need psoriasis is defined as psoriasis in patients for whom at least two systemic 
treatments are unsuitable due to lack of efficacy, intolerance or contraindication.1 These 
patients are generally severely affected by psoriasis, and many are treated with tertiary 
care pharmaceuticals in the course of the disease. Examples of such pharmaceuticals are 
biologics, such as etanercept, efalizumab, adalimumab and infliximab. Most guidelines 
state that patients with psoriasis are eligible for a biologic if they have a Psoriasis Area 
and Severity Index (PASI)2 of at least 10, and have failed to respond to phototherapy, 
methotrexate, and ciclosporin in the past, or have a contraindication to or intolerance for 
these treatments. Therefore, all patients with psoriasis eligible for biological therapies may 
be termed 'high need'.
For patients with psoriasis who are treated with biologics, safety monitoring is extremely 
important. On the one hand, these patients are exposed to innovative antipsoriatic agents 
of which long-term safety data are lacking. On the other hand, hypotheses exist that this 
category of patients is characterized by an exceptional profile of comorbidity.
For many years, the association of psoriasis with other diseases has been investigated. An 
increased incidence of occlusive vascular diseases in patients with psoriasis had already 
been described in 1973 by McDonald and Calabresi.3 In 1986, Lindegard was the first 
to find a concomitance of psoriasis and cardiovascular risk factors, such as alcoholism, 
hypertension, diabetes, and obesity.4 Now that concerns about lifestyle issues influencing 
public health in western countries are growing, general health in psoriasis is studied more 
and more as well.
Currently, the evidence of associations between psoriasis and cardiovascular risk factors 
and cardiovascular comorbidity is convincing. The associations are reported to be stronger 
as psoriasis severity increases.5 For this reason, studying cardiovascular risk factors in 
severely affected patients with psoriasis who are eligible for biological therapy is necessary.
158 Patients with high-need psoriasis may hypothetically exhibit a highly unfavourable 
cardiovascular risk profile compared with non-psoriatic dermatological patients.
The objective of this study was to survey the prevalence of cardiovascular risk factors and 
comorbidity in a high-need psoriasis cohort, and to compare these data with a group of 
patients with other dermatological diseases referred to the same centre. Furthermore, the 
implications of these findings for patients treated with biological therapies were outlined. 
Results of this study are important considering safety management during biological 
therapy, and may influence treatment strategies.
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Patients and methods
The prevalence of cardiovascular risk factors was investigated in patients with high-need 
psoriasis, and compared with patients with skin diseases other than psoriasis. Data about 
psoriasis patients were extracted from an existing database. This database contains the 
prospective, daily practice demographic, efficacy and safety data of all patients who were 
treated with biologics at the Radboud University Nijmegen Medical Centre Department of 
Dermatology from February 2005. For all patients included in this cohort, medication history 
was characterized by failure to respond to phototherapy, methotrexate, and ciclosporin in 
the past due to lack of efficacy, intolerance or contraindication. For this reason, patients in 
this cohort are designated as 'high-need'. Furthermore, all registered patients had a PASI 
of at least 10 before initiation of therapy.
A control group was composed of other patients from the same hospital with a 
dermatological disease other than psoriasis, who filled out a questionnaire about the 
presence of cardiovascular risk factors during their outpatient clinic visit. Patients were 
questioned about age, sex, height, weight, reason for dermatology outpatient clinic visit, 
smoking habits, and alcohol consumption. In addition, the existence of a diagnosis of 
diabetes, hypertension, hyperlipidemia, myocardial infarction, and cerebrovascular 
disease was registered. Only completely filled out questionnaires were used. If possible, 
data were verified using the hospital's electronic patient file. Patients younger than 18 
years of age or with a diagnosis of psoriasis were excluded.
For each group, the mean age and body mass index (BMI) were calculated. BMI was 
calculated as weight in kilograms (kg) divided by height in meters (m) squared. The number 
of obese patients was registered. Obesity was defined as a BMI > 30 kg/m2. The number 
of patients who had ever smoked and who were currently smoking was counted. Current 
smokers included those who were smoking at the moment of analysis as well as those who 
had stopped smoking for less than 1 year. The mean number of pack years, calculated 
as duration of smoking (years) multiplied by the number of cigarette packs (number of 
cigarettes divided by 20) a day, was computed for each group. Also, the number of patients 
who had ever used alcohol was analysed, including the current mean number of units 
of alcohol per month. Furthermore, the number of patients with a diagnosis of diabetes, 
hypertension, hyperlipidemia, myocardial infarction or cerebrovascular disease was 
registered. For the high-need psoriasis group, all systemic therapies used for psoriasis in 
the past were recorded.
The two groups were compared using SPSS 14.0.2 for Windows (SPSS Inc., Chicago, 
IL, USA). Descriptive statistics were used to reproduce study results as numbers, 
percentages, and means. Continuous variables were analysed using the independent
159
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samples t-test. Dichotomous variables were analysed using Mantel-Haenszel common 
odds ratio estimates, after stratifying data by age and sex. Backward stepwise multiple 
logistic regression analysis was performed to identify independent risk factors associated 
with the high-need psoriasis. All tests are two-tailed. P < 0.05 was considered statistically 
significant.
Results
The high-need psoriasis cohort consisted of 107 patients. The control group was 
composed of 396 patients with dermatological diseases other than psoriasis. This group 
was representative of the dermatological outpatient clinic population, as all patients 
from different dermatological subspecialisms were included. In total, 533 completed 
questionnaires were received. Fifty-one of these were unusable or filled out incompletely. Of 
the remaining questionnaires, 38 patients were under 18, and 48 patients had a diagnosis 
of psoriasis. These patients were excluded from analysis. Finally, 396 questionnaires were 
suitable for analysis.
In contrast with the control group, there was a female predominance in the high-need 
psoriasis cohort (p < 0.001). Mean age was slightly lower in the high-need psoriasis 
cohort than in the control group (p = 0.05). Mean BMI was significantly different (p <
0.001) between both groups (i.e. 28.5 kg/m2 for patients with high-need psoriasis and 24.9 
kg/m2 for controls). Remarkably, 35.5% of all high-need psoriatic patients were obese, 
compared with 10.4% of the controls (OR 5.49, p < 0.001). Of the individuals in the high­
need psoriasis group, 75.7% had ever smoked, compared with 58.8% of the control group 
(OR 1.92, p = 0.01). Also, the mean number of pack years was significantly higher in the 
high-need psoriasis group (p = 0.02). Respectively, 46.7% and 28.8% of patients with 
high-need psoriasis and controls were currently smoking (OR 1.73, p = 0.02). Compared 
with the control group, a significantly lower percentage of patients in the psoriasis cohort 
160 had ever used alcohol (70.1% versus 83.8%, p < 0.001), but the mean monthly amount of 
alcohol consumption was higher for the patients with high-need psoriasis. A diagnosis of 
diabetes, hypertension, and hyperlipidemia was more common in the patients with high­
need psoriasis than in controls. However, only data for hypertension were significantly 
different (high-need psoriasis 34.6%, controls 24.2%, p = 0.01). Slightly more patients in 
the control group had a history of myocardial infarction and cerebrovascular diseases, but 
low numbers were found (Table 1).
Backward stepwise multiple logistic regression analysis showed an independent 
association of high-need psoriasis with age, sex, obesity, smoking, alcohol use, and 
hypertension.
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Table 1. Patient characteristics.
Patient characteristics High-need 
psoriasis 
(n =107)
Controls 
(n = 396)
Odds ratio (95% CI) P-value
Demographics
Male, no. (%) 37 (34.6) 226 (57.1) 2.62 (1.6S-4.11) < 0.001
Mean age (years) 4S.5 51.2 a 0.05
Stature
Mean BMI (kg/m2) 2S.5 24.9 a < 0.001
Obesity (BMI > 30 kg/m2), no. (%) 38 (35.5) 41 (10.4) 5.49 (3.09-9.74) < 0.001
Smoking
Ever smoking, no. (%) 81 (75.7) 233 (5S.S) 1.92 (1.14-3.22) 0.01
Mean number of pack years 19.S 14.9 a 0.02
Current smoking, no. (%) 50 (46.7) 114 (2S.S) 1.73 (1.0S-2.75) 0.02
A lcohol
Ever used alcohol, no. (%) 75 (70.1) 332 (83.8) 0.36 (0.20-0.63) < 0.001
Mean alcohol consumption 
(number of units/month) 2S.2 20.9 a 0.12
C om orbid ity
Diabetes, no. (%) 14 (13.1) 35 (S.S) 1.91 (0.91-4.04) 0.09
Hypertension, no. (%) 37 (34.6) 96 (24.2) 1.93 (1.16-3.23) 0.01
Hyperlipidemia, no. (%) 22 (20.6) 68 (17.2) 1.17 (0.66-2.09) 0.59
Myocardial infarction, no. (%) 4 (3.7) 19 (4.S) 1.59 (0.46-5.49) 0.47
Cerebrovascular disease, no. (%) 4 (3.7) 17 (4.3) 1.14 (0.33-3.99) 0.83
“Continuous variables were analysed by the independent samples t-test. CI, Confidence Interval; BMI, Body 
Mass Index.
Previous treatments
More than 76% of all patients with psoriasis had used methotrexate, UVB or ciclosporin 
previously. Other previously used therapies were PUVA, retinoids, fumaric acid, etanercept, 
alefacept, onercept, efalizumab, adalimumab, and infliximab (Table 2). Compared with 161 
patients who had never used ciclosporin, fewer patients who had ever used ciclosporin 
previously were affected by hypertension. These data probably comprehend cases in 
which ciclosporin was contraindicated because of hypertension. Analysis of the influence 
of other previous treatments on cardiovascular risk factors was not reasonable due to the 
unequal distribution of percentages.
Discussion
In the current study, a significantly higher prevalence of obesity, smoking, and hypertension 
was found for patients with high-need psoriasis compared with non-psoriatic controls.
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Furthermore, the mean monthly amount Table 2. Previous treatments. 
of alcohol consumption was higher in the 
patients with high-need psoriasis than in 
controls. Striking differences between the 
high-need psoriasis cohort and the control 
group were found with respect to BMI and 
obesity. The mean BMI was 28.5 kg/m2 
for patients with high-need psoriasis and 
24.9 kg/m2 for controls. The prevalence of 
obesity was more than three times higher 
in the high-need psoriasis group than in the 
control group. In The Netherlands, Bos et al. 
performed a study in which the prevalence 
of the metabolic syndrome in two general, 
non-psoriatic populations in the age category 28-59 years was estimated. In this study, the 
mean BMI was 25.2 kg/m2 for women in both populations, and 25.9 kg/m2 and 25.7 kg/m2 
for men.6 A recent European cohort study by Gisondi et al. showed a mean BMI of 27.6 
kg/m2 in patients with psoriasis eligible for etanercept treatment.7 In the United States, a 
study was performed to investigate the impact of obesity and smoking on psoriasis. The 
mean BMI in that study was 29.1 kg/m2 for the psoriasis cohort compared with 26.2 kg/m2 
for controls.8 In contrast, the mean BMI of the control group in our study was slightly lower 
than the data represented in the Dutch study, but the BMI values of the patients with high­
need psoriasis come close to the data from the United States.
The results of our study are consistent with the results of studies in which the prevalence 
of cardiovascular risk factors was determined for patients with psoriasis who did not fulfil 
the criteria for high-need psoriasis. In these studies, obesity, metabolic syndrome, and 
162 cardiovascular diseases were significantly more common in patients with psoriasis than 
in non-psoriatic controls.5 Also, a higher prevalence of smoking and alcohol consumption 
was found in patients with psoriasis compared with controls.8-11
Furthermore, the literature shows that cardiovascular risk factors are more strongly 
associated with severe psoriasis than with mild psoriasis. Severely affected psoriasis 
patients are more overweight8;12-14, tend to smoke more and longer9;12;14-16, consume 
more alcohol17-19, show more signs of insulin resistance and diabetes12;14;20-22, are more 
frequently affected by hypertension and hyperlipidemia 12;14;22, and have a heightened risk 
of myocardial infarction and cerebrovascular accident1222-24 compared with less severely 
affected patients. Also, severe psoriasis is associated with an increased mortality, even
Previous treatments No. o f patients (%)
Methotrexate 104 (97.2)
UVB 92 (86.0)
Ciclosporin 82 (76.6)
PUVA 76 (71.0)
Retinoids 76 (71.0)
Fumaric acid 50 (46.7)
Etanercept 14 (13.1)
Alefacept 13 (12.1)
Onercept 6 (5.6)
Efalizumab 3 (2.8)
Adalimumab 1 (0.9)
Infliximab 1 (0.9)
UVB, Ultraviolet B; PUVA, Psoralen-Ultraviolet A.
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after adjustment for risk factors for death.25 In contrast with the studies cited here, in our 
study, specifically patients with high-need psoriasis were investigated. These patients 
not only had severe psoriasis, but had also failed to respond to at least three systemic 
therapies. In this special population, the occurrence of cardiovascular risk factors may be 
even higher than in patients with severe psoriasis. This makes extensive, multidisciplinary 
medical monitoring of patients with high-need psoriasis essential.
Results from our study may be biased by the fact that prevalence of cardiovascular 
risk factors and diseases was measured in different ways for patients with high-need 
psoriasis and controls. Moreover, estimating the prevalence of these issues by means 
of questionnaires could have led to overreporting or underreporting.26 27 We believe, 
nevertheless, the accuracy of this method to be sufficient to constitute a solid control 
group. Besides, received data were verified using the hospital's electronic patient file. 
Differences in the baseline characteristics of both groups could have influenced study 
outcomes. Mean age was slightly lower in the high-need psoriasis group than in the control 
group. Also, the percentage of males was lower. As increasing age and male sex are 
associated with higher cardiovascular risk, the difference in prevalence of cardiovascular 
risk factors in the examined groups may in fact be larger.
Whether psoriasis promotes the development of cardiovascular diseases or vice versa, 
is still unclear. Recently, two large prospective cohort studies were accomplished, 
examining the relationship between obesity, smoking, and incident psoriasis in more than 
75,000 women. Results showed that obesity and smoking are strong risk factors for the 
development of psoriasis.2829 Conversely, psoriasis itself may lead to an increased risk of 
cardiovascular diseases as a consequence of chronic systemic inflammation, unhealthy 
lifestyle of patients with psoriasis, and arousal of cardiovascular risk factors induced by 
antipsoriatic medication, such as ciclosporin and retinoids.30
The current data were unsuitable for a sensible analysis on the influence of previous 
treatments on cardiovascular risk factors. For each individual pharmaceutical, potential 
cardiovascular side effects are known. However, whether a patient's risk profile is affected 
by successive or concomitant systemic treatments during life needs further research.
To what extent biological therapies influence the risk of cardiovascular diseases is 
currently under investigation. As TNF-a is involved in lipid metabolism and adipose tissue 
regulation, anti- TNF-a therapy may influence body weight, insulin resistance, lipid profile, 
and vascular function. However, studies investigating these items for rheumatoid arthritis 
patients show controversial results.31 For psoriasis, no comparable data are available yet. 
A highly interesting question is whether early intervention with biological treatment reduces 
the long-term risk for cardiovascular diseases. If so, this may be an additional argument to
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introduce biologics early in the course of disease, and to use drugs with potentially severe 
side effects, such as ciclosporin, only if acute intervention is needed. Contrarily, obesity 
may lead to a suboptimal response of fixed-dose biologics such as etanercept.32 
In conclusion, patients with high-need psoriasis show a significantly higher prevalence 
of cardiovascular risk factors compared with non-psoriatic dermatological patients, and 
may consequently be predisposed to cardiovascular diseases. Furthermore, the extensive 
systemic medication history makes these high-need psoriasis patients particularly 
vulnerable. As a consequence, cardiovascular risk should be evaluated for each high­
need psoriasis patient both before and during systemic treatment, especially biologics. 
Caution should be exercised when prescribing retinoids or ciclosporin in these patients. 
Furthermore, patients should be encouraged to display healthy behaviour, to stop smoking, 
to moderate alcohol consumption, and to lose weight.
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Prevalence of self-reported joint complaints in patients with
psoriasis
Abstract
Background: Psoriatic arthritis (PsA) is a rheumatic joint disease associated with psoriasis 
of the skin and the nails. Estimates of the prevalence of arthritis among patients with 
psoriasis range widely from 6 to 42%.
Objective: To investigate the prevalence of self-reported joint complaints in patients with 
psoriasis in The Netherlands.
Methods: A total of 6000 questionnaires was sent to members of the Dutch psoriasis 
society. The forms contained questions about skin disease and joint complaints. Psoriasis 
severity was assessed using the Self-Administered Psoriasis Area and Severity Index 
(SAPASI). Formal joint counts and skin assessment were performed in a subsample of the 
responders, stratified according to self-reported joint complaints.
Results: Of the 6000 questionnaires, 1562 (26%) were returned to the study centre. Twenty- 
four responders were under 18 years of age and were excluded. From the 1538 remaining 
patients, 503 (33%) patients reported no joint complaints, and 98 (6%), 309 (20%), and 
628 (41%) patients had mono-, oligo-, and polyarticular complaints, respectively. After 
correction using the physical examination of the subsample, it was estimated that the 
prevalence of polyarticular complaints attributable to synovitis was 27%. Twenty percent of 
the patients had an Amor score of at least 6, indicating an increased risk for the presence 
of spondylitis.
Conclusions: The prevalence of self-reported joint complaints in patients with psoriasis 
168 is high, but the prevalence of synovitis is considerably lower. Polyarticular involvement is 
the most prevalent complaint in these patients. The prevalence of polyarticular complaints 
increased with disease duration.
Adapted from: Popa-Diaconu DA, Driessen RJ, van de Kerkhof PC, van Riel PL, Fransen J, 
de Jong EM. Psoriasis and arthritis. Prevalence of self-reported joint complaints in patients 
with psoriasis. Submitted.
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Introduction
The relationship between psoriasis and psoriatic arthritis (PsA) has been well established 
clinically and genetically.1 The typical clinical picture of PsA consists of peripheral joint 
inflammation with an asymmetric pattern of involvement. With longer disease duration, 
there is a propensity to develop a (symmetric) polyarthritis out of an initial (asymmetric) 
mono- or oligoarthritis. Other manifestations, such as spondylitis, sacroiliitis, enthesitis, 
dactylitis, and nail lesions do also appear in PsA. Within two years after onset of the 
disease, a substantial percentage of PsA patients develops irreversible damage of the 
involved joints.2 Consequently, PsA may not be seen as a benign disease.3 Nowadays, 
PsA can be treated using disease modifying anti-rheumatic drugs and biological response 
modifiers.4 However, it appears that the presence of arthritis in patients with psoriasis is 
often missed, as dermatologists generally do not actively search for articular involvement.5 
Screening for arthritis in patients with psoriasis may improve timely diagnosis and treatment 
of PsA. It has repeatedly been found that the prevalence of inflammatory arthritis is raised 
in populations with psoriasis, and that the prevalence of psoriasis is raised in populations 
with inflammatory arthritis.67 There have only been a few studies estimating the prevalence 
of psoriatic arthritis (PsA) in the general population, providing rates between 0.04 and
0.1%.8-10 These studies likely underestimate the “true” prevalence of psoriatic arthritis, 
because the dermatological and rheumatological criteria applied will often lead to exclusion 
of cases with mild or early disease.11 In patients with severe psoriasis, the estimates of the 
prevalence of PsA among patients with psoriasis range widely from 6 to 42%.12 
The aim of this study is to estimate the prevalence of self-reported joint complaints in 
patients with psoriasis in The Netherlands.
Materials and methods
Design
The study has a two-stage design. In the first stage, a survey by questionnaire was 
performed in 6000 patients with psoriasis who were members of the Dutch Psoriasis 
Society (Psoriasis Vereniging Nederland). The questionnaire assessed the presence of 
joint complaints in general, peripheral arthritis, undifferentiated spondylitis and the extent 
of psoriatic lesions of the skin and the nails. The questionnaires were enclosed in an issue 
of the Dutch Psoriasis Society journal, which is regularly distributed among all members 
(patients with psoriasis) in The Netherlands. Patients were invited to complete the 
questionnaire and send it to the data collection centre of the Department of Rheumatology 
of the Radboud University Nijmegen Medical Centre. In the second stage, a subsample
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of 98 patients stratified according to the amount of self-reported joint complaints (none, 
1-4 joints and > 5 joints) has been investigated. These patients were invited to visit the 
Department of Dermatology for physical examination. The study was approved by the 
responsible medical ethics committee.
Survey
The questionnaire items included the modified Amor criteria for the diagnosis of ankylosing 
spondylitis13 and also included a mannequin to evaluate the tender joints (self-administered 
joint form)14. The extent and severity of psoriasis was assessed by means of the Self­
Administered Psoriasis Area and Severity Index (SAPASI).15 To estimate the body surface 
area covered with psoriatic lesions, patients were instructed to shade a line-drawing 
silhouette of a body in the areas currently affected by psoriasis. In addition, information 
regarding family history, demography, dates of onset of joint complaints and psoriasis and 
treatment were recorded.
Physical examination
It was aimed to recruit a subsample of 100 patients from the survey, stratified in three 
equally sized strata by the amount of self-reported joint complaints (none, 1-4 joints and 
> 5 joints). The patients from the subsample were clinically examined for the presence of 
arthritis by skilled assessors who performed a 68 tender- and a 66 swollen joint count. The 
joints assessed for tenderness included the distal interphalangeal, proximal interphalangeal 
and metacarpophalangeal joints of the hands and the metatarsophalangeal joints of the 
feet, the carpometacarpal and wrist joints (counted separately), the elbows, the shoulders, 
the acromioclavicular and sternoclavicular joints, the hip, the knee and the talo-tibial and 
mid-tarsal joints. All of these except for the hips were also assessed for swelling.16 
The extent of psoriasis was assessed by the Psoriasis Area and Severity Index (PASI).17 
170 Finger- and toenails were examined for pitting, ridging, subungual hyperkeratosis, 
onycholysis, dystrophy, discoloration, leukonychia and elevation. The Nail Psoriasis 
Severity Index (NAPSI) was calculated to assess the severity of nail involvement.18
Statistical analysis
Statistical analyses were conducted using SPSS version 16.0 (SPSS Inc., Chicago, 
IL, USA). The prevalence of self-reported joint complaints in the complete sample was 
obtained from the mannequin using descriptive statistics. The occurrence of synovitis 
in the subsample was assessed using the swollen joint count. The prevalence of joint 
complaints attributable to synovitis ('corrected prevalence') in the complete sample was
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estimated using the information of the synovitis assessment in the subsample by multiple 
imputation techniques.19 Patterns of joint involvement were described using the Moll and 
Wright criteria.20 The relation between disease duration and joint complaints was analysed 
using logistic regression, with joint complaints as the dependent variable, and gender 
and duration of complaints as the independent variables. The Chi-square test was used 
to analyse the distribution of mono-, oligo- and polyarticular involvement according to 
gender. A p-value of less than 0.05 was used to indicate statistical significance.
Results
Patients
Of the 6000 questionnaires, 1562 (26%) were returned to the study centre. Twenty-four 
responders were under 18 years of age and were excluded. From the 1538 remaining 
patients, 49% was female. The mean age of the patients was 55 years (SD 14.0), ranging 
from 18 to 90 years. The mean duration of skin psoriasis was 27 years (SD 15.8) and the 
mean duration of joint complaints was 15 years (SD 10.3), indicating that in most patients 
psoriasis preceded joint complaints. Of the total group of responding patients, 1077 (70%) 
were treated by a dermatologist, 275 (18%) were treated by a rheumatologist, and 186 
(12%) were treated by both specialists. Ninety-eight patients in the subsample underwent 
a physical exam for this study. Their mean age was 51 years (SD 14.5). Forty-four patients 
(45%) were female. The mean duration of skin complaints was 26 years (SD 15.2) and the 
mean duration of joint complaints was 15 years (SD 12.5).
Severity of psoriasis
The median (interquartile range, IQR) SAPASI in the complete sample was 4.8 (2.8-7.0).
Of all patients, 733 (48%) had a mild psoriasis (SAPASI < 5), 537 (35%) had a moderate 
psoriasis (SAPASI > 5 and < 10), and 150 (10%) had a severe psoriasis (SAPASI > 10). 171 
For 118 (8%) patients the SAPASI was not available.
In the subsample, nearly all patients had active psoriasis with a median (IQR) PASI of 3.7 
(2.2-5.1) and a median (IQR) NAPSI of 16.0 (3.7-40.5). Of these patients, 73 (74%) had 
a mild psoriasis (PASI < 5), 19 (19%) had a moderate psoriasis (PASI > 5 and < 10), and
6 (6%) had a severe psoriasis. Most patients (89%) had nail involvement (NAPSI > 0) 
whereas only 11% had no nail involvement (NAPSI = 0).
Prevalence of joint complaints
Among the 1538 patients, 67% had self-reported complaints in one or more peripheral
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joints. The median (IQR) number of painful joints was 3.0 (0.0-9.0). Of all patients, 503 
(33%) reported to have no joint complaints, and 98 (6%), 309 (20%), and 628 (41%) 
patients reported complaints in one joint, 2 to 4 joints, or 5 or more joints, respectively (Table 
1). According to the swollen joint count in the patients of the subsample who underwent 
physical examination, it appeared that in 45% of these patients there was no synovitis 
present, 28% of the patients had synovitis in 1 to 4 joints, and 27% of the patients had 
synovitis in at least 5 joints (Table 1). The correction by using the information of observed 
synovitis in the strata of the subsample led to lower estimations of joint involvement in the 
sample. Consequently, the percentage of patients without joint involvement increased, the 
percentage of patients with 1 to 4 involved joints also increased, and the percentage of 
patients with 5 or more joints involved decreased (Table 1). The prevalence of polyarticular 
synovitis in patients with psoriasis may be estimated at 27%. In 315 (20%) of the returned 
questionnaires an Amor score of at least 6 was calculated, indicating an increased risk for 
the presence of spondylitis
Table 1. Prevalence o f jo in t involvement.
Sample 
n = 1538
Subsample
n = 98
Corrected 95% CI
No involvement 0.33 0.45 0.40 0.30-0.50
Mono/oligoarticular involvement 0.26 0.28 0.32 0.22-0.41
Polyarticular involvement 0.41 0.27 0.27 0.22-0.32
95% CI, 95% confidence interval.
Patterns and course of joint involvement 
In the complete sample and according to the self­
assessment, the most frequently affected large
172 joint was the knee, followed by the shoulder and 
the hip (Table 2). The small joints of the hands 
and feet, as well as the wrists, were frequently 
involved. According to the patterns as described 
by the Moll & Wright criteria, 2.2% of the patients 
had predominant distal interphalangeal joint 
complaints, 30.0% had symmetric polyarticular 
complaints, 9.6% had asymmetric polyarticular 
complaints, 25.2% had oligoarticular complaints 
and 33.0% of patients had no joint complaints at
Table 2. D istribution o f se lf­
assessed jo in t involvement.
Jo in t involvement Percentage
Distal interphalangeal 20.6
Proximal interphalangeal 36.4
Metacarpophalangeal 31.3
Wrist 21.7
Elbow 15.3
Shoulder 24.8
Hip 20.3
Knee 29.1
Ankle 17.1
Metatarsophalangeal 28.6
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all. Twenty percent of the patients had a relatively high number of signs and symptoms of 
spondylitis (Amor score > 6), while 1.6% of the patients had spondylitis as their only joint 
complaint. Joint involvement was more common in female patients (43%) than in males 
(p < 0.05). Also polyarticular involvement was more frequently reported by women (58%) 
than by men (p < 0.05).
In Figure 1 it is shown that with increase of complaint duration and age, the prevalence of 
patients with mono/oligoarticular complaints decreases (Figure 1A), while the prevalence of 
patients with polyarticular complaints increases (Figure 1B). The prevalence of spondylitis 
complaints also increases with time (Figure 1C).
Among patients with polyarticular complaints, 210 (33%) were regularly seen by a 
rheumatologist.
Figure 1. Probabilities o f mono/oligoarticular, polyarticular and spondylitis 
complaints according to gender.
A.
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Discussion
In the present study we used a survey to estimate the prevalence of self-reported joint 
complaints in patients with psoriasis. Secondly, a physical examination in a subsample 
of patients was performed to estimate the prevalence of joint complaints that could be 
attributed to synovitis. According to the results of this study, a high prevalence (67%) of self­
reported joint complaints in the sample of patients with psoriasis was found. The prevalence 
of polyarticular complaints was higher in women and increased with disease duration. The 
proportion of patients visiting a rheumatologist was 30%. Using the physical examination 
results in the subsample as a correction factor, it was estimated that the prevalence of joint 
complaints attributable to synovitis was 27%. Most patients of the subsample (74%) had 
a mild psoriasis and 89% of the patients showed psoriasis of the nails. Given the large 
prevalence of joint complaints in these patients, the relevant question is who and how 
many of these patients do have arthritis, notably PsA or rheumatoid arthritis.
Diagnosing PsA is a difficult task for a clinician because this is hampered by the absence 
of a “gold standard”. Persistent arthritis or spondylitis, probably enthesitis, in patients 
with manifestations of psoriasis who are Rheumatoid Factor negative may be the best 
description of what characterizes the clinical picture of PsA. The ClASsification criteria for 
Psoriatic Arthritis (CASPAR criteria) are a means to formally classify patients as having 
PsA.21 However, there is still a lack of universal agreement on the diagnosis of PsA.22 
The lack of proper case definitions may also contribute to the difficulty in estimating the 
prevalence of PsA in the population. Estimates of the prevalence of PsA among patients 
with psoriasis range widely from 6 to 42%12, which may also be caused by differences in 
populations and study design.
It has been shown that in most of the patients with PsA the skin lesions develop before 
the arthritis (70%), whereas in 15% both types of manifestations start at the same time, 
leaving 15% of patients with PsA who firstly develop arthritis.23 That prompted us in the 
present study to use the self-assessment method in a large population of patients with 
psoriasis for reasons of efficiency. It was not possible to invite all participants for physical 
examination. Therefore, we used a two-stage sampling method in order to 'correct' the 
self-reported estimations by using the information of a stratified subsample of patients 
who underwent a physical exam. As a result, the estimated prevalence decreased, but 
remained high. As suggested by the high prevalence of complaints in the large load 
bearing joints, osteoarthritis is one of the underlying disorders. Nevertheless, polyarticular 
involvement and involvement of the small joints of the hand and feet also are suggestive 
for a high prevalence of arthritis. There are some other studies that report the pattern of 
joint complaints in patients with PsA.2425 Inconclusively, polyarthritis was predominant in
175
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some PsA groups26;27, while oligoarthritis was predominant in others28;29. Until now, the 
highest prevalence of self-reported joint complaints in patients with psoriasis was found 
by Van Romunde et al., who found a prevalence of self-reported joint complaints of 49% 
in a Dutch population-based cohort regarding patients with psoriasis. The small group (41 
versus 1538 patients) and perhaps a lower mean age (44 versus 55 years) may contribute 
to the difference with our study. Of note, after physical and radiological examination of the 
group of patients with psoriasis, the authors found a prevalence of arthritis of 20%.30 
In the current study, major spinal complaints were present in 20% of the patients, with 
a tendency to increase with time. Spinal involvement in clinically diagnosed PsA (axial 
PsA) has a prevalence between 40% and 78%, depending on the criteria utilized for 
classification.31 For assessment purposes, axial PsA was considered similar as ankylosing 
spondylitis.3233 Although there are studies that underscore the need for a clinical evaluation 
of axial involvement in psoriatic arthritis, in clinical practice there is currently no established 
way for classifying and evaluating spinal involvement in PsA. Therefore, spinal disease 
may not be properly recognized and the incidence of spinal involvement in patients with 
PsA may be underestimated.34
This study has limitations. The two-stage sampling procedure relies on joint count 
assessments in a subsample of the patients instead of a complete ascertainment. The 
response rate of the survey was 26%, which is quite low in comparison with population 
based surveys that may have response rates of 40%. The low response rate makes the 
survey more liable to selection bias, presumably in direction of overestimation of the 
prevalence of joint complaints. For reasons of privacy, it was not possible to achieve data 
of non-responders for comparison with responders to the survey. However, even in the 
unlikely scenario that all non-responders do not have joint complaints, the prevalence of 
joint complaints would be 15%.
In conclusion, we found a high prevalence of articular complaints in Dutch patients with 
176 psoriasis, who showed polyarticular complaints and complaints indicative of spondylitis.
A considerable portion of these patients may have PsA. Therefore, to detect patients with 
PsA in a population of patients with psoriasis, a screening procedure may be fruitful. PsA 
can be treated well nowadays.35 Early screening, proper diagnosis and early effective 
treatment are the keys for an optimal treatment strategy for PsA.
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CHAPTER 17 
Daily practice assessment of liver injury in patients with psoriasis 
on methotrexate
Adapted from: Driessen RJ, van de Kerkhof PC, de Jong EM. Daily practice assessment 
of liver injury in patients with psoriasis on methotrexate. Br.J.Dermatol. 2010; 162: 211-3. 
(Correspondence)
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The antimetabolite methotrexate is one of the most widely used systemic therapies for 
psoriasis. However, its use is limited by potential side effects such as bone marrow toxicity 
and hepatic fibrosis. The use of liver biopsy has been advocated for monitoring patients 
with psoriasis who are receiving methotrexate.1 This recommendation is controversial, 
as evidence points out that liver biopsies are not routinely necessary in patients with 
rheumatoid arthritis who are undergoing treatment with methotrexate.2 
Recently, several biochemical parameters have been investigated as a marker of liver 
toxicity with the main aim to predict the development of liver fibrosis in order to avoid liver 
biopsies. The amino-terminal propeptide of type III procollagen (PIIINP) is an extension 
peptide of the type III procollagen, which is cleaved off during conversion from type III 
procollagen to type III collagen and released into serum. Elevated serum PIIINP reflects 
enhanced collagen turnover, including synthesis and deposition as well as alteration in 
degradation and elimination. One of the earliest studies in psoriasis showed that patients 
with liver fibrosis had significantly higher PIIINP levels.3
Despite the optimism that PIIINP measurement might be used as a biomarker for liver 
fibrosis in methotrexate-treated patients with psoriasis, there are still a few unresolved 
questions. The diagnostic value of a single measurement is unclear as a single serum 
PIIINP level does not discriminate between individuals with and without significant liver 
pathology. Moreover, a relatively high frequency of abnormal results has been reported in 
patients with normal or nonspecific liver histology.4 This may be partially explained by the 
fact that PIIINP levels can be raised in patients with psoriatic arthritis, which is a common 
comorbidity in patients with psoriasis.
In each patient treated with methotrexate at the Radboud University Nijmegen Medical 
Centre Department of Dermatology, a liver biopsy is performed after a cumulative dose 
of 1.5 g methotrexate according to the guidelines of the Dutch Society of Dermatology 
and Venereology. Since April 2006, patients with psoriasis treated with methotrexate are 
additionally monitored for liver injury by assessment of PIIINP (UniQ PIIINP RIA, Orion 181 
Diagnostica Oy, Espoo, Finland), preferably each 3 months.
At the end of 2008, PIIINP serum levels were assessed in 211 patients with psoriasis, 
including 113 males and 98 females with a mean age of 49.4 years. In this group, PIIINP 
levels were determined 686 times. The number of PIIINP values assessed per patient 
ranged from 1 to 11. For 110 patients, three or more consecutive PIIINP values were 
available.
In the same group, a liver biopsy was performed 164 times in 75 patients since 1986. The 
number of liver biopsies performed per patient ranged from 1 to 9. Of all 164 liver biopsies,
124 were classified as Roenigk grade I, 25 as Roenigk grade II, and 11 as Roenigk grade
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IIIA. For 4 liver biopsies no histological classification was provided. No cases of moderate 
to severe liver fibrosis (Roenigk grade IIIB) or cirrhosis (Roenigk grade IV) were found.5 
According to the Manchester protocol, indications for considering liver biopsy are elevation 
of pretreatment PIIINP above 8.0 microgram/litre (pg/l), elevation of PIIINP above the 
normal range (1.7-4.2 pg/l) in at least three samples over a 12-month period, or elevation 
of PIIINP above 8.0 pg/l in two consecutive samples. Withdrawal of methotrexate 
is indicated after elevation of PIIINP above 10.0 pg/l in at least three samples in one 
12-month period.6 In our cohort, 72 patients showed at least one PIIINP value of more 
than 4.2 pg/l. Nineteen patients had an indication for considering liver biopsy according to 
the Manchester protocol. In two of these patients a single serum PIIINP level of more than 
10.0 pg/l was found. In 5 of the 19 patients with increased PIIINP series, a liver biopsy 
was actually performed during or after the PIIINP measurements. These liver biopsies did 
not reveal any sign of significant liver damage as 4 biopsies were classified as Roenigk 
grade I and one biopsy was classified as Roenigk grade IIIA (in a patient with a history of 
hepatitis A and type II diabetes). Ten of the 19 patients with increased PIIINP levels had a 
history of psoriatic arthritis.
The present study shows that hepatotoxicity is limited in a cohort of patients with psoriasis 
treated with methotrexate according to the guidelines of the Dutch Society of Dermatology 
and Venereology. Since 1986 no case of serious liver fibrosis or cirrhosis was discerned 
in this group. As investigated previously, liver injury in long-term methotrexate treatment 
in psoriasis is relatively infrequent.7 Likewise, only 19 out of 211 patients had increased 
PIIINP series, of whom 10 had psoriatic arthritis, which may have influenced PIIINP levels. 
Furthermore, in 5 of the 19 patients with increased PIIINP levels (including one patient with 
psoriatic arthritis), a liver biopsy did not reveal any significant liver damage. These data 
reconfirm that routine liver biopsies may be abolished as serious liver injury is uncommon. 
Monitoring liver damage only by PIIINP has been shown to reduce the number of liver 
182 biopsies considerably and provides an acceptable tool to monitor for liver damage.6
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Summary and discussion
Introduction
In the present thesis, the outcomes of observational studies on biological treatment for 
severe psoriasis in daily practice have been described. Most study data were obtained 
from a patient registry, in which efficacy and safety data on biological therapies for 
psoriasis were prospectively collected. Additional studies concentrated on the economic 
impact of psoriasis and psoriasis treatment, procedures on prescription and application of 
biological therapies in daily practice and comorbidities in patients with (severe) psoriasis. 
In this chapter, the main conclusions of the current thesis will be outlined and discussed in 
accordance with the objectives as formulated in Chapter 5.
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Prospective investigation o f the effects and side effects o f biological treatment in 
patients with severe psoriasis in daily practice.
Effects
In the current thesis, the results of different studies on the effects and side effects of 
biological therapies for patients with severe psoriasis in daily practice have been outlined. 
This type of investigation is part of 'outcomes research', which is the science of defining 
the patient experience and measuring the end result or consequence of medical care.1 In 
most studies the term ‘efficacy’ was used to describe the effects of biological therapies. 
However, as these studies were conducted in a real life setting, the term 'effectiveness’ 
would have been more appropriate.2 Outcomes research has the potential to further define 
the effectiveness and generalization of randomized controlled trials (RCTs).1 To keep 
consistency with the content of this thesis, the term efficacy will be used all the same in 
the following paragraphs.
Chapter 6, 7 and 8 of this thesis include the outcomes of the analyses after one, two 
and three years of investigation, respectively. Efficacy of biologics can be obtained from 
these studies, as well as from the reimbursement application data analysis (Chapter 12) 
and antibody analysis (Chapter 10). Most study data concern etanercept, followed by 
efalizumab and adalimumab.
In general, biologics proved effective and safe treatments of psoriasis in daily clinical 
practice, even in a high-need population. In contrast to etanercept, efalizumab was 
beneficial only in small percentage of patients. The dropout rate in the efalizumab- 
treated group was substantial, i.e. 29% after 12 weeks, 47% after 24 weeks, 62% after 
approximately two years, and 71% after approximately three years of treatment (data not 
presented). Moreover, antibodies against adalimumab were associated with lower serum 
adalimumab concentrations and non-response or loss of response to treatment with 
188 adalimumab (Chapter 10).
In Table 1 an overview of efficacy of biological treatment in patients with severe psoriasis in 
daily practice compared with RCTs is given.34 Initially, the efficacy data of etanercept and 
efalizumab seemed roughly comparable to the results of RCTs, although no head-to-head 
comparison could be made. However, as the study population grew, critical comparison 
with RCT data revealed that the efficacy of biological treatment in daily clinical practice 
was actually lower than the efficacy of biologics in RCTs. This is the matter not only when 
observing the registry data, but also with respect to the efficacy data presented in the 
reimbursement application study and the study on antibodies against adalimumab. As 
expected, the efficacy percentages obtained from per protocol (PP) analyses appear to be
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slightly higher than the percentages obtained from intention to treat (ITT) analyses.
The reason for the lower efficacy of biologics for psoriasis in daily clinical practice compared 
with RCTs could not exactly be discerned in the studies performed. Multiple factors related 
to the patient, the physician (or investigator) and the pharmaceutical may play a role.
First of all, the study population in RCTs may be different from the population observed in 
daily practice with respect to baseline Psoriasis Area and Severity Index (PASI), weight, 
medication history, comorbidities and interfering medication. As outlined in Chapter 8, the 
influence of patient characteristics (including baseline PASI, body mass index, number 
of previous systemic treatments and duration of psoriasis) on the response of biological 
treatment was limited. The study population in this analysis, however, was small, but trends 
were observable. To establish the actual contribution of patient factors to the outcomes of 
biological treatment in daily practice, a multivariate analysis should be executed in a much 
larger cohort.
Secondly, the course of biological treatment in RCTs may be different from daily practice, 
as a result of differences in the usage of biologics by patients or differences in intervention 
by the physician (defined as 'clinical strategies' in Chapter 7). Compared with treatment 
and follow-up schedules in daily practice, protocols for RCTs are generally more extensive 
and stricter. Such strictness may increase compliance and adequate use of medication 
by patients, known as the 'Hawthorne effect'.5 Furthermore, as outlined in Chapter 7, 
frequently applied clinical strategies such as treatment interruptions, dosage adjustments 
and combinations of treatment influence treatment outcome of biological therapies for 
psoriasis in routine practice. However, to what extent these interventions influence the 
outcomes is difficult to measure, as most interventions are done reactively, and not 
proactively. With regard to combination of systemic therapies, Chapter 9 shows that 
combining etanercept with methotrexate is beneficial and apparently safe when efficacy of 
etanercept monotherapy is insufficient.
Thirdly, outcomes may be influenced as a result of industry sponsorship, conflicts of 
interest, competitive inclusion of patients and specific treatment targets, which may play 
a role in RCTs and observational studies to a different extent. In an article by Perlis et al., 
studies with potential conflicts of interest were associated with greater methodological 
quality scores, greater number of study participants and greater likelihood of reporting 
a result favourable to the study intervention compared with studies without conflicts of 
interest.6 Another study found that systematic bias favoured products which were made by 
the company funding the research. Explanations included the selection of an inappropriate 
comparator to the product being investigated and publication bias.7 
From a purely scientific point of view, all factors that may have influenced the treatment
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Table 1. Overview o f efficacy o f biological treatment in patients with severe psoriasis 
in daily practice compared to randomized controlled trials.
190
Week 12 Week 24
P A S I P A S I P A S I P A S I P A S I P A S I
50 75 90 50 75 90
One-year analysis, ITT1 and PPb 
(Chapter 6)
Etanercept 2 x 50 mg group 82 39 - 71 50 -
Etanercept 2 x 25 mg group 71 24 - 79 57 -
Efalizumab 59 6 - 100 25 -
Two-year analysis, ITT (Chapter 7)
Etanercept 2 x 50 mg group 66 20 S - - -
Etanercept 2 x 25 mg group 68 21 5 - - -
Efalizumab 57 10 0 - - -
Three-year analysis, PP (Chapter 8)
Etanercept - - - 69 39 18
Reimbursement application data 
analysis, ITT (Chapter 12)
Etanercept 69 - - - - -
Efalizumab 50 - - - - -
Antibody analysis, ITT (Chapter 10)
Adalimumab 50 32 21 53 32 11
Systematic review Bansback3, ITT 
(Chapter 2)
Etanercept 2 x 50 mg 74-77 47-49 21-22 - - -
Etanercept 2 x 25 mg 58-70 30-34 11-12 - - -
Efalizumab 52-61 22-39 4-12 - - -
Adalimumab 76-88 53-80 24-52 - - -
Systematic review BAD guidelines 
20094, ITT
Etanercept 2 x 50 mg - 48 21 - 57 -
Etanercept 2 x 25 mg - 34 11 - 43 -
Efalizumab - - - - - -
Adalimumab - 69 43 - 69 -
Presented numbers indicate the percentage of patients achieving a specific PASI response. PASI, Psoriasis 
Area and Severity Index; PASI 50, 50% reduction in PASI relative to baseline; PASI 75, 75% reduction in PASI 
relative to baseline; PASI 90, 90% reduction in PASI relative to baseline; ITT, Intention To Treat; PP, Per Protocol; 
BAD, British Association of Dermatologists. aWeek 12 data were obtained by ITT analysis. bWeek 24 data were 
obtained by PP analysis.
outcomes would have been labelled 'confounders'. However, the primary aim of the 
observational studies in this thesis was to prospectively investigate the effects and side
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effects of biological treatment in patients with severe psoriasis in a real life setting, and 
not under ideal circumstances. The analyses performed did therefore not measure the 
internal validity of biological therapies. Additionally, within the framework of the current 
thesis, treatment efficacy data on RCTs were adapted from systematic reviews. Relevant 
RCTs not included in the review may therefore be missing. Moreover, data analysis was 
performed differently in the studies performed. Missing values may cause both systematic 
and unpredictable bias, leading to a discordance between reported ITT and PP analyses.8 
In most publications on RCTs, only results for a treatment-optimised subpopulation (per 
protocol analysis) are presented, whereas for daily routine therapy the ITT data appear to 
be more relevant. In a study on differences in efficacy between ITT and PP analyses for 
patients with psoriasis and atopic dermatitis, striking differences in the therapeutic effect 
between both groups were found using relative PASI and SCORAD (SCORing Atopic 
Dermatitis) score improvement.9 All data from the publications included in the reviews 
presented in Table 1, however, were obtained through ITT analyses, mostly in combination 
with methods of non-responder imputation or last observation carried forward in case of 
missing data. In spite of that, the efficacy data presented in this review are still higher than 
the observational study data obtained through ITT analyses.
Side effects
In all studies performed, biological therapies were apparently safe as serious adverse 
events were infrequent. After two years of treatment, 93% of all patients reported at least 
one adverse event that was mild in most cases (Chapter 7). After three years of treatment, 
serious adverse events included exacerbations of psoriasis requiring hospitalization, 
muscle and joint complaints, basal cell carcinomas, squamous cell carcinomas, one 
cerebrovascular accident, one pneumonia, one infusion reaction, one case of breast 
cancer and one oesophageal carcinoma. Moreover, two female patients died of a sudden 
cardiac arrest during etanercept treatment (Chapter 8). 191
Whether adverse events were related to the use of biologics was usually difficult to 
establish. Besides, comparison of frequencies of adverse events with other studies is 
problematic due to differences in interpretation and classification of such events.10 In 
the studies performed, adverse events were of the same nature as those observed in 
RCTs. It would be sensible, though, to have a control group, either composed of healthy 
individuals, patients with psoriasis using systemic therapies other than biologics, or 
patients with diseases other than psoriasis who are treated with biologics. Confounding 
factors, as mentioned earlier, may not only affect outcomes on treatment efficacy, but also 
outcomes on safety of treatment.
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Although biological therapies were apparently safe for the treatment of severe psoriasis 
in the short term, long-term safety data on biologics are sparse, and long-term safety data 
on these therapies for psoriasis in daily practice are lacking. That pharmacovigilance is 
extremely important for relatively new drugs such as biologics was illustrated recently 
by the efalizumab case. In February 2009, efalizumab was withdrawn from the market, 
because there was a risk of serious side effects in patients receiving the medicine. These 
included three confirmed cases of progressive multifocal leukoencephalopathy (PML) 
reported between September 2008 and January 2009 in patients who had been receiving 
efalizumab for more than three years. Remarkably, in May 2008 an article on efalizumab 
was published, which enclosed the longest continuous study data (up to 36 months) 
using a biologic therapy for psoriasis at that moment. In that study, the safety profile of 
efalizumab was stable, with no new or no increase in common events over 36 months of 
treatment.11 So, besides RCTs and observational studies, spontaneous reports of adverse 
events are essential to preserve safety when using biological therapies.
Investigation o f the economic impact o f psoriasis and psoriasis treatment, including 
biological therapies.
Part III, Chapter 11 of the current thesis concerned a study on the economic impact of 
high-need psoriasis in daily clinical practice before and after the introduction of biologics. 
In this study, direct costs, related to the treatment of high-need psoriasis in daily clinical 
practice, appeared significantly higher during the biological treatment period than during 
the period before. In the biological treatment period, direct costs increased by €7,566.- per 
patient per year. For 6 patients in the cohort, introduction of biologics led to a reduction of 
direct costs, as these patients did not need long hospitalizations. Introduction of biological 
therapies for psoriasis may therefore have cost-neutral or cost-saving effects, especially 
for patients who otherwise require long hospitalizations. Besides, biological therapy was 
192 accompanied by a high patient satisfaction, indicated by a mean Treatment Satisfaction 
Questionnaire for Medication (TSQM) score of 77.8.
The results of this study and other studies on health economics with reference to psoriasis 
therapies are essential for policy makers. Although cost estimations for different therapies 
can be made during RCTs, the actual cost of illness may best be measured using real life 
practice data.12 The current study did not reflect the cost of illness on psoriasis in total, 
as only patients with high-need psoriasis were analysed, costs on comorbidities were not 
measured and indirect costs were not included.
Considering the fact that only 0.4% of all patients with psoriasis appeared to be treated 
with biologics (Chapter 12), the effect of the increase in direct costs due to introduction
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of biological therapies on the cost of illness for psoriasis as a whole may be limited. 
However, as for other indications, the number of prescriptions of biologics for psoriasis 
may increase as experience with these pharmaceuticals is growing. Without intervention 
of the government, the expenditures for different drugs in The Netherlands will rise 9 to 
10% per year, particularly as a result of the use of expensive medication. In 2008, the 
sales of these expensive drugs increased with 158 million Euro to 852 million Euro.13
Investigation o f procedures on prescription and application o f biological therapies 
in daily practice.
Chapter 12, 13 and 14 focused on procedures on prescription and application of 
biological therapies in daily practice. Chapter 12 and 13 concerned analyses of national 
reimbursement application data on biologics, indicated for psoriasis and psoriatic 
arthritis, respectively. Outcomes of both analyses demonstrated that dermatologists and 
rheumatologists are familiar with the demanded criteria for reimbursement of biological 
therapies. Of all initial treatment applications, 94.5% and 94.6% were approved by LABAG 
(LAndelijke Beoordeling Aanvragen Geneesmiddelen, National Evaluation of Applications 
of Drugs) for psoriasis and psoriatic arthritis, respectively. In the meantime, biologics were 
prescribed for only a small percentage of patients. In January 2008, only 0.4% of Dutch 
patients with psoriasis were treated with etanercept or efalizumab.
As long as long-term efficacy and safety data on biologics are lacking, careful compilation 
of treatment and reimbursement criteria is important for patients as well as for health 
care providers. These criteria enable correct treatment indication and prevent needless 
continuation of ineffective therapy. Furthermore, such criteria enable regulation of costs 
for medical care.
On the contrary, as a consequence of treatment and reimbursement criteria, physicians 
may not always be able to choose freely between different therapeutic options. Patients 
may therefore not always be treated with the most appropriate therapy available. According 
to the new psoriasis treatment guideline formulated by the Dutch Society of Dermatology 
and Venereology (Nederlandse Vereniging voor Dermatologie en Venereologie, NVDV), 
biologics may be prescribed for the treatment of psoriasis if patients are unresponsive, 
intolerant or have contraindications to UVB or PUVA, and methotrexate or ciclosporin.14 
As these treatment criteria are slightly less strict compared with the criteria in the former 
guideline, more patients will currently be eligible for biological therapy.
Chapter 14 concerned the outcomes of a panel meeting on the use of infliximab amongst 
dermatologists, gastroenterologists and rheumatologists. Taken the guidelines from 
dermatology, gastroenterology and rheumatology together, it becomes obvious that
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differences exist between the recommended dosage of infliximab for each indication 
(e.g. 3 mg/kg for rheumatoid arthritis and 5 mg/kg for Crohn's disease). Besides, none 
of the guidelines from each specialty gives indicators how and when to choose for 
dosage adjustment or frequency intensification in case of loss of response. The need of 
concomitant administration of immunosuppressants during treatment with infliximab has 
been stressed by most, but not all, of the guidelines throughout the different specialties. In 
the opinion of the panel, routine measurement of vital signs during infusion is not valuable 
in detecting acute infusion reactions.
Not only the high prevalence of comorbidities in patients with immune-mediated 
disorders15, but also the shared knowledge of different medical specialists on the use of 
immunomodulative therapies including biologics advocates a multidisciplinary approach 
for chronic inflammatory diseases such as psoriasis.
Investigation o f the occurrence o f comorbidities in patients with (severe) psoriasis.
In Chapter 15, 16 and 17, the prevalence and relevance of comorbidities in patients 
with psoriasis was studied. Special attention was paid to cardiovascular risk factors and 
cardiovascular diseases, joint complaints including psoriatic arthritis, and liver injury in 
patients using methotrexate.
Regarding cardiovascular risk factors, a significantly higher prevalence of obesity, 
smoking, and hypertension was found for patients with high-need psoriasis compared with 
non-psoriatic controls. Furthermore, the mean monthly amount of alcohol consumption 
was higher in the patients with high-need psoriasis. Most striking was the high prevalence 
of obesity in the high-need psoriasis cohort. This was observed not only in the study on 
cardiovascular risk factors, but also in the three-year analysis (Chapter 8). Likewise, in the 
antibody analysis (Chapter 10) mean body mass index was 29 kg/m2.
As in the general population, monitoring weight in patients with psoriasis is essential to 
194 assess the risk for development of cardiovascular disease. Moreover, measurement of 
patients' weight may be necessary for adequate selection and dosing of systemic therapies, 
especially biologics.1617 For ustekinumab, which is a fixed-dosed therapy in principle, the 
prescribed dosage should ideally depend on whether a patients has a body weight below 
or above 100 kg.18 Dosage modifications like these may be needed for other fixed-dosed 
biologics as well. In the cohort investigated currently, the used etanercept dosage was 
considerably higher than in RCTs, as depicted in the economic analysis in Chapter 11.
In Chapter 16, the outcomes of a survey on joint complaints in patients with psoriasis were 
described. As deduced from the survey, the prevalence of self-reported joint complaints in 
patients with psoriasis is high (67%). The prevalence of synovitis, however, is considerably
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lower. Osteoarthritis is probably one of the underlying disorders, since the prevalence of 
complaints in the large load bearing joints was substantial. Nevertheless, the frequent 
polyarticular involvement and involvement of the small joints of the hand and feet are 
suggestive for a high prevalence of arthritis. Making the right diagnosis in patients with 
psoriasis who report joint complaints is crucial for prognostication and therapeutic decision 
making. A solid rheumatologic examination in these patients is therefore essential. 
Chapter 17 focussed on liver injury in patients with psoriasis using methotrexate. The 
study showed that hepatotoxicity was limited in a cohort of Dutch patients with psoriasis 
treated with methotrexate. Since 1986 no case of serious liver fibrosis or cirrhosis was 
discerned in this group. This is remarkable, especially as non-alcoholic fatty liver disease 
seems to be frequent in patients with severe chronic plaque psoriasis.19 Routine liver 
biopsies may consequently be abolished or substituted by amino-terminal propeptide of 
type III procollagen (PIIINP) measurement.
Even in the era of biological therapies, methotrexate is still a convenient therapeutic 
option in the treatment of psoriasis. As shown in Chapter 9, combining etanercept with 
methotrexate is reasonable when efficacy of etanercept monotherapy is insufficient, or when 
rapid deterioration of psoriasis after abrupt discontinuation of methotrexate is expected. 
Furthermore, addition of methotrexate to biological therapy may prevent development of 
anti-biologic antibodies, and may relief symptoms related to psoriatic arthritis.
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CHAPTER 19 
Samenvatting en discussie
Introductie
In dit proefschrift worden de uitkomsten van observationele onderzoeken naar de 
behandeling van patiënten met ernstige psoriasis met biologicals in de dagelijkse praktijk 
beschreven. De meeste onderzoeksgegevens kwamen voort uit een patiëntenregistry 
waarin effectiviteits- en veiligheidsdata ten aanzien van behandeling van psoriasispatiënten 
met biologicals prospectief verzameld werden. Daarnaast werden er studies verricht naar 
de economische impact van psoriasis en behandelingen van psoriasis, naar procedures 
rondom het voorschrijven en aanvragen van biologicals in de dagelijkse praktijk, en 
naar comorbiditeiten bij patiënten met (ernstige) psoriasis. In dit hoofdstuk zullen de 
belangrijkste conclusies van dit proefschrift worden uiteengezet en bediscussieerd aan de 
hand van de doelstellingen zoals geformuleerd in hoofdstuk 5.
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Prospectief onderzoek naar de effecten en neveneffecten van behandeling met 
biologicals bij patiënten met ernstige psoriasis in de dagelijkse praktijk.
Effecten
In dit proefschrift worden de resultaten van verschillende studies met betrekking tot de 
effecten en neveneffecten van behandeling met biologicals van patiënten met ernstige 
psoriasis in de dagelijkse praktijk uiteengezet. Dit type onderzoek maakt deel uit van 
'outcomes research', wat is gedefinieerd als de wetenschap waarin de ervaring van de 
patiënt met medische zorg wordt nagegaan, en waarin het eindresultaat of consequenties 
van medische zorg wordt gemeten.1 In de meeste studies werd de Engelse term 'efficacy’ 
gebruikt om de effectiviteit van biologicals te beschrijven. Echter, aangezien vrijwel alle 
onderzoeken werden uitgevoerd in de dagelijkse praktijk zou de term 'effectiveness’ 
wellicht geschikter zijn geweest.2 Met behulp van outcomes research kan de effectiviteit en 
de generaliseerbaarheid van gerandomiseerde gecontroleerde onderzoeken (randomized 
controlled trials, RCTs) verder bepaald worden.1
Hoofdstuk 6, 7 en 8 van dit proefschrift bevatten de uitkomsten van de analyses na 
respectievelijk één, twee en drie jaar onderzoek. De effectiviteit van biologicals kan herleid 
worden uit deze onderzoeken, evenals uit de analyse van de gegevens over de aanvragen 
voor vergoeding van biologicals (Hoofdstuk 12) en de antistoffenanalyse (Hoofdstuk 
10). De meeste onderzoeksgegevens betreffen etanercept, gevolgd door efalizumab en 
adalimumab.
Over het algemeen waren biologicals aantoonbaar effectief en veilig bij de behandeling 
van patiënten met ernstige psoriasis in de dagelijkse praktijk. In tegenstelling tot etanercept 
was efalizumab slechts effectief bij een klein percentage van alle patiënten. Het percentage 
uitvallers in de met efalizumab behandelde groep was substantieel, i.e. 29% na 12 weken, 
47% na 24 weken, 62% na ongeveer twee jaar en 71% na ongeveer drie jaar behandeling 
(data niet getoond). Daarnaast waren antilichamen tegen adalimumab geassocieerd met 
lagere concentraties van adalimumab in het serum, en verminderde effectiviteit of verlies 
van effectiviteit van het middel (Hoofdstuk 10).
In Tabel 1 wordt een overzicht gegeven van de effectiviteit van biologicals bij de behandeling 
van patiënten met ernstige psoriasis in de dagelijkse praktijk in vergelijking met de resultaten 
zoals weergegeven in RCTs.34 In eerste instantie leken de effectiviteitsdata ten aanzien 
van etanercept en efalizumab grofweg vergelijkbaar met de resultaten van RCTs, hoewel 
er geen directe vergelijking gemaakt kon worden. Echter, naarmate de studiepopulatie 
in omvang toenam werd duidelijk dat de effectiviteit van biologicals in de dagelijkse 
praktijk feitelijk lager uitviel dan de effectiviteit van deze middelen in RCTs. Dit is niet
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alleen het geval wanneer de registrydata worden bekeken, maar ook ten aanzien van de 
effectiviteitsdata zoals weergegeven in het onderzoek naar de aanvragen voor vergoeding 
van biologicals en de studie naar antistoffen tegen adalimumab. Zoals verwacht lijken de 
effectiviteitspercentages verkregen via 'per protocol' (PP) analyses enigszins hoger uit te 
vallen dan de percentages verkregen door middel van 'intention to treat' (ITT) analyses. 
De reden voor de lagere effectiviteit van biologicals in de dagelijkse praktijk vergeleken 
met RCTs kon in de studies die gedaan werden in het kader van dit onderzoeksproject 
niet exact worden vastgesteld. Multipele factoren, gerelateerd aan de patiënt, de arts (of 
onderzoeker) en het geneesmiddel, spelen mogelijk een rol hierbij.
Ten eerste is er mogelijk een verschil tussen de onderzoekspopulatie in RCTs en 
de populatie die werd gevolgd in de dagelijkse praktijk op het gebied van baseline 
Psoriasis Area and Severity Index (PASI), gewicht, medicatiehistorie, comorbiditeiten 
en interfererende medicatie. Zoals weergegeven in hoofdstuk 8 bleek de invloed van 
patiëntkarakteristieken (zoals baseline PASI, body mass index, het aantal systemische 
behandelingen in het verleden en de duur van de psoriasis) op de respons op behandeling 
met biologicals beperkt. De studiepopulatie van dit onderzoek was klein, maar desondanks 
waren er trends waarneembaar. Om de werkelijke bijdrage van patiëntfactoren aan de 
outcomes van behandeling met biologicals in de dagelijkse praktijk vast te stellen zou een 
multivariate analyse uitgevoerd moeten worden in een veel groter cohort.
Ten tweede is er mogelijk een verschil tussen het beloop van de behandeling met 
biologicals in RCTs en de dagelijkse praktijk als het gevolg van verschillen in het 
gebruik van medicatie door de patiënt, of verschillen in interventies verricht door de arts 
(gedefinieerd als 'clinical strategies' in hoofdstuk 7). Vergeleken met behandelings- en 
follow-upschema's in de dagelijkse praktijk zijn protocollen voor RCTs in het algemeen 
uitgebreider en strikter. Mogelijk leidt een dergelijke striktheid tot een grotere compliance 
van patiënten en een meer adequaat gebruik van medicatie, iets wat bekend staat als 
200 het 'Hawthorne effect'.5 Daarnaast beïnvloeden frequent toegepaste klinische strategieën, 
zoals onderbreking van de behandeling, dosisaanpassingen en combinatiebehandelingen 
de uitkomsten van behandeling van psoriasispatiënten met biologicals in de dagelijkse 
praktijk, zoals weergegeven in hoofdstuk 7. In welke mate dergelijke interventies de 
uitkomsten beïnvloeden is echter lastig vast te stellen, aangezien de meeste interventies 
reactief, en niet proactief, worden verricht. Met betrekking tot combinaties van systemische 
behandelingen laat hoofdstuk 9 zien dat de combinatie van etanercept met methotrexaat 
zinvol en ogenschijnlijk veilig is indien de effectiviteit van etanercept monotherapie 
onvoldoende blijkt.
Ten derde worden uitkomsten van onderzoeken mogelijk beïnvloed door sponsoring door
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Tabel 1. Overzicht van de effectiv iteit van biologicals bij de behandeling van patiënten 
met ernstige psoriasis in de dagelijkse praktijk in vergelijking met gerandomiseerde 
gecontroleerde onderzoeken.
Week 12 Week 24
P A S I P A S I P A S I P A S I P A S I P A S I
50 75 90 50 75 90
Eénjaars-analyse, ITTa and PPb 
(Hoofdstuk 6)
Etanercept 2 x 50 mg groep 82 39 - 71 50 -
Etanercept 2 x 25 mg groep 71 24 - 79 57 -
Efalizumab 59 6 - 100 25 -
Tweejaars-analyse, ITT (Hoofdstuk 7)
Etanercept 2 x 50 mg groep 66 20 S - - -
Etanercept 2 x 25 mg groep 68 21 5 - - -
Efalizumab 57 10 0 - - -
Driejaars-analyse, PP (Hoofdstuk 8)
Etanercept - - - 69 39 18
Analyse aanvragen vergoeding 
biologicals, ITT (Hoofdstuk 12)
Etanercept 69 - - - - -
Efalizumab 50 - - - - -
Antistoffenanalyse, ITT (Hoofdstuk 10)
Adalimumab 50 32 21 53 32 11
Systematic review Bansback3, ITT 
(Hoofdstuk 2)
Etanercept 2 x 50 mg 74-77 47-49 21-22 - - -
Etanercept 2 x 25 mg 58-70 30-34 11-12 - - -
Efalizumab 52-61 22-39 4-12 - - -
Adalimumab 76-88 53-80 24-52 - - -
Systematic review BAD guidelines 
20094, ITT
Etanercept 2 x 50 mg - 48 21 - 57 -
Etanercept 2 x 25 mg - 34 11 - 43 -
Efalizumab - - - - - -
Adalimumab - 69 43 - 69 -
De getoonde getallen geven het percentage patiënten weer dat een specifieke PASI respons bereikt. PASI, 
Psoriasis Area and Severity Index; PASI 50, 50% reductie in PASI ten opzichte van baseline; PASI 75, 75% 
reductie in PASI ten opzichte van baseline; PASI 90, 90% reductie in PASI ten opzichte van baseline; ITT, 
Intention To Treat; PP, Per Protocol; BAD, British Association of Dermatologists. aWeek 12 data werden 
verkregen door middel van ITT analyse. bWeek 24 data werden verkregen door middel van PP analyse.
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industrieën, belangenverstrengeling, competitieve inclusie van patiënten en specifieke 
behandelingstargets. De mate waarin deze factoren een onderzoek beïnvloeden verschilt
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mogelijk tussen RCTs en observationele onderzoeken. In een artikel van Perlis et al. werd 
aangetoond dat studies met potentiële belangenconflicten geassocieerd waren met grotere 
methodologische kwaliteitsscores, een groter aantal studieparticipanten en een grotere 
kans op publicatie van onderzoeksresultaten in het voordeel van de interventie vergeleken 
met studies waarin belangenconflicten geen rol speelden.6 Een ander onderzoek toonde 
dat systematische bias het product wat afkomstig is van de firma die de studie bekostigd 
vaak ten goede komt. Verklaringen hiervoor omvatten de selectie van een verkeerd 
controleproduct ter vergelijking van het onderzoeksproduct, evenals publicatiebias.7 
Uit puur wetenschappelijk oogpunt zouden alle factoren die de behandelingsuitkomsten 
mogelijk beïnvloed hebben 'confounders' genoemd worden. Het primaire doel van de 
observationele onderzoeken in dit proefschrift was echter juist het prospectief onderzoeken 
van effecten en neveneffecten van behandeling met biologicals van patiënten met 
ernstige psoriasis in een dagelijkse praktijk setting, en niet onder ideale omstandigheden. 
De uitgevoerde analyses zeggen dientengevolge niets over de interne validiteit van 
biologicals. Daarnaast werden, ten behoeve van dit proefschrift, de effectiviteitscijfers 
van RCTs afgeleid uit systematic reviews. Relevante RCTs die niet zijn opgenomen in 
deze reviews ontbreken dus mogelijk. Bovendien werden data-analyses in de studies op 
verschillende manieren verricht. Het ontbreken van gegevens veroorzaakt mogelijk een 
systematische en onvoorspelbare bias, wat leidt tot verschillen tussen gerapporteerde 
ITT en PP analyses.8 In de meeste publicaties omtrent RCTs worden enkel de resultaten 
van een subpopulatie met een geoptimaliseerd behandelingsbeloop gepresenteerd (PP 
analyse), terwijl voor behandelingen in de dagelijkse praktijk de ITT gegevens relevanter 
blijken te zijn. In een onderzoek over de verschillen in effectiviteit tussen ITT en PP analyses 
bij patiënten met psoriasis en atopisch eczeem werden opvallende verschillen gevonden 
in het therapeutisch effect tussen de twee groepen wanneer gebruik werd gemaakt van 
de relatieve verbetering van de PASI en SCORAD (SCORing Atopic Dermatitis) score.9
202 Echter, alle gegevens uit de publicaties die geïncludeerd werden voor de reviews zoals 
weergegeven in Tabel 1 werden verkregen door middel van ITT analyses, meestal in 
combinatie met methodes als 'non-responder imputation' of 'last observation carried 
forward' in het geval van ontbrekende gegevens. Desondanks zijn de effectiviteitscijfers 
van deze reviews nog steeds hoger dan de data van de observationele onderzoeken die 
door ITT analyses verkregen werden.
Neveneffecten
In alle onderzoeken die verricht werden in het kader van dit proefschrift leek behandeling 
met biologicals veilig te zijn. Ernstige bijwerkingen kwamen weinig voor. Na twee jaar
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behandeling rapporteerde 93% van alle patiënten ten minste één bijwerking, die meestal 
mild van aard was (Hoofdstuk 7). Na drie jaar behandeling werden er enkele ernstige 
bijwerkingen gemeld, namelijk exacerbaties van psoriasis leidend tot ziekenhuisopname, 
spier- en gewrichtspijnen, basaalcelcarcinomen, plaveiselcelcarcinomen, een 
cerebrovasculair accident, een pneumonie, een infusiereactie, een mammacarcinoom en 
een oesofaguscarcinoom. Tevens overleden er twee vrouwelijke patiënten aan een acute 
hartstilstand tijdens behandeling met etanercept (Hoofdstuk 8).
Of bijwerkingen gerelateerd waren aan het gebruik van biologicals was over het algemeen 
moeilijk vast te stellen. Daarnaast is de vergelijking van bijwerkingenfrequenties met 
andere studies problematisch vanwege verschillen in interpretatie en classificatie van 
dergelijke events.10 In de verrichte studies waren bijwerkingen van dezelfde aard als 
de bijwerkingen die gezien werden in RCTs. Het zou desondanks zinvol zijn om een 
controlegroep te hebben, samengesteld uit gezonde individuen, psoriasispatiënten met 
systemische therapieën anders dan biologicals, of patiënten met ziektes anders dan 
psoriasis die behandeld worden met een biological. Confounders, zoals eerder genoemd, 
beïnvloeden mogelijk niet alleen de effectiviteitcijfers, maar ook de uitkomsten ten aanzien 
van de veiligheid van de behandeling.
Hoewel de behandeling met biologicals van patiënten met ernstige psoriasis veilig leek te 
zijn op de korte termijn zijn lange termijn veiligheidsgegevens over biologicals schaars, 
en zijn lange termijn veiligheidsgegevens over deze behandelingen voor psoriasis 
in de dagelijkse praktijk überhaupt niet beschikbaar. Dat geneesmiddelenbewaking 
buitengewoon belangrijk is voor relatief nieuwe geneesmiddelen zoals biologicals werd 
recent geïllustreerd door de efalizumab casus. In februari 2009 werd efalizumab van 
de markt gehaald, omdat er een risico was op ernstige bijwerkingen bij patiënten die dit 
medicament gebruikten. Dit omvatte drie bevestigde gevallen van progressieve multifocale 
leuko-encefalopathie (PML) gerapporteerd tussen september 2008 en januari 2009 bij 
patiënten die langer dan drie jaar met efalizumab werden behandeld. Opmerkelijk genoeg 
verscheen er in mei van 2008 een artikel over efalizumab, waarin de op dat moment 
langste continue studiedata (tot 36 maanden) ten aanzien van het gebruik van een 
biological voor psoriasis werd weergegeven. In dat onderzoek was het veiligheidsprofiel 
van efalizumab stabiel, zonder nieuwe of toename van veelvoorkomende bijwerkingen 
gedurende 36 maanden behandeling.11 Naast RCTs en observationele studies is spontane 
rapportage van bijwerkingen daarom noodzakelijk om veiligheid te kunnen handhaven 
tijdens behandeling met biologicals.
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Onderzoek naar de economische gevolgen van psoriasis en de behandeling van 
psoriasis waaronder biologicals.
Deel III, hoofdstuk 11 van dit proefschrift betrof een onderzoek naar de economische 
gevolgen van ernstige psoriasis in de dagelijkse praktijk, voor en na de introductie van 
biologicals. In dit onderzoek bleken de directe kosten, gerelateerd aan de behandeling 
van ernstige psoriasis in de dagelijkse praktijk, significant hoger in de periode waarin 
behandeld werd met biologicals dan in de periode daarvoor. In de periode waarin 
behandeld werd met biologicals stegen de directe kosten met €7.566,- per patiënt per 
jaar ten opzichte van de periode eerder. Voor zes patiënten uit het cohort resulteerde de 
behandeling met biologicals in een afname van de directe kosten, aangezien langdurige 
ziekenhuisopnames hiermee werden voorkomen. De behandeling van psoriasis met 
biologicals kan dus mogelijk een kostenneutraal of kostenbesparend effect hebben, in 
het bijzonder voor patiënten bij wie langdurige ziekenhuisopnames anders noodzakelijk 
zijn. Daarnaast ging de behandeling met biologicals gepaard met een grote tevredenheid 
van patiënten, wat blijkt uit een gemiddelde Treatment Satisfaction Questionnaire for 
Medication (TSQM) score van 77.8.
De resultaten van deze en andere onderzoeken op het gebied van 'health economics’ 
ten aanzien van behandelingen van psoriasis zijn essentieel voor beleidsmakers. Hoewel 
er ook bij RCTs een inschatting gemaakt kan worden van de kosten voor verschillende 
therapieën, kunnen de daadwerkelijke ziektegerelateerde kosten ('cost of illness’) het 
beste worden berekend met behulp van gegevens uit de dagelijkse praktijk.12 De huidige 
studie geeft niet de totale cost of illness voor psoriasis weer, aangezien alleen patiënten 
met een ernstige psoriasis werden geanalyseerd, en indirect kosten en kosten met 
betrekking tot comorbiditeiten buiten beschouwing warden gelaten.
Gezien het feit dat slechts 0,4% van alle psoriasispatiënten behandeld bleek te worden 
met biologicals (Hoofdstuk 12), is het effect van de toename van directe kosten door 
204 de komst van biologicals op de totale cost of illness voor psoriasis in zijn geheel 
waarschijnlijk beperkt. Echter, zoals ook voor andere indicaties zal het aantal voorschriften 
van biologicals voor psoriasis wellicht stijgen naarmate de ervaring van artsen met deze 
middelen toeneemt.
Zonder ingrijpen van de overheid stijgen de geneesmiddelenuitgaven op dit moment jaarlijks 
met 9 tot 10%, in het bijzonder ten gevolge van het gebruik van dure geneesmiddelen. 
In 2008 nam de omzet van deze dure geneesmiddelen met € 158 miljoen toe tot € 852 
miljoen.13
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Onderzoek naar procedures omtrent het voorschrijven en aanvragen van biologicals 
in de dagelijkse praktijk.
Hoofdstuk 12, 13 en 14 van dit proefschrift gaan over procedures omtrent het voorschrijven 
en aanvragen van biologicals in de dagelijkse praktijk. Hoofdstuk 12 en 13 betreffen 
analyses van data van nationale vergoedingsaanvragen voor biologicals, respectievelijk 
met als indicatie psoriasis en artritis psoriatica. De uitkomsten van beide analyses laten 
zien dermatologen en reumatologen bekend zijn met de vereiste criteria voor vergoeding 
van biologicals. Van alle eerste behandelingsaanvragen voor psoriasis en artritis psoriatica 
werd respectievelijk 94,5% en 94,6% goedgekeurd door de stichting LABAG (LAndelijke 
Beoordeling Aanvragen Geneesmiddelen). Ondertussen werden biologicals slechts 
voor een klein percentage van alle patiënten voorgeschreven. In januari van 2008 werd 
slechts 0,4% van de Nederlandse patiënten met psoriasis behandeld met etanercept of 
efalizumab.
Zolang er geen gegevens zijn over de effectiviteit en veiligheid van biologicals op de 
lange termijn is het zorgvuldig formuleren van behandelings- en vergoedingscriteria 
in het belang van zowel patiënten als zorgverleners. Dergelijke criteria maken een 
correctie indicatiestelling voor een behandeling mogelijk en voorkomen dat ineffectieve 
behandelingen te lang worden gecontinueerd. Daarnaast kunnen met behulp van zulke 
criteria de kosten voor de gezondheidszorg beter gereguleerd worden.
Aan de andere kant beperken behandelings- en vergoedingscriteria de vrijheid van 
artsen om uit verschillende behandelingsopties te kunnen kiezen. Patiënten worden 
daarom mogelijk niet altijd behandeld met de op dat moment meest geschikte therapie. 
Volgens de nieuwe behandelingsrichtlijn voor psoriasis, die is opgesteld door de 
Nederlandse Vereniging voor Dermatologie en Venereologie (NVDV), mogen biologicals 
voorgeschreven worden bij falen van, of contra-indicaties of intoleranties voor UVB of 
PUVA, en methotrexaat of ciclosporine.14 Aangezien deze behandelingscriteria minder 
strikt zijn dan de criteria zoals geformuleerd in de oude richtlijn zullen er momenteel meer 
patiënten in aanmerking komen voor behandeling met biologicals.
Hoofdstuk 14 beschrijft de uitkomsten van een panelmeeting tussen dermatologen, gastro­
enterologen en reumatologen over het gebruik van infliximab. Wanneer de richtlijnen van 
dermatologie, gastro-enterologie en reumatologie worden samengevat, wordt duidelijk dat 
er verschillen bestaan tussen de aanbevolen dosering van infliximab voor verschillende 
indicaties (e.g. 3 mg/kg voor reumatoïde artritis en 5 mg/kg voor de ziekte van Crohn). 
Daarnaast geeft geen van de richtlijnen een indicatie over hoe en wanneer er gekozen 
dient te worden voor dosisaanpassing of intensivering van de toedienigsfrequentie 
in het geval van verlies van effectiviteit. De noodzaak van het gelijktijdige gebruik van
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immunosuppressiva tijdens behandeling met infliximab wordt door de meeste, maar niet 
door alle, richtlijnen voor de verschillende specialismen benadrukt. Het panel is verder 
van mening dat het routinematig meten van vitale tekenen tijdens infliximab infusie om 
daarmee acute infusiereacties te detecteren niet zinvol is.
Niet alleen de hoge prevalentie van comorbiditeiten bij patiënten met immuungemedieerde 
aandoeningen15, maar ook de gemeenschappelijke kennis van de verschillende medisch 
specialisten ten aanzien van het gebruik van immunomodulerende therapieën waaronder 
biologicals, bepleiten een multidisciplinaire aanpak van chronische inflammatoire 
aandoeningen zoals psoriasis.
Onderzoek naar het vóórkomen van comorbiditeiten bij patiënten met (ernstige) 
psoriasis.
In hoofdstuk 15, 16 en 17 van dit proefschrift werd de prevalentie en de relevantie van 
comorbiditeiten bij patiënten met psoriasis onderzocht. In het bijzonder werd er aandacht 
besteed aan cardiovasculaire risicofactoren en cardiovasculaire ziektes, gewrichtsklachten, 
inclusief artritis psoriatica, en leverschade bij patiënten die methotrexaat gebruiken.
Ten aanzien van cardiovasculaire risicofactoren werd er in de groep van zeer ernstige 
('high-need') psoriasispatiënten een significant hogere prevalentie gevonden van obesitas, 
roken en hypertensie vergeleken met dermatologische patiënten zonder psoriasis. Verder 
was ook de hoeveelheid alcoholgebruik per maand hoger in de groep van high-need 
psoriasispatiënten. Het meest opvallend was de hoge prevalentie van obesitas in het high­
need psoriasiscohort. Dit werd niet alleen gezien in het onderzoek naar cardiovasculaire 
risicofactoren, maar eveneens in de drie-jaars analyse (Hoofdstuk 8). Bovendien was de 
gemiddelde body mass index ook in de antistoffenanalyse hoog, namelijk 29 kg/m2 
Net zoals in de normale bevolking is het ook bij patiënten met psoriasis essentieel om gewicht 
te monitoren, om zo een inschatting te kunnen maken van het risico op cardiovasculaire 
206 ziektes. Daarnaast is het meten van gewicht vaak noodzakelijk voor adequate selectie en 
dosering van systemische therapieën, in het bijzonder biologicals.1617 Voor ustekinumab, 
in principe een therapie met een vastgestelde dosering, dient de voorgeschreven dosering 
af te hangen van of een patiënt meer of minder dan 100 kg weegt.18 Dosisaanpassingen 
zoals deze zijn mogelijk ook voor andere biologicals met een vastgestelde dosering nodig. 
In het cohort dat onderzocht werd ten behoeve van dit onderzoek was de gebruikte dosis 
etanercept aanmerkelijk hoger dan in RCTs, zoals weergegeven in de economische 
analyse in hoofdstuk 11.
In hoofdstuk 16 werden de uitkomsten van een enquête over gewrichtsklachten bij 
patiënten met psoriasis uiteengezet. Uit de enquête bleek dat de prevalentie van
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zelfgerapporteerde gewrichtsklachten bij patiënten met psoriasis hoog was (67%). De 
prevalentie van synovitis was echter beduidend lager. Mogelijk is artrose één van de 
onderliggende aandoeningen, gezien de hoge prevalentie van klachten van de grote, 
zwaar belaste gewrichten. Desalniettemin zijn de frequente polyarticulaire betrokkenheid 
en betrokkenheid van de kleine gewrichten van de handen en voeten suggestief voor 
een hoge prevalentie van artritis. Het stellen van de juiste diagnose bij patiënten met 
psoriasis die aangeven gewrichtsklachten te hebben is cruciaal voor het vaststellen van 
de prognose en maken van de juiste keuzes ten aanzien van de behandeling. Een solide 
reumatologisch onderzoek is bij dergelijke patiënten daarom essentieel.
Hoofdstuk 17 richt zich op leverschade bij patiënten die methotrexaat gebruiken. Het 
onderzoek toont aan dat hepatotoxiciteit beperkt is in een cohort van Nederlandse 
psoriasispatiënten die behandeld worden met methotrexaat. Sinds 1986 werd er in deze 
groep geen enkel geval van ernstige leverfibrose of levercirrose gezien. Dit is opmerkelijk, 
vooral omdat non-alcoholische leververvetting vaak lijkt voor te komen bij patiënten met 
ernstige chronische plaque psoriasis.19 Het routinematig uitvoeren van leverbiopsieën kan 
dus mogelijk afgeschaft worden of worden vervangen door meting van het procollageen III 
aminoterminaal peptide (PIIINP).
Zelfs in het tijdperk van biologicals is methotrexaat nog steeds een waardevolle 
therapeutische optie voor de behandeling van psoriasis. Zoals weergegeven in hoofdstuk 
9 is het combineren van etanercept met methotrexaat zinvol als de effectiviteit van 
etanercept monotherapie ontoereikend is, of wanneer een snelle uitbraak van psoriasis 
na het abrupt staken van methotrexaat verwacht wordt. Tevens voorkomt het toevoegen 
van methotrexaat aan een behandeling met biologicals waarschijnlijk de ontwikkeling van 
antistoffen tegen deze biologicals, en geeft het verlichting van symptomen van artritis 
psoriatica.
207
PART VI
208
Referenties
1. Canto JG, Kiefe CI, Williams OD et al. Comparison of outcomes research with 
clinical trials using preexisting data. Am.J.Cardiol. 1999; 84: 923-7, A6.
2. Ernst E, Pittler MH. Efficacy or effectiveness? J.Intern.Med. 2006; 260: 488-90.
3. Bansback N, Sizto S, Sun H et al. Efficacy of Systemic Treatments for Moderate 
to Severe Plaque Psoriasis: Systematic Review and Meta-Analysis. Dermatology 
2009; 219: 209-18.
4. Smith CH, Anstey AV, Barker JN et al. British Association of Dermatologists’ 
guidelines for biologic interventions for psoriasis 2009. BrJ.Dermatol. 2009; 161: 
987-1019.
5. McCarney R, Warner J, Iliffe S et al. The Hawthorne Effect: a randomised, controlled 
trial. BMC.Med.Res.Methodol. 2007; 7: 30.
6. Perlis CS, Harwood M, Perlis RH. Extent and impact of industry sponsorship 
conflicts of interest in dermatology research. J.Am.Acad.Dermatol. 2005; 52: 967­
71.
7. Lexchin J, Bero LA, Djulbegovic B et al. Pharmaceutical industry sponsorship and 
research outcome and quality: systematic review. BMJ 2003; 326: 1167-70.
8. Porta N, Bonet C, Cobo E. Discordance between reported intention-to-treat and per 
protocol analyses. J.Clin.Epidemiol. 2007; 60: 663-9.
9. Schiffner R, Schiffner-Rohe J, Gerstenhauer M et al. Differences in efficacy between 
intention-to-treat and per-protocol analyses for patients with psoriasis vulgaris and 
atopic dermatitis: clinical and pharmacoeconomic implications. BrJ.Dermatol. 
2001; 144: 1154-60.
10. Richesson RL, Fung KW, Krischer JP. Heterogeneous but “standard” coding 
systems for adverse events: Issues in achieving interoperability between apples 
and oranges. Contemp.Clin.Trials 2008; 29: 635-45.
11. Leonardi C, Menter A, Hamilton T et al. Efalizumab: results of a 3-year continuous 
dosing study for the long-term control of psoriasis. BrJ.Dermatol. 2008; 158: 1107­
16.
12. Marshall DA, Hux M. Design and analysis issues for economic analysis alongside 
clinical trials. Med.Care 2009; 47: S14-S20.
13. Stichting Farmaceutische Kengetallen. Data en Feiten 2009. http://www.sfk.nl/ 
publicaties/2009denf.pdf.
14. Richtlijn: Foto(chemo)therapie en systemische therapie bij ernstige chronische 
plaque psoriasis. Herziene versie 2005, aanvulling 2009. http://www.huidarts.info/ 
documents/uploaded_file.aspx?id=203.
CHAPTER 19
15. Robinson D, Jr., Hackett M, Wong J et al. Co-occurrence and comorbidities in 
patients with immune-mediated inflammatory disorders: an exploration using US 
healthcare claims data, 2001-2002. Curr.Med.Res.Opin. 2006; 22: 989-1000.
16. Downs AM. Switching between antitumour necrosis factor alpha biologic agents--is 
patient weight an important consideration? BrJ.Dermatol. 2009; 160: 1123-4.
17. Clark L, Lebwohl M. The effect of weight on the efficacy of biologic therapy in 
patients with psoriasis. J.Am.Acad.Dermatol. 2008; 58: 443-6.
18. Stelara® (ustekinumab). Summary of Product Characteristics. Janssen-Cilag 
International NV, Beerse (BE). 2009.
19. Gisondi P, Targher G, Zoppini G et al. Non-alcoholic fatty liver disease in patients 
with chronic plaque psoriasis. J.Hepatol. 2009; 51: 758-64.
209
PART VI
210
PART VII
DANKWOORD
o
s©
»
û
IPi
DVI/IKMOOKD
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DANKWOORD
Vele handen maken licht werk. Zonder de hulp van onderstaande mensen, evenals vele 
anderen, was dit proefschrift er niet geweest. Mijn dank is daarom groot!
Elke de Jong (Co-promotor) Elke, een groot deel van dit proefschrift was niet tot stand 
gekomen zonder jouw goede ideeën, eindeloos enthousiasme en doorzettingsvermogen. 
Met het “biologicalscircus” reisden we door heel Nederland, en zelfs door delen van 
Europa, waarbij we vaak in de meest wonderlijke contreien terechtkwamen. Dergelijke 
trips waren steeds weer een bron van inspirerende, gezellige en soms zelfs hilarische 
momenten. Dank voor al je inspanningen de afgelopen jaren. Hopelijk lukt het om na deze 
promotie samen nog veel leuke onderzoeksprojecten op te zetten.
Prof. dr. Peter van de Kerkhof (Promotor) Beste professor, bedankt voor het vertrouwen 
dat u mij de afgelopen jaren heeft gegeven. Telkens weer sloeg u “de spijker op zijn kop” 
als het ging om de afronding van verschillende artikelen. Daarbij had u ook altijd aandacht 
voor de mens achter de onderzoeker, en dat waardeer ik zeer.
Rosanne van Lingen Lieve Rosanne, tijdens de verdediging had jij naast mij moeten 
staan, zoals ik nog maar zo kort geleden ook naast jou stond. Dat het niet zo mocht zijn 
is onverteerbaar. Ik mis je.
Michelle de Jager (Paranimf) Lieve Mies, wat fijn dat jij mijn paranimf bent. Het 
onderzoek wat ik deed bij de volwassenen doe jij bij de kinderen, en daarom werden we 
onderzoeksmaatjes en konden we onze database delen. Het duurde wel even voordat de 
naam “CAPTURE” er stond, maar nu staat het als een huis. Daarnaast delen we de passie 
voor wijn en lekker eten. Een betere paranimf kon ik me daarom niet wensen.
Marisol Kooijmans-Otero (Onderzoeksverpleegkundige) Niet voor niks noemden we je 
vaak liefkozend “Ma Risol”. Je bent als een moeder voor alle onderzoekers. Zowel op het 
werk als privé kon ik altijd op je rekenen. Je bent de zon en de zee!
Maartje Berends Maartje, je gelooft het vast niet als ik zeg dat ik hier zonder jou (letterlijk 
en figuurlijk) niet gestaan had. Toch is het zo. Bij jou is dit allemaal begonnen, en daar ben 
ik heel blij om.
Collega onderzoekers Michelle, Kim, Haike, Paula, Esther, Inge en Margit Wat een 
fantastische tijd hebben we gehad! Terwijl de productiviteit behouden bleef was er 
regelmatig tijd voor koffie, thee, soep, broodjes, snoep, gebak, een goede roddel en een 
biertje op z'n tijd. Ik mis de onderzoekstijd nu al. Veel succes met de afronding van jullie 
projecten.
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Collega’s van de afdeling dermatologie De afdeling dermatologie staat bekend om zijn 
unieke sfeer, en dat maakt het werken hier ontzettend leuk. Hopelijk kunnen we ook in de 
komende jaren de goede samenwerking voortzetten.
Administratie en verpleging Dank voor het opzoeken en uitlenen van honderden dossiers, 
het prikken van tientallen extra buisjes bloed, het wegen en meten, het verzamelen 
van enquêtes en het ondersteunen van alle andere zaken die dit onderzoek en het 
biologicalsspreekuur met zich meebrachten.
Jan Boezeman Beste Jan, toen ik hier begon had ik nog nooit wat met Excel of SPSS 
gedaan. Gelukkig kon ik altijd even bij je aankloppen voor wat hulp. De “truc” met de 
draaitabellen komt nog dagelijks van pas.
Delia Popa-Diaconu (Arts-onderzoeker Reumatologie) In het onderzoek naar 
gewrichtsklachten bij patiënten met psoriasis vormden we een goed team. Bedankt voor 
je enthousiaste inzet, en wie weet tot ziens in de dermatologie.
Martijn van Oijen (Onderzoeker Maag-, Darm- en Leverziekten) Je wordt door 
collega's “dokter Odds Ratio” genoemd, vanwege je kundigheid op het gebied van 
onderzoeksproblematiek. Dank dat ik je hiervoor af en toe in consult mocht vragen. 
Collega’s Reumatologie/Maag-, Darm- en Leverziekten Door de komst van de biologicals 
zit er steeds meer overlap in onze vakgebieden en kunnen we veel van elkaar leren. 
Bedankt voor de prettige en constructieve samenwerking.
Lidian Lecluse (Arts-onderzoeker/ dermatoloog in opleiding AMC Amsterdam) De 
afgelopen jaren zaten we in hetzelfde vaarwater, jij in Amsterdam en ik in Nijmegen. Leuk 
dat we wat projecten samen konden doen.
Collega’s Dermatologie AMC Amsterdam en Erasmus MC Rotterdam Drie weten meer 
dan één. Bedankt voor de prettige samenwerking bij het opzetten en uitvoeren van 
verschillende onderzoeken op het gebied van psoriasis.
Lauke Bisschops (Student Geneeskunde 2008) Het tellen en analyseren van alle 
214 verschillende kostenposten ten behoeve van de economische analyse was monnikenwerk, 
maar het resultaat mag er wezen. Bedankt voor je inzet.
Eddy Adang (Epidemiologie, Biostatistiek en HTA) Bedankt voor de nuttige adviezen ten 
aanzien van het farmaco-economisch onderzoek.
Frank van den Hoogen (Reumatoloog Sint Maartenskliniek) Beste Frank, bedankt voor je 
bijdrage aan het stuk over de vergoedingsaanvragen voor biologicals bij de behandeling 
van arthritis psoriatica.
Patiënten Onderzoeken als deze kunnen alleen verricht worden met medewerking 
van de patiënt. Bedankt voor de tijd en moeite die u hebt gestoken in de verschillende 
ziekenhuisbezoeken, het afstaan van buisjes bloed en het invullen van vragenlijsten en
DANKWOORD
andere onderzoeksformulieren.
Clinical PhD Council Dat er in het belang van de klinische onderzoekers nog heel wat 
te regelen valt, dat is wel gebleken. Leuk dat ik hier samen met jullie over mee mocht 
denken. Veel succes met de afronding van jullie eigen onderzoeken.
Farmaceutische industrie Wanneer we open en eerlijk met elkaar samenwerken kunnen 
we de kwaliteit van zorg verbeteren. Bedankt voor jullie uitgebreide informatievoorziening 
ten behoeve van dit onderzoek en de ondersteuning van de patiëntenzorg.
John Schraven Bedankt voor de hulp bij het opmaken van dit proefschrift.
Zatte Hennies Gelukkig gaat het bij jullie meestal over iets anders dan over de 
gezondheidszorg. In tijden van opleiding en promotieonderzoek als deze is dat een 
verademing. Da ge bedankt zèt, da witte!
Cristy, Elmie, Joyce, Marijn, Suzanne en de jongens We hebben het allemaal veel te druk, 
en daardoor zien we elkaar veel te weinig. Ook ik heb me daaraan schuldig gemaakt de 
afgelopen tijd. Volgend jaar gaan we weer gewoon met z'n allen op wintersport!
Peter en Mieke Lieve Peter en Mieke, bij jullie is mijn tweede “thuis”. Fijn dat we altijd 
welkom zijn.
Anke Lieve Anke, dat we zeven jaar schelen is eigenlijk wel leuk. Dankzij jou hou ik nog bij 
wat hip is. Nog even en dan ben je ook een “stuudje”. En dan nu ook nog paranimf! Had 
je nooit gedacht hè? Luv-u!
Papa en mama Lieve pap en mam, zonder jullie had ik hier nooit gestaan. Met jullie warmte 
en nuchterheid stonden jullie aan de basis van alles wat ik de afgelopen jaren gedaan heb. 
En nog steeds is er maar één echte thuisbasis, en dat is in Druten. Dit boekje is voor jullie! 
Roel Lieve Roel, je bent mijn manager, mijn maatje en mijn mannetje. We vormen samen 
een onafscheidelijk duo, en hebben grootse plannen voor de toekomst. Daarom daag ik je 
uit! Ben jij de volgende die promoveert?
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Rieke Johanna Bernardina Driessen werd op 14 juli 
1982 geboren in het UMC St Radboud (het toenmalige St 
Radboudziekenhuis) in Nijmegen. Zij groeide op in Druten, 
een dorp centraal gelegen in het Land van Maas en Waal. Na 
het behalen van het VWO diploma aan het Pax Christi College 
in Druten in 2000 begon zij aan haar studie geneeskunde 
aan de Radboud Universiteit te Nijmegen (destijds Katholieke 
Universiteit Nijmegen). In het kader van haar opleiding deed 
zij in 2006 een onderzoeksstage op de afdeling dermatologie 
van het UMC St Radboud, onder supervisie van dr. Elke 
M.G.J. de Jong en prof. dr. dr. Peter C.M. van de Kerkhof. Hiermee werd het begin gemaakt 
van een promotieonderzoek naar de effecten en neveneffecten van de behandeling van 
psoriasispatiënten met biologicals in de dagelijkse praktijk. In september van 2009 is Rieke 
Driessen gestart met de opleiding tot dermatoloog, eveneens in het UMC St Radboud. 
Rieke Driessen is getrouwd met Roel van Vugt op 5 februari 2010.
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